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Executive Summary 
 
 
Background 
 
It is now well recognised that people who have a transient ischaemic attack (TIA) 
are at high risk of going on to have a stroke, and the risks of this happening are 
highest in the first few days following the event. There are several interventions, 
both medical and surgical, that can potentially substantially reduce this risk of 
stroke following a TIA. Therefore, it is relevant for health services to consider how 
best to provide services for patients who have had a TIA so as to ensure that they 
receive speedy diagnosis and prompt treatment to reduce the chance that they will 
have a stroke. National guidelines and policy recommend that the solution is to 
have patients seen rapidly by a specialist in an out-patient setting. It has been 
suggested that some patients at particularly high risk of stroke should be admitted 
to hospital so that if they do have a stroke, then they will receive prompt treatment 
to minimise the impact of that stroke (e.g. with thrombolysis). A further option is to 
encourage patients to contact the emergency services when they have symptoms. 
Alternatively, patients might be managed by their general practitioner.  
 
 
 
Aim 
 
The aim of this research was to conduct mathematical modelling to determine what 
is the optimum pattern of service provision for people presenting with a transient 
ischaemic attack or minor stroke.  
 
 
 
 
About this study 
 
In order to do this, it was necessary to gather data to populate the model. These 
data were obtained from the Oxford Vascular Study (OXVASC), the Newcastle Rapid 
Ambulance Protocol Study, the QRESEARCH general practice database, and the 
literature. From the OXVASC study, data were obtained on the incidence of TIA and 
minor stroke, and the risk of stroke following these events. The Newcastle data 
provided data on how long it took people to reach hospital when they attended via 
the emergency services. The QRESEARCH database provided data on the current 
management of TIA in general practice. The literature was used to determine the 
impact of treatments on reducing risks of subsequent stroke, accuracy with which 
GPs diagnose TIA, and to obtain costing data. In addition, we performed a patient 
survey to determine patient costs and patient preferences for different types of 
service.  
 
The model comprised a discrete event simulation, programmed in Borland Delphi. 
It predicted what would happen under different patterns of service provision to 
people who present to the health service with symptoms suggestive of TIA or minor 
stroke. The model simulated 10 years of time for a population of 500,000. Current ©NCCSDO 2008  Page 5 
practice was compared to different patterns of service provision, including daily 
rapid access clinics, twice weekly clinics and weekly clinics. It was assumed that 
the rapid access clinic would provide accurate diagnosis, rapid assessment for 
carotid endarterectomy where appropriate, and optimal medical management 
(blood pressure lowering; statin therapy; dual anti-platelet therapy; anticoagulation 
if atrial fibrillation). For each type of service provision, it tested what would happen 
if the referral threshold was changed according to predicted risk of stroke using the 
ABCD2 scoring system. It also modelled what would happen if high risk people 
were admitted to hospital, if greater use was made of emergency services, and if 
GPs improved their diagnosis and management. The principal outcome of the model 
was number of major strokes (i.e. strokes that lead to hospital admission) 
prevented and cost. This enabled incremental cost effectiveness ratios (ICERs) to 
be calculated.  
 
 
Key findings 
 
Daily rapid access clinics were more cost-effective than current practice. If a 
referral threshold was set at an ABCD2 score of 4 or more, then this would on 
average lead to 4 referrals per week, and prevent 4 strokes per year at an average 
cost of £27,000 per stroke. Referring all patients (approximately 16 per week) with 
possible TIAs was also cost-effective, with an ICER of £50,000 per major stroke 
prevented compared to the refer at ABCD2 score of 4 strategy. Admitting patients 
with high ABCD2 scores for three days observation was not cost-effective, with an 
ICER of over £1,000,000 per major stroke prevented as compared to referring all 
suspected cases to a daily rapid access clinic. Twice weekly and weekly clinics were 
less effective and less cost effective than daily clinics, but were cost effective 
compared to current practice. For example, referring to a twice weekly clinic with a 
threshold of ABCD2 score of 4 or more prevents 3.3 additional major strokes per 
year as compared to current practice at an ICER of £33,000 per stroke prevented. 
The conclusions of the model were unchanged if greater use was made of 
emergency ambulance services. However, it was not cost effective to encourage 
use of emergency ambulances to expedite rapid treatment of TIAs. If GPs initiated 
optimal medical management on seeing the patient, then it is only cost effective to 
use rapid access clinics if all patients are referred (regardless of whether the GP 
has made a diagnosis of TIA, or what the patient’s ABCD2 score is). If GPs were 
better at diagnosis of TIA than suggested by the literature then the option of 
referring all suspected TIAs is no longer cost effective.  
 
 
 
Conclusion 
 
We estimate that to prevent a stroke that would lead to a hospital admission is on 
average the equivalent of saving about 4 QALYs. Therefore, around £80,000 per 
major stroke averted is likely to be considered cost-effective. Therefore, we drew 
the following conclusions for service provision from the simulation model: 
 
Configuration of rapid access neurovascular clinics: 
•  Where possible, these should allow for same day referrals. Daily clinics are more 
cost effective than less frequent clinics (e.g. twice weekly or weekly). The referral 
threshold for these clinics can be varied according to clinic capacity using an 
ABCD2 score cut off between 4 and 7. ©NCCSDO 2008  Page 6 
•  On grounds of cost-effectiveness the optimal threshold would be to refer patients 
with suspected TIA with an ABCD2 score of 4 or more if capacity is limited to 
around 1 patient per day (serving a population of 500,000).If capacity is not 
limited, then it is cost effective to see all possible TIAs  
•  If daily clinics are not possible, twice or once weekly clinics are cost effective with 
a referral threshold of ABCD2 of 4 or more.  
•  Flexible clinics, i.e where staff can do other work when capacity is not required on 
a given day, are more cost-effective than fixed clinics.  
 
In patient admission: 
•  We do not recommend in-patient admission to facilitate thrombolysis for patients 
at high risk of stroke because of high ABCD2 score 
Use of emergency services: 
We do not recommend that patients are encouraged to use 999 services where 
symptoms have resolved 
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The Report 
 
1: Introduction 
 
The importance of early management of TIA and minor stroke was recognised in 
the 2004 National Clinical Guidelines for Stroke, which recommended that patients 
first seen in the community with TIA or stroke from which they have recovered 
should be assessed and investigated in a specialist service as soon as possible 
within 7 days. (Intercollegiate Stroke Working Party, June 2004). It is now 
recognised that there is significant potential for reducing stroke risk following 
transient ischaemic attack (TIA) if treatment is initiated promptly. This is reflected 
in the National Stroke Strategy that was published in December 2007, which 
recommended that high-risk TIA patients needed to be assessed by experts within 
24 hours of experiencing symptoms, and that lower risk groups needed to be seen 
within seven days. (Department of Health, 2007). 
 
This strategy is based upon key advances in our understanding of the epidemiology 
and treatment of TIA in recent years: 
 
• The incidence of TIA is rising: 
The Oxford Vascular Study (OXVASC) has found that the age specific incidence has 
doubled over the last twenty years in comparison to data from the Oxford 
Community Stroke Project. (Rothwell, 2004a). Given the increased risk of TIA with 
increasing age, this represents a substantial increase in absolute numbers of people 
who have had such an event.  Using modern definitions of TIA, the annual 
incidence is of the order of 0.7 per 1,000 (data on file from OXVASC).  The 
incidence of presumptive diagnosis of TIA by a general practitioner is nearly twice 
this. (Hippisley-Cox, 2005). Thus, in a PCT of 100,000 population, it would be 
anticipated that 123 people would suffer an event per annum that a GP will label as 
a TIA. A similar number of patients will have an event labelled as a minor stroke. 
 
• The risk of stroke after TIA is high: 
Currently, around 8% of people who have had a transient ischaemic attack (TIA) 
will go on to have a stroke within 7 days, and 12% within a month.
 (Coull, 2004; 
Lovett, 2003). Similarly, someone who has had a minor stroke has a 12% risk of a 
recurrence within 7 days, and a 15% risk within a month.  Indeed, 16% of first 
strokes are preceded by a TIA, and about 30% of all strokes are recurrent events. 
(Rothwell, 2004a; Mant 2004a) 
 
• A simple clinical score can differentiate between people at high early risk and lower 
risk following TIA: 
Rothwell et al found that a six point score, the ABCD score,  based on simple 
clinical features (age, blood pressure, whether or not there was unilateral weakness 
or speech disturbance, and duration of symptoms), was highly predictive of 7 day 
risk of stroke following TIA. (Rothwell, 2005). A subsequent refinement of this 
score, the ABCD2 score, that incorporated whether the patient had diabetes, was 
validated in four independent groups of patients and found to be a better predictor 
than the ABCD score. (Johnston, 2007).The ABCD2 score gives a total between 0 
and 7, and is scored as follows: 
•  Age ≥ 60, 1 point 
•  Blood pressure ≥ 140/90 mmHg, 1 point 
•  Clinical features: unilateral weakness, 2 points; speech impairment 
without weakness 1 point. 
•  Duration of symptoms: ≥ 60 mins, 2 points; 10-59 mins, 1 point ©NCCSDO 2008  Page 8 
•  Diabetes, 1 point.  
 
        Treatments can reduce this risk: 
There is strong evidence that interventions can reduce the risk of stroke recurrence 
following TIA, including blood pressure lowering, cholesterol lowering, anti-platelet 
therapy, and carotid endarterectomy. (PROGRESS Collaborative group, 2001; Heart 
Protection Study Collaborative Group, 2002; Antithrombotic Trialists’ Collaboration, 
2002; Rothwell, 2003).While, with the exception of carotid endarterectomy and 
aspirin, there is a lack of evidence on the effect of early application of these 
treatments, recent observational studies suggest that early administration can be 
dramatic. A before and after study set in Oxfordshire found that changing the 
median delay to first prescription for treatment from 20 days to less than 1 day 
was associated with an 80% reduction of the risk of stroke at 90 days. (Rothwell, 
2007). Similarly, introduction of a 24-hour access hospital clinic for suspected TIA 
in France was associated with an observed rate of stroke that was over 80% lower 
than the expected rate from applying the ABCD2 score. (Lavallée, 2007). 
Therefore, it is plausible that optimal management of TIA and minor stroke could 
lead to a significant reduction in stroke incidence, thereby reducing morbidity and 
mortality in the community and helping to meet government targets. (Secretary of 
State for Health, 1999; Department of Health 2001). 
   
 
In the UK, there is variation in terms of both availability of these specialist services 
and what they provide. (Redfern, 2002).  Many patients with a presumptive 
diagnosis of TIA continue to be managed entirely in primary care. (Mant, 2003a). 
On the other hand, a proportion of people with a TIA are assessed by emergency 
medical services while they still have symptoms, e.g. through dialling ‘999’. 
Therefore, the strategy raises questions as well as answers.  Should the emphasis 
be on the development of rapid access specialist clinics (analogous to rapid access 
chest pain clinics)? (Mant, 2004b). What is the trade off in terms of cost versus 
outcome if these clinics have the capacity to see all patients on the same day that 
they are referred, or if there is a maximum wait (e.g. 7 days)? What would be the 
impact if more patients with TIA were seen in hospital within a few hours of 
symptom onset (e.g. if health education campaigns alert people to the symptoms 
of stroke, and are encouraged to dial ‘999)? Alternatively, should GPs manage 
patients more actively, without referring all to specialist clinics? 
A further issue is whether a single model of care should be applied to all patients 
with TIA or whether different models are more appropriate for different categories 
of patient.  It may be that people with a low risk of recurrence may be managed 
appropriately in primary care, whereas people at high risk would benefit from 
urgent specialist assessment. 
One way to answer this multiplicity of research questions in a single study is to 
perform mathematical modelling whereby ‘what if’ scenarios are constructed on the 
basis of what is already known. The purpose of such modelling is to work out the 
likely outcome of different patterns of service provision on the basis of the best 
available evidence. Here we report the development and results of one such 
mathematical model, the aim of which was to compare the predicted outcomes (in 
terms of strokes prevented, quality adjusted life years and cost) of different models 
of service provision for patients with transient ischaemic attack (TIA).  
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1.1 Structure of this report 
There were two phases to this research, which ran in parallel. Data collection for 
the model, and development of the model. The methods used to collect data and 
their results are given in chapter 3. Chapter 4 describes the construction of the 
model, and chapter 5 the results of the model. Chapter 6 discusses the findings of 
the research. While the focus is on discussing the results of the model, there is also 
discussion of the findings of some of the specific research that was carried out to 
collect data for the model, namely an analysis of routine general practice data, and 
a survey of patients with TIA. The concluding chapter makes recommendations for 
policy and research.  
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2:Aims and Objectives 
 
2.1 Focus of this research 
This research focuses on the optimum management of patients who present to 
their GP with symptoms suggestive of a TIA or minor stroke.  The distinction 
between these two conditions is arbitrary. Conventionally, using the WHO criteria, 
an event is classified as a TIA if the symptoms last for less than 24 hours, and a 
stroke if the symptoms last for over 24 hours. (Dennis, 1989). However, a 
proportion of TIAs by this definition are associated with infarcts on brain scans, 
while a proportion of people with stroke have normal scans. (Laloux, 1996). While 
the research is not directly concerned with the management of more severe stroke, 
there is overlap in that some patients with TIA have emergency admissions to 
hospital (the recommended treatment pathway for acute stroke). 
 
2.2 Aim 
 
To compare the predicted outcomes (in terms of strokes prevented, quality 
adjusted life years and cost) of different models of service provision for patients 
with transient ischaemic attack (TIA) through the use of mathematical modelling. 
 
2.3 Objectives 
 
1. To construct a discrete-event simulation model to compare four different 
patterns of service provision: current practice; enhanced primary care service; a 
‘999’ service; and a rapid access neurovascular clinic. 
2. To populate the discrete-event simulation model with data from:  
a. The ongoing Oxford Vascular Study 
b. The Newcastle Rapid Ambulance Protocol study  
c. The QRESEARCH general practice database  
d. The literature  
3. To undertake primary research to ascertain patient preferences with regard to 
the different types of model 
4. To make recommendations regarding service delivery (where sensitivity analysis 
demonstrates that the results of the model are robust)  
5. To make recommendations regarding primary research (where sensitivity 
analysis demonstrates that the results of the model vary according to the 
underlying assumptions) ©NCCSDO 2008  Page 11 
 
3: Data inputs into the model 
 
We populated the model with data from a variety of sources: 
1. The Oxford Vascular Study (OXVASC).  OXVASC is an ongoing community 
based incidence study of stroke and TIA set in Oxfordshire. (Rothwell, 2004a) Its 
approach (intensive contact with approximately 90 GPs covering a population of 
just under 100,000 and early validation by a study clinician) results in very high 
and accurate ascertainment of TIAs and minor strokes in patients who are not 
admitted to hospital and who tend to be under-ascertained in hospital based 
incidence studies. OXVASC data was used to provide estimates of the incidence of 
TIA & minor stroke; their prognosis (time specific up to 3 months following the 
event); the proportion of people with TIA that see a GP and with what time lag; the 
accuracy of GP diagnosis of TIA and minor stroke. OXVASC is currently the only 
source of reliable population-based data on TIAs in the UK. 
2. The Newcastle Rapid Ambulance Protocol Study.  This was a prospective 18 
month study of all referrals of patients with suspected acute stroke / TIA, including 
direct triage of patients by ambulance paramedics, to an acute stroke unit. (Nor, 
2004). This was used to provide data on how quickly patients with TIA and minor 
stroke use ‘999’ services. 
3. Analysis of routine general practice data exploiting the QRESEARCH 
database. This dataset comprises 3.3 million current patients and 4 million past 
patients. (QRESEARCH, 2005). This was used to provide data on current practice in 
terms of their management (namely, drugs used, investigations, and whether 
referred). This complemented the epidemiological data from OXVASC data by 
providing data from a broader population base. It was also the principal source for 
ascertaining current practice. 
4. Patient survey. This was required to identify costs incurred by patients, and 
information on patient preferences (which while not used to inform the model, was 
relevant for interpreting the results of the model). We established a patient 
advisory group comprising people who have had a history of TIA/ minor stroke. 
This group helped us to identify key themes. A short survey instrument was then 
developed and distributed to a TIA/ minor stroke population. 
5. Data from the literature. We used the literature to obtain estimates of 
effectiveness for key interventions, where possible, in relation to timing after TIA/ 
minor stroke, impact of stroke on quality adjusted life years and costing studies.  
Systematic methods were employed to identify, appraise and extract data from 
relevant literature. (Centre for Reviews and Dissemination, 2001) 
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3.1 The Oxford Vascular Study 
 
OXVASC data was used in two ways. For some of the questions, the answers were 
available from existing publications, or from analyses being performed by the 
OXVASC investigators at the time that this research was being carried out. For 
other questions, the OXVASC database was analysed de novo.  
 
3.1.1 Specific analyses of the OXVASC data set 
 
These analyses were performed on OXVASC data from three full years (April 2002 
to March 2005) of patients presenting to the OXVASC clinic with a TIA or minor 
stroke. This comprised 589 patients with TIA or minor stroke, and 277 patients with 
symptoms suggestive of TIA where the final diagnosis was non-cerebrovascular 
disease.  
 
3.1.1.1 What is the incidence of presentation with symptoms suggestive of TIA 
where final diagnosis is non-cerebrovascular disease? 
 
For the model, we needed to know how many patients presented with symptoms 
suggestive of TIA that turned out to have an alternative diagnosis. These patients 
are referred to as ‘TIA mimics’.  Table 3.1 shows number of patients attending 
OXVASC study clinics referred as possible TIA where the final diagnosis was non-
cerebrovascular over the three year time period. 
 
Table 3.1 Other clinic attenders (TIA mimics) in OXVASC by age and 
sex. 
           
      
Age 
(years) 
Men Women  Total 
           
      
< 35  3  9  12 
35 - 44  16  10  26 
45 - 54  14  20  34 
55 - 64  32  22  54 
65 - 74  28  31  59 
75 - 84  33  35  68 
≥ 85  9  15  24 
Total 135  142  277 
 
 
 
The OXVASC study population over this time period is shown in table overleaf. ©NCCSDO 2008  Page 13 
 
 
Table 3.2 OXVASC study population by age and 
sex. 
           
      
Age (years)  Men  Women  Total 
           
      
< 35  22581  20273  42854 
35 - 44  7515  6411  13926 
45 - 54  6092  5589  11681 
55 - 64  4983  4776  9759 
65 - 74  3443  3524  6967 
75 - 84  1936  2615  4551 
≥ 85  420  948  1368 
Total 46970  44136  91106 
           
Data are the means of the three mid-year populations in 
the study practices. 
 
Thus, crude three-year incidence is 277/91106, which is 3 per 1,000, which 
equates to an annual incidence of 1 per 1,000.  
3.1.1.2 What are the characteristics of patients with TIA, minor stroke and TIA 
mimic? 
 
For programming reasons it is necessary to assign a complete set of values to all 
patient characteristics, although some are only applicable to one or two of the three 
types of patient. A discrete event simulation model assigns patient characteristics 
on the basis of underlying probabilities. Therefore, the relevant presentation of 
these data is as probabilities.  These underlying probabilities were obtained from 
the OXVASC data.  
 
a. Age and sex: 
Table 3.3 shows the probability that a patient will be of a given age group if they 
present with a TIA mimic, genuine TIA or stroke derived from the OXVASC data set. 
Table 3.4 shows these adjusted for age and sex distribution of the population of 
England and Wales.  
 ©NCCSDO 2008  Page 14 
Table 3.3 Probability that a patient will be in a given age group if they 
present with TIA mimic, genuine TIA or stroke (OXVASC data) 
 
 Actual  condition 
Age group  TIA mimic  Genuine TIA  Stroke 
20-25 0.0034  0.0034  0.0000 
25-30 0.0069  0.0069  0.0000 
30-35 0.0000  0.0000  0.0000 
35-40 0.0000  0.0000  0.0100 
40-45 0.0207  0.0207  0.0201 
45-50 0.0069  0.0069  0.0201 
50-55 0.0380  0.0380  0.0267 
55-60 0.0551  0.0551  0.0368 
60-65 0.0724  0.0724  0.0870 
65-70 0.1414  0.1414  0.1404 
70-75 0.1242  0.1242  0.1572 
75-80 0.1655  0.1655  0.1572 
80-85 0.1965  0.1965  0.1739 
85-90  0.0897 0.0897 0.1037 
90-95 0.0655  0.0655  0.0636 
95-100  0.0138 0.0138 0.0033 
sum 1  1  1 
(TIA mimic assumed as for TIA.) 
 
The probability that a patient will be male can be represented in the following 
formula: 
 
Patient is male with probability p depending on age group j (j = 4, …, 19), where 
  ,
1
log j
p
p
β α + = ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
−
 
and the parameters α and β are given in the following table (OXVASC data): 
 
Parameter value 
α  1.534 
β -0.121 
 
a1. Age and sex adjusted for general population 
Adjustments were comparing the OXVASC population with the general population of 
England and Wales. The age and sex breakdown is based on data from 
http://www.statistics.gov.uk/statbase/ssdataset.asp?vlnk=9398&More=Y accessed 
4 June 2007. 
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Table 3.4 Probability that a patient will be in a given age group if they 
present with TIA mimic, genuine TIA or stroke (adjusted for general 
population) 
 
 Actual  condition 
Age group  TIA mimic  Genuine TIA  Stroke 
20-25 0.0029  0.0029  0.0000 
25-30 0.0057  0.0057  0.0000 
30-35 0.0000  0.0000  0.0000 
35-40 0.0000  0.0000  0.0087 
40-45 0.0172  0.0172  0.0173 
45-50 0.0063  0.0063  0.0179 
50-55 0.0329  0.0329  0.0231 
55-60 0.0523  0.0523  0.0351 
60-65 0.0696  0.0696  0.0829 
65-70 0.1350  0.1350  0.1345 
70-75 0.1193  0.1193  0.1496 
75-80  0.1663 0.1663 0.1580 
80-85 0.1971  0.1971  0.1749 
85-90 0.1036  0.1036  0.1201 
90-95 0.0757  0.0757  0.0740 
95-100 0.0161  0.0161  0.0039 
(TIA mimic assumed as for TIA.) 
 
The adjustment of the formula for predicting sex, taking into account general 
population characteristics, is shown below: 
 
Patient is male with probability p depending on age group j (j = 4, …, 19), where 
  ,
1
log j
p
p
β α + = ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
−
 
and the parameters α and β are given in the following table: 
 
Parameter value 
α  1.439 
β -0.119 
 
b. Blood pressure 
Blood pressure data for systolic blood pressure is drawn from a normal distribution 
dependent on patient type as shown below. It is rounded to the nearest mmHg. For 
the purposes of the model, raised blood pressure is taken to be a systolic blood 
pressure of over 140mmHg (as per ABCD2 score).  
 
Patient type  Mean  S.D.  Source 
TIA mimic  140  30  Assumption 
Genuine TIA  153.8  29.9  OXVASC data 
Stroke 155.4  26.3  OXVASC data 
 
c. Clinical symptoms score 
This variable can take values 0=neither weakness nor speech disturbance, 
1=speech disturbance without weakness, 2=any weakness. It is strictly only 
relevant for prognosis in the case of genuine TIAs. For programming convenience, 
it is set to value 0 for TIA mimics, and to value 2 for strokes. For genuine TIAs, C 
score is sampled from an age-dependent distribution. The probability  i p  of a C 
score of at most i (i = 0, 1) for a patient in age group j (j = 4, …, 19) is given by ©NCCSDO 2008  Page 16 
  ,
1
log j
p
p
i
i
i β α + = ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
−
 
where the parameters  i α  and β were found by ordinal logistic regression from the 
OXVASC dataset, using only the TIA data, as follows: 
Parameter Value 
0 α   0.336 
1 α   1.278 
β -0.082 
 
d. Duration of symptoms score 
This variable can take values 0=0-9 mins, 1=10-59 mins, 2=60 mins or more. It is 
strictly only relevant for prognosis in the case of genuine TIAs. For programming 
convenience, it is set to value 0 for TIA mimics, and to value 2 for strokes. For 
genuine TIAs, D score is sampled from an age-dependent distribution. The 
probability  i p  of a D score of at most i (i = 0, 1) for a patient in age group j (j = 4, 
…, 19) is given by 
  ,
1
log j
p
p
i
i
i β α + = ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
−
 
where the parameters  i α  and β were found by ordinal logistic regression from the 
OXVASC dataset, which only contained data on this parameter for TIA patients, as 
follows: 
Parameter Value 
0 α   -0.407 
1 α   1.330 
β -0.093 
 
e. Total Cholesterol 
This is sampled from a normal distribution with mean 5.34 and standard deviation 
1.24 (OXVASC data). 
 
f. Atrial Fibrillation status 
This variable can take values 0=no AF, 1=undiagnosed AF, 2=diagnosed AF. The 
OXVASC dataset contained information about AF status and whether on warfarin 
pre-event. Patients without AF were coded 0, although a small number of these 
were on warfarin. Those with AF were coded 1 or 2 according to warfarin status. 
The probability  i p  of a score of at most i (i = 0, 1) for a patient in age group j (j = 
4, …, 19) is given by the formula: 
  ,
1
log j
p
p
i
i
i β α + = ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
−
 
where the parameters  i α  and β were found by ordinal logistic regression from the 
OXVASC dataset (interpreted as described above) as follows: 
 
 
Parameter Value 
0 α   4.894 
1 α   6.383 
β -0.226 
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g. Diabetes 
Diabetes is set with probability p depending on age group j (j = 4, …, 19), where 
  ,
1
log j
p
p
β α + = ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
−
 
and the parameters α and β are given in the following table (OXVASC data): 
 
Parameter Value 
α  -0.460 
β -0.116 
 
h. Antiplatelet therapy pre-event 
The patient is already on antiplatelet therapy with probability p depending on age 
group j (j = 4, …, 19), where 
  ,
1
log j
p
p
β α + = ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
−
 
and the parameters α and β are given in the following table (OXVASC data): 
 
Parameter Value 
α  -2.591 
β 0.162 
 
i. Statin pre-event 
The patient is already on statin with probability p depending on cholesterol level x, 
where 
  ,
1
log x
p
p
β α + = ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
−
 
and the parameters α and β are given in the following table (OXVASC data): 
 
Parameter Value 
α  0.793 
β -0.373 
Note that patients with higher cholesterol are less likely to be on statin pre-event. 
 
j. Suitability for Carotid Endarterectomy 
OXVASC data was used to determine suitability for assessment for carotid 
endarterectomy. The presence of an entry for symptomatic stenosis was taken as 
indicating suitability for investigation. This applied only to patients for whom the 
territory was given as carotid, and not to all such patients: in other words, the 
absence of an entry for symptomatic stenosis in patients where the territory was 
carotid was taken as implying a contraindication for carotid endarterectomy. For 
the base case, it was assumed that only those with symptomatic stenosis from 70 
to 99 percent are suitable for carotid endarterectomy. 
 
Based on OXVASC data, the probability that a patient is suitable for assessment is 
0.611, while the probability that the patient is suitable for carotid endarterectomy 
is set to 0.041. If the category from 50 to 69 percent is also included, then the 
probability that a patient is suitable for carotid endarterectomy increases to 0.070. 
These probabilities are not correlated with any other patient characteristic. 
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3.1.2 Data inputs from published Oxvasc analyses and how they 
were incorporated into the model 
 
3.1.2.1 Incidence of TIA and minor stroke, and ‘TIA mimic’ 
The incidence of TIA comes from the OXVASC data. Published incidence of TIA from 
OXVASC was 0.6 per 1,000 standardised to the England & Wales population. 
(Rothwell, 2004a) Analysis of further data from OXVASC (unpublished – provided 
for this study) suggests incidence 0.7 per 1,000.  
 
The incidence of minor stroke used for the model (a stroke that does not lead to 
significant disability or lead to hospital admission) is difficult to derive from the 
literature. In OXVASC, the incidence of minor stroke (defined as a Rankin score of 
0-1 at 30 days) was found to be 0.55 per 1,000. We have assumed that 
approximately half (45%) of these minor stroke events will have resulted in 
hospital admission. This gives a total ratio of genuine cerebrovascular events (TIA 
and minor stroke) to non-cerebrovascular events of 1:1, which fits with our review 
of the literature that found that approximately half of patients referred by a GP to 
specialist neurovascular clinic with a query TIA/ minor stroke have actually had a 
cerebrovascular event (see section on accuracy of GP diagnosis of TIA below).  
 
The incidence of TIA mimic (i.e people presenting with possible cerebrovascular 
symptoms whose final diagnosis is non-cerebrovascular) is given above – in section 
3.1.1.1  
 
The age and sex specific incidences of these events is shown in the table below: 
 
 
Table 3.5 Incidence of TIA mimic, genuine TIA, minor and major stroke 
(per 1,000 patients per year) 
A.Observed incidence of stroke events – males 
 
Age group  TIA mimic Genuine  TIA  Minor Stroke  Major Stroke 
< 35  0.01  0.01  0.00  0.00 
35 – 44  0.22  0.22  0.27  0.00 
45 – 54  0.33  0.33  0.38  0.35 
55 – 64  1.14  1.14  1.40  0.37 
65 – 74  3.39  3.39  5.03  1.43 
75 – 84  6.71  6.71  7.92  1.50 
≥ 85  10.32  10.32  14.29  5.44 
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B. Observed incidence of stroke events – females 
Age group  TIA mimic Genuine  TIA  Minor Stroke  Major Stroke 
< 35  0.03  0.03  0.00  0.00 
35 - 44  0.05  0.05  0.16  0.00 
45 - 54  0.42  0.42  0.42  0.12 
55 - 64  1.40  1.40  1.12  0.63 
65 - 74  3.97  3.97  3.50  0.58 
75 - 84  8.67  8.67  6.76  3.75 
≥ 85  12.66  12.66  11.60  3.47 
 
 
In order to achieve these incidences of the different diagnoses, the mean time 
between successive arrivals of a given patient type were set as follows: 
 
Event  Mean time between arrivals (hours) 
TIA mimic  17.6 
Genuine TIA  25.1 
Minor stroke  58.7 
 
Summary: 
The population size is set at 500,000, with 1,000 people presenting per annum with 
symptoms suggestive of a TIA or minor stroke. This comprises 35% genuine TIAs, 
15% minor strokes and 50% ‘TIA mimics’, and equates to an incidence of TIA of 
0.7 per 1,000, an incidence of minor stroke of 0.3 per 1,000 and an incidence of 
TIA mimic of 1 per 1,000.   
 
3.1.2.2 Initial patient action on getting symptoms of TIA 
 
There are two aspects of patient actions to consider for the model. The first is the 
choice between contacting A&E or GP and the second is the time from onset to the 
first contact with A&E or the GP. The aim here is to produce a reasonable 
representation of reality without overcomplicating the model. The relevant data 
source is the OXVASC data set, and important summary information is reported in 
Giles et al (2006). (Giles, 2006). 
 
Patient response is classified as emergency or non-emergency. Essentially, an 
emergency response is defined as one where the patient responds as soon as 
physically capable of so doing. 
 
Programming code was added to the model to reproduce the Giles et al study with 
the modelled patient group. The results of the model were compared to the findings 
of Giles et al and the parameters of the model adjusted as necessary. 
 
The baseline probability of an emergency response was taken according to ABCD 
score as follows: 
 
ABCD score  0 to 
3 
4  5  6 
P(Emergency)  0.3 0.5 0.55  0.6 
 
This was then increased by 0.1 on Monday and Tuesday and decreased by 0.1 on 
Friday and Saturday. An across the board increase of 0.2 was used when the 
enhanced use of 999 services option was applied.  
 
Only 20 percent of emergency responses involve a direct call to A&E. Others 
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symptomatic. This is interpreted as applying to all strokes, and to 30 percent of 
TIAs for which the symptom duration is over 60 minutes. 
 
The time taken to see an A&E doctor following onset of symptoms is based on an 
analysis of the Newcastle ambulance data set – see section 3.2 below. 
 
γ = 1.12; λ = 0.466, where γ and λ represent parameters of a Weibull distribution.  
 
In case of emergency contact with GP, the time to appointment is taken from the 
same distribution. This can be either a visit to the GP surgery or a GP home visit. 
 
Non-emergency contact with GP is taken to be available only between 9.30am and 
5.30pm on Monday to Friday. It is assumed that the earliest possible contact time 
for non-emergency contact is 5 hours after onset. First sampling the day on which 
contact is made, and then sampling the time for that day determine the actual 
contact time. 
 
For day of non-emergency GP contact, the basic rule is that if the earliest possible 
contact time is before 2.00pm on any day, then it is equally likely that contact will 
be made on any of three days including that day. If the earliest possible contact 
time is after 2.00pm on any day, then it is equally likely that contact will be made 
on any of the next three days. If application of this basic rule gives contact on a 
Saturday or Sunday, then contact is postponed to the following Monday. 
 
The time of day for non-emergency GP contact is sampled uniformly between 
9.30am and 5.30pm where possible. The only exception is for same day contact 
when the earliest possible contact time is between 9.30am and 2.00pm. In that 
case the time is sampled uniformly between the earliest possible contact time and 
5.30pm. 
 
The following table gives some examples of the application of this rule: 
 
Table 3.6: Illustrations of how patient initial contact with GP was built into 
the model 
 
Earliest possible contact time  Actual contact time 
4.00pm Tuesday  Equal probability of Wednesday, 
Thursday, or Friday of that week. Time 
sampled uniformly between 9.30am 
and 5.30pm. 
11.00am Friday  One-third probability between 11.00am 
and 5.30pm that Friday. Two-thirds 
probability between 9.30am and 
5.30pm following Monday. 
11.00am Saturday  Uniformly between 9.30am and 5.30pm 
the following Monday. 
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3.2 Newcastle Rapid Ambulance Protocol Study  
 
In Newcastle, in collaboration with the ambulance service, a database has been 
maintained to monitor what happens to suspected stroke patients who are brought 
to hospital under a rapid ambulance protocol. While the purpose of the rapid 
ambulance protocol is to fast track care for patients with acute stroke who might 
benefit from thrombolysis, a proportion of patients also went through the service 
that had non-cerebrovascular diagnoses and also TIA. It is the data on these latter 
groups of patients that are relevant to the generation of our model, since this gives 
us plausible data on how long it takes patients to be seen by a doctor if they use 
the ‘999’ route which is one of the pathways being explored in the model. The data 
set has already been used to explore the accuracy of the Face Arm Speech Test 
(FAST), the stroke recognition instrument, by paramedics in the scene as compared 
to stroke physicians after admission. (Nor, 2004) 
 
In addition to data on patients who attended A&E following a 999 call, the database 
also includes information on patients who attended A&E either as self-referrals, or 
referred by their GP.  
 
For each patient, the computerised database captures time delay between 
paramedic and specialist stroke physician assessment as well as time between this 
set of initial set of assessments and formal admission. In addition, stroke subtypes 
by Oxford Community Stroke Project (OCSP) classifications were recorded. For 
patients with suspected stroke but who ultimately received a non-stroke diagnosis 
the diagnosis was specified.  
 
3.2.1. What is the final diagnosis of patients sent to A&E with 
suspected stroke? 
 
The mean age of this population was 71, with 47% male. 193 (11%) of the 1790 
patients in the data set had a TIA, 945 (53%) had a stroke, 32 (2%) a sub-
arachnoid haemorrhage. The remaining 620 patients had a non-cerebrovascular 
diagnosis, of which the commonest were sepsis, seizure and syncope. These are 
illustrated in figure 3.1 
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Figure 3.1 Non-stroke diagnoses 
Non stroke diagnosis by frequency (n=668)
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3.2.2 How long does it take people to get to hospital? 
 
This was measured in two ways – the time lapse between being assessed by a 
paramedic and having a diagnosis made by a physician, and the time lapse 
between being assessed by a paramedic and getting to hospital.  
 
Time delay between paramedic assessment and stroke diagnosis by a physician 
For all diagnoses, the median time delay (n=1610) from the data was [IQR] 3.35 
hours [1.15-10.72] – see figure 3.2. 
 
Figure 3.2 Time delay to seeing physician by diagnosis 
Median time from Paramedic 
assessment to Physician assessment
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Stroke - TACS: total anterior circulation infarction 
Stroke - PACS: partial anterior circulation infarction 
Stroke - LCI: lacunar circulation infarction 
Stroke – PCI: posterior circulation infarction 
TIA – Transient ischaemic attack 
SAH – Sub-arachnoid haemorrhage 
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Time delay between paramedic assessment and admission to hospital 
For all diagnoses the median [IQR] time delay was 0.44 [0.17-0.99] hours 
(n=1587).   
 
Time delay from onset of symptoms to admission 
For all diagnoses the median [IQR] time delay was 6.72 [1.52-19.23] hours 
(n=1587).   
 
 
Figure 3.3 Time delay from onset of symptoms to admission 
Median time from onset of symptoms by diagnosis
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Calculation for the model 
From the Newcastle dataset, a formula was derived to approximate the time taken 
to see an A&E doctor for the model for patients who dialled 999:  
 
γ = 1.12; λ = 0.466, where γ and λ represent parameters of a Weibull distribution.  
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3.3 Analysis of the QRESEARCH database 
 
The purpose of this analysis was to provide data from a large representative GP 
database as to what secondary prevention medications people are put on following 
a TIA under current practice and the average time delay before treatment is 
initiated.  
 
3.3.1 Data on current practice from other sources 
 
Rothwell and colleagues in Oxford found that premorbid blood pressure prior to an 
incident TIA (2002-4) was 147/80 mmHg with cholesterol of 5.6 mmol/l. (Rothwell, 
2004a). Premorbid preventative medication included 38% receiving an antiplatelet 
agent, 46% were taking an antihypertensive and 22% a lipid-lowering drug.  These 
data were gathered from a small cohort of less than 100 individuals suffering a TIA 
in the study period.  Previous studies have shown that secondary prevention 
following TIA is sub optimal in terms of both blood pressure and lipid control as well 
as prescribed medication.  Work using a GPRD cohort from 1992-6 showed that anti 
platelet medication was prescribed to between 30-45% of people following TIA. 
(Gibbs, 2001). 
  
The National Sentinel Audit for Stroke currently only includes people admitted to or 
seen in hospital with Stroke or TIA. (Rudd, 2004).   In 2001, of 7,884 patients 
whose pre-admission medication was known, 46% (3,666) were taking an anti-
thrombotic drug. Anti-thrombotic therapy was given by the time of discharge in 
91% (4,583/5,020) of applicable patients.  By 2006, 100% of eligible patients were 
receiving antithrombotic therapy at discharge. (Rudd, 2004). 
 
Data from Ontario describing post TIA management in an emergency room setting 
found that although 45% of people with TIA received neuro imaging, only 63% 
were prescribed antithrombotic medication before discharge. (Gladstone, 2004). A 
primary care based study from North Carolina found that primary care physicians 
changed (added to or started) antiplatelet medication in 47% of people presenting 
with TIA on the day of presentation. (Goldstein, 1995). 
 
This study examines both process measures (risk lowering management) and 
outcome measures (risk factor control) before and up to a year after an index TIA 
in UK General Practices contributing to the QRESEARCH database.  The results from 
these data inform the model with regard to baseline GP performance. 
 
 
3.3.2 Methods 
 
Data regarding demographic details, cerebrovascular risk factors and prescribed 
medication were extracted from the anonymised primary care records of people 
who were coded as suffering a first transient ischaemic attack between 1.4.2004 
and 30.3.2005 in the disease registers of 463 practices contributing to the 
QRESEARCH database (see page 35 for list of Read Codes used). Eligible patients 
were registered at least 3 months before the date of their first TIA and had no 
evidence of a prior TIA or stroke before that date.   
 
Eligible practices had used the EMIS clinical computer system at least six months 
before 1/4/2003. The last upload of data from the practice to QRESEARCH had to 
be later than 30/4/2006.  QRESEARCH (www.qresearch.org) is a joint venture 
between Nottingham University and EMIS, a GP software supplier, which consists of 
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registered with participating practices from which datasets such as the one used in 
this study can be extracted.   
 
Cases were followed up within the dataset from the date of their incident TIA until 
the first of the following occurred: patient has non-fatal stroke; patient dies; 
patient leaves practice; or TIA index date plus 12 months. 
 
Outcome definitions: mortality and morbidity  
Death: The patient is recorded (in the date-of-death field) as having died within 
one year of the TIA.  
 
Non-fatal stroke: The patient has a first-ever Read-coded mention of stroke within 
one year of the TIA. Additionally, they must still have been alive one month after 
the stroke, and only the first such stroke was counted in each case.
  
 
Analysis 
Analysis was performed using STATA 9 SE (Statacorp).  Patients were censored at 
the time of deregistration (if before the end of the study) or at the end of the study 
period.  Blood pressure control, cholesterol level and preventive medication 
prescription were evaluated in the 12 months before and after the index TIA.  
Paired comparisons of normally distributed data were made using paired t tests and 
paired comparisons of proportions were made using McNemar’s test.  In view of 
multiple testing a p value of <0.01 was chosen for significance. 
 
A Kaplan-Meier analysis was used to estimate mortality and non-fatal stroke in the 
year following index TIA.   
 
3.3.3 Results 
 
3405 individuals suffered an index (first) TIA during the study of whom 3366 
(99%) were alive one month after their index TIA and 3042 (89%) were still alive 
after one year (see table 3.7).  At the time of the TIA, mean age was just over 72 
and 56% were women.  Mean age for women suffering a TIA was 73.6 compared to 
70.9 for men. 
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Table 3.7. baseline and follow up raw data 
  1 month Pre TIA  1 month Post 
TIA 
12 months Post 
TIA 
Population at Risk (n)  3405  3366  3042 
Mean Age (SD)  72.4 (13.4)  72.3 (13.4)  71.7 (13.1) 
Sex (%Male)   44.3%  44.2%  44.4% 
Number (%) with BP 
measurement in last 12 
months* 
2677 (79%)  N (93%)  2885 (95%) 
Number (%) with 
cholesterol measurement 
in last 12 months* 
1497 (44%)  N 1145(63%)  2419 N (80%) 
Number (%) receiving 
Antiplatelet or 
anticoagulants 
1312 (38%)  2454 (72%)  2430 (79%) 
Number (%) receiving 
Lipid Lowering Therapy  
612 (17%)  1255 (37%)  1290 (42%) 
Number (%) receiving 
Antihypertensive 
Medication  
1340 (39%)  1635 (48%)  1534 (50%) 
Number (%) receiving 
combination of 
antiplatelet/anticoagulants, 
statin, Anti HT Rx 
370 (10%)  742 (22%)  879 (28%) 
* Any individual with a reading in the previous 12 months 
 
3.3.3.1 Risk Factors 
 
Three thousand and forty two individuals were still present in the data set (ie had 
survived and not moved away from the contributing practices) one year after TIA.  
The systolic and diastolic blood pressure were evaluated in the 2297 (75%) 
individuals alive after 1 year with a result both before and after their TIA.  
Similarly, the total cholesterol was evaluated in the 1110 (36%) individuals alive 
after 1 year who had a result both before and after their TIA.   
 
Blood Pressure  
In the year prior to TIA, the majority (79%) of individuals had a blood pressure 
measurement recorded with a mean of 144/80mmHg for the last reading and 39% 
were receiving blood pressure lowering medication.  One month following TIA, most 
(93%) had had a blood pressure check in the last year, which was sustained one 
year following TIA (95%). When only those individuals with both a blood pressure 
recorded in the year before and after TIA were included (=2297/3042 (82%) alive 
at one year), mean blood pressure fell from 145/80mmHg to 139/77mmHg, t >12, 
p<0.0001. (Table 3.8).  The proportion with a last blood pressure in the previous 
year equal to or below 150/90 mmHg improved from 68% to 79% (X
2 =100, 
p<0.0001) and similarly for a target of 140/90 mmHg the proportion improved 
from 48% to 60% (X
2 = 79, p<0.0001). 
Cholesterol 
In the year before TIA, 44% of individuals had total cholesterol measurement 
recorded in the previous year.  This rose to 63% one month after TIA and 80% one 
year after TIA.  When only those individuals with both a total cholesterol recorded 
in the year before and after TIA were included (=1164/3042 (38%) alive at one ©NCCSDO 2008  Page 28 
year), mean total cholesterol fell from 5.3 mmol/l to 4.5 mmol/l, t = 18.3, 
p<0.0001 (table 3.8).  The proportion at or below a target total cholesterol of 5 
mmol/l improved from 44.3% to 76% (X
2 = 279, p<0.0001). 
 
Table 3.8: Paired blood pressure and cholesterol readings before and after 
TIA** 
 
 1  month  Pre 
TIA 
12 months 
Post TIA 
difference  t  p  
SBP* 
N=2297 
145.3 
(144.4, 
146.1) 
139.1 
(138.4, 
139.9) 
-6.1 (-
7.0, -5.2) 
12.8  <0.0001 
DBP* 80.1  79.7, 
80.6) 
77.0 (76.5, 
77.4) 
-3.2 (-
3.7, -2.6) 
12.12  <0.0001 
Target 
150/90 
 
1321 (67.6)  1823 (79.4)    X
2 = 
100.2 
<0.0001 
Target 
140/90 
 
1103 (48.0)  1368 (59.6)    X
2 = 79.2  <0.0001 
Total 
Cholesterol* 
N=1110 
5.33 (5.24, 
5.42) 
4.53 (4.46, 
4.59) 
0.80 
(0.72, 
0.89) 
-18.3 <0.0001 
Target 5 
mmol/l 
 
492 (44.3)  844 (76.0)   -  X
2 = 279  <0.0001 
*Mean (95% CI)   
** In each case, only individuals alive at 1 year with the relevant reading in 
both the year before and year after TIA are included. 
3.3.2 Risk factor Management 
 
Data are presented here for those people alive one year after suffering a TIA in 
order to allow comparison of prescribing both before and after the event.  Baseline 
data are similar for the whole cohort compared to those alive at one year: for 
example baseline prescription of an antithrombotic or patient noted to be taking 
over the counter (OTC) aspirin was 1312/3405 (39%) of all those alive one month 
before TIA, compared to 1170/3042 (39%) when just those alive one year post TIA 
are considered. 
Antithrombotic medication 
Of those alive 12 months post TIA, prescription of antithrombotic medication or 
record of OTC aspirin was 1170/3042 (39%) before TIA compared to 2333/3042 
(77%), X
2=1005, p<0.0001
 after TIA.
 (table 3.9) 
Antiplatelet medication 
Aspirin alone was prescribed or noted to be taken OTC by 956/3042 (31%) pre TIA 
and 55% post.  Aspirin and dipyridamole were prescribed pre TIA to 26/3042 
(0.9%) vs 187/3042 (6%) post TIA. Similarly clopidogrel prescription increased 
from 41/3042 (1%) to 177/3042 (6%).  In each case these differences were all 
highly statistically significant (table 3.9).  Smaller but still statistically significant 
increases in prescription were see in dipyridamole alone and Antiplatelet PLUS 
warfarin. (All table 3.9) ©NCCSDO 2008  Page 29 
Anticoagulant medication 
Prescription of warfarin alone increased from 87/3042 (3%) to 156/3042 (5%), X
2 
= 44, p<0.0001. (table 3.9) 
 
Table 3.9: Anti platelet / anticoagulant paired data 
 1  month 
Pre TIA 
(N=3042) 
12 
months 
Post TIA 
(N=3042) 
Χ
2**
 
df=1 in 
each 
case 
p 
Aspirin OR other antiplat. OR 
warfarin 
1170 
(39) 
2333 
(77) 
1005  <0.0001 
Aspirin alone  956 (31)  1680 
(55) 
422  <0.0001 
Aspirin AND dipyridamole   26 (0.9)  187 (6)  142  <0.0001 
Dipyridamole alone  18 (0.6)  41(1)  12  0.0008 
Clopidogrel alone  41 (1)  177 (6)  116  <0.0001 
Aspirin/other antiplat. AND  
warfarin  
17 (0.6)  71 (2)  47  <0.0001 
Warfarin alone  87 (3)  156 (5)  44  <0.0001 
         
*n(%)     ** McNemar’s test 
 
Antihypertensive medication 
Immediately before diagnosis of TIA, of the 50% of individuals with a last BP 
reading above 140 mmHg, 2/3 were not prescribed anti hypertensive medication.  
For a threshold of 160 mmHg, 18% had a last reading above this and 8% of all 
patients had a last blood pressure reading above 160 mmHg and no medication 
prescribed.  After TIA, 39% of individuals had a last recorded BP reading of over 
140 mmHg, of whom 56% were not prescribed blood pressure lowering medication 
(table 3.10). 
 
Considering those alive after one year, the proportion of individuals prescribed any 
antihypertensive 1 month pre TIA was 1203/3042 (40%) compared with 
1525/3042 (50%) twelve months later (table 3.8).  After TIA, there were increases 
in the proportion of people prescribed one, two and three antihypertensives and the 
median number of antihypertensives increased from 0 (IQR 0,4) to 1 (0, 5), 
p<0.0001.   
 
One month prior to TIA, 39% of women were prescribed an antihypertensive as 
were 40% of men.  One year following TIA, 50% of women and 50% of men were 
receiving antihypertensive mediation. 
By Class 
There were large increases in the proportion prescribed ACE inhibitors and thiazide 
diuretics (absolute increases of 7% and 5% respectively) with smaller increases in 
Calcium Channel Blockers, Angiotensin Receptor Blockers and Beta Blockers.  Little 
change was seen in the prescription of alpha blockers following TIA. 
 
Table 3.10: Use of anti-hypertensives in before and after TIA 
 1  month 
Pre TIA* 
(N=3042) 
12 
months 
Post TIA* 
(N=3042) 
Χ
2**
 
df=1 in 
each 
case 
p 
Any  antihypertensive  1203 1525 128  <0.0001 ©NCCSDO 2008  Page 30 
(40)  (50%) 
Number of antihypertensives n 
(%) 
       
0   1,839 
(60) 
1,517 
(50) 
   
1 658  (22)  799 (26)     
2 381  (13)  502 (17)     
3 133  (4)  188 (6)     
4 29  (1)  31 (1)     
5 2  5     
Median number of 
antihypertensives 
0 (0, 4)  1 (0,5)  -12.3***  <0.0001 
ACEI 461  (15)  674 (22)  89  <0.0001 
ARB 152  (5)  221 (7)  29  <0.0001 
Thiazide 391  (13)  537 (18)  50  <0.0001 
Calcium-channel  blockers 367  (12)  459 (15)  25  <0.0001 
Beta-blockers 483  (16)  528 (18)  5.6  0.018 
Alpha blocker  91 (3)  97 (3)  0.4  0.59 
*n(%)     ** McNemar’s test    ***Wilcoxan Rank  
 
Lipid Lowering medication 
Lipid lowering prescription (both statins and fibrates) increased from 565/3042 
(19%) pre TIA to 1280/3042 (42%) post TIA, the vast majority of which reflects 
increased statin prescription.  Of those receiving a statin pre TIA who had a total 
cholesterol recorded in the previous year, 320/487 (66%) had a cholesterol below 5 
mmol/l.  Following TIA, of those with a cholesterol in the last year who were 
prescribed a statin, 928/1143 (81%) had a cholesterol below 5mmol/l.  Of those 
people not prescribed a statin who had a cholesterol recorded, before suffering a TIA, 
345/1010 (34%) had a cholesterol below 5 compared with 715/1262 (57%) following 
TIA.   
The proportion of people receiving a statin at each level of last recorded statin 
increased following TIA compare to before (Figures 3.4 and 3.5). 
 
One month before TIA 16% of women and 19% of men were prescribed a statin.  
One year after TIA, 690/1865 (41%) of women and 574/1357 (42%) of men were 
prescribed a statin.  
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Figure 3.4: Recorded Total Cholesterol by Statin Prescription Pre TIA 
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Figure 3.5: Recorded Total Cholesterol by Statin Prescription Post TIA 
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By Class 
Following TIA, simvastatin prescription increased threefold and atorvatastatin 
prescription doubled with much smaller changes in other statins.  The prescription 
of statins was correlated with cholesterol at 1 year with 65% of those with a total 
cholesterol below 3mmol/l prescribed a statin compared to only 25% of those with 
a cholesterol over 6 mmol/l (table 3.11). 
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Table 3.11: Use of lipid lowering therapy before and after TIA 
 1  month 
Pre TIA* 
(N=3042) 
12 
months 
Post TIA* 
(N=3042) 
Χ
2**
 
df=1 in 
each 
case 
p 
Statin / fibrate  565 (19)  1280 
(42) 
494  <0.0001 
Statin 552  (18)  1264 
(42) 
489  <0.0001 
Fibrate 16  (0.5)  19 (0.6)  0.5  0.6 
Simvastatin 344  (11)  1017 
(33) 
541  <0.0001 
Atorvastatin 234  (8)  472 (16)  161  <0.0001 
Pravastatin 41  (1)  61 (2)  8  0.005 
Fluvastatin 21  (0.7)  17 (0.6)  1.1  0.4 
Rosuvastatin 19  (0.6)  33 (1)  7  0.013 
*n(%)     ** McNemar’s test 
 
3.3.3 Survival Curves 
 
Kaplein – Meier Survival curves were calculated for both death and non fatal stroke 
post TIA (figures 3.6 & 3.7).  220 (6.5%) people died in the first 12 months 
following TIA.  One year after TIA, 3042 (89%) of individuals were still alive and 
registered.  In terms of non fatal stroke, incidence was highest in the 1 month 
following TIA consisting of 306/493 (62%) of all non fatal strokes with a further 
187 (38%) in the subsequent 11 months. 
 
Figure 3.6: Survival (months) following TIA 
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Figure 3.7: Non fatal stroke following TIA 
 
 
 
3.3.4 Incorporating the QRESEARCH results into the model 
 
Table 3.12 Parameters defining standard GP treatment (derived from 
QRESEARCH analysis) 
 
Parameter Value 
Probability of referral for CE assessment if suitable  0.15 
Probability of antiplatelet monotherapy  0.324 
Probability of antiplatelet dual  0.089 
Probability of cholesterol test  0.226 
Probability of immediate BP/AF  0.59 
Probability of delayed BP/AF  0.381 
Minimum time to delayed BP/AF  7 days 
Mean time to delayed BP/AF  123 days 
 
For antiplatelet therapy, QRESEARCH data shows 65.5 percent on aspirin including 
8.9 percent on dual treatment. In the starting population, 44.0 percent are on 
antiplatelet. After 8.9 percent of the population have been put on to dual therapy, 
40.1 percent remain on monotherapy, with 51.0 percent on no therapy. To produce 
a total of 65.5 percent on aspirin, we must switch 16.5 percent of the population 
from no therapy to monotherapy. Thus the probability of being switched to 
monotherapy is 16.5/51.0 = 0.324. 
 
For statin therapy, QRESEARCH data shows 40.4 percent on statin. In the starting 
population, 24.2 percent are already on statin and a further 71.8 percent are not 
on statin but have cholesterol over 3.5. To reach a target of 40.4 percent on statin, 
the proportion needed to convert is 18.0/71.8 = 0.226. 
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For time to blood pressure assessment, the proportion with missing BP over time 
was fitted to a curve of the form  .
t Be A
λ − +  The value of A gives the proportion 
never tested, B gives the proportion with a delayed test and so  B A− − 1  gives the 
proportion tested immediately. The reciprocal of λ  is the mean time to testing in 
the case of a delayed test. The minimum time to testing is an assumption. It was 
assumed that AF testing would be at the same time as blood pressure. 
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3.4 Patient survey 
 
In order to ascertain the costs incurred by patients who have a TIA, and to identify 
patient preferences with regard to patterns of service delivery, a questionnaire 
survey was developed. Development was done in conjunction with a patient advisory 
group and was piloted on patients participating in the OXVASC study. The finalised 
questionnaire was then sent to patients from selected practices in the West Midlands 
and Hertfordshire.  
 
West Midlands Multi-centred Research Ethics Committee (MREC) approval (MREC Ref: 
06/MREC07/69) and Trust permission from the South Birmingham PCT Consortium 
and Hertfordshire PCT consortium were obtained for the questionnaire study. 
 
3.4.1 Patient survey methods 
Patient Advisory Group 
A Patient Advisory Group (PAG) was established to advise on the content and 
structure of the questionnaire. Patients registered with a West Midlands practice 
and who had had a TIA were sent a letter inviting them to participate in the PAG. 
Those who expressed an interest were invited to attend a meeting at their surgery. 
The PAG comprised seven patients.  
 
During the meeting the patients were asked to complete the draft questionnaire 
and then feedback their thoughts on both the structure and content. To ensure all 
possible courses of action were included in the questionnaire, patients also 
discussed what they did when they had their TIA. Comments, suggestions and 
feedback were incorporated into the survey. This was then sent to the PAG 
members who completed and returned the questionnaire to us with any further 
comments and/or suggestions. No further amendments were necessary at this 
point. 
 
The PAG was also asked to comment on the information sheet and the covering 
letter that would accompany the questionnaire. All PAG members felt that these 
were clear, easily understood and contained all the information that people would 
need to enable them to decide whether or not to complete the questionnaire. 
Therefore, no changes were made to these in light of PAG feedback. 
The Questionnaire 
The questionnaire was split into four main areas: information about the patient; 
information about their TIA; questions about the type of service they would prefer; 
details about what they did and what costs they incurred when they had their TIA. 
It was sent together with the information sheet, covering letter from the patient’s 
GP and a pre-paid envelope.  
Pilot Questionnaire Distribution 
The questionnaire was piloted on patients identified as having a recent TIA through 
the OXVASC study, with the aim of identifying any areas in the survey that were 
inconsistently or incorrectly completed. The questionnaire was distributed to 
patients 6 months post event. Approximately 25 OXVASC patients were sent a 
questionnaire. 
Main Questionnaire Distribution 
Practices in the South Birmingham Primary Care Trust and Hertfordshire Primary 
Care Trust consortiums were invited to participate in the questionnaire survey 
study.  ©NCCSDO 2008  Page 36 
 
Those practices agreeing to take part were asked to run a report on their clinical 
computer system to identify all patients who had been diagnosed as having a TIA in 
the preceding 12 months. The practice would then screen the list to ensure that 
any person where it would be inappropriate to send a questionnaire was excluded 
(for example: recently deceased; diagnosed with a terminal illness). Anonymised 
patient details (date of birth; gender; postcode; practice computer number) were 
sent to the study office at the University of Birmingham. Packs comprising a 
questionnaire, introductory letter, information sheet and prepaid envelope were 
then sent to the practices, who distributed the questionnaire to their patients. 
Completed questionnaires were returned to Birmingham University. A reminder was 
sent to all non-responders after one month. 
Analysis 
Analysis was carried out using SPSS software (v14.0). All analysis was done on the 
104 patients who returned a completed questionnaire unless otherwise stated. P 
values have only been given where results were statistically significant. Missing 
data accounts for any proportions that do not total 100%. 
 
3.4.2 Main questionnaire Results 
Practices 
19 practices in the West Midlands and Hertfordshire areas agreed to participate in 
the questionnaire survey study. Practices represent a range of characteristics, with 
single-handed practices right through to practices with 16 GPs participating. 
Practices were also a mix of urban/rural, and all levels of socio-economic status 
were included. (Socio-economic status was derived from the Index of Multiple 
Deprivation).   
 
A total of 186 patients were identified as having had a TIA and were sent a 
questionnaire. There was a wide variation between practices in the number of 
eligible patients: the average per practice was 9.8 (range 2-22). Patient mean age 
was 78.8 years (range 35.5-100.2).  
 
114 (61%) patients returned a questionnaire. However, 10 (5%) of patients 
returned a blank questionnaire: these were classed as non-responders for the 
analysis. 104 (56%) surveys were completed and returned. 
Responders and Non-Responders 
There were few significant differences between responders and non-responders. 
Patients from bigger practices were more likely to return a questionnaire, although 
there was no clear linear association, as patients from the largest practices (those 
with 9 or more GPs) were less likely to respond. The mean age of responders was 
74.5 years (range 43.6-100.2), while non-responders were slightly older, with a 
mean age of 75.3 (range 35.5-97.1): this difference was not statistically significant. 
There was no difference in the response rates between men and women, or 
between the different practice socio-economic levels (see table 3.13).  
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Table 3.13: Characteristics of responders versus non-responders 
Characteristic    Responders 
n (%) 
P Value* 
Size of practice (no. of GPs)  1-4  37 (51%)   
  5-6  28 (62%)   
  7-8  22 (79%)   
  9+  17 (43%)  0.013 
Practice Index of Multiple 
Deprivation (quartile) 
 
1 (least deprived) 
 
31 (61%) 
 
  2  41 (59%)   
  3  10 (38.5%)   
  4  22 (55%)   
       
Sex  M  54 (62%)   
  F  49 (62%)   
* p value only given if statistically significant 
Characteristics of Respondents 
The mean age of respondents was 74.5 years (range 43.6-100.2). A reasonable 
balance of proportions between men and women was found. The patient completed 
the majority of questionnaires themselves, although the patient’s carer returned a 
number. Very few patients were in paid employment: most patients were retired, 
although a few were unemployed or unable to work due to illness. 
 
There was also a reasonable balance of proportions across the practice 
characteristics, with all the different practice sizes and deprivation levels having 
patients who returned completed questionnaires. (See table 3.14) 
 
Table 3.14: Characteristics of Respondents 
Patient Characteristic    Number (%) 
Sex Male  54 (52) 
 Female  49(47) 
Who completed questionnaire  Patient  93 (89) 
 Carer  10 (10) 
In Paid employment  Yes  13 (12.5) 
 Retired  77 (74) 
 Unemployed/Sick  3  (3) 
  Caring for relative  6 (6) 
Practice Characteristic     
Size of practice (no. of GPs)  1-4  37 (36) 
 5-6  28 (27) 
 7-8  22 (21) 
 9+  17 (16) 
Index of Multiple Deprivation 
(quartile) 
1 (least deprived)  31 (30) 
  2  41 (39) 
  3  10 (10) 
  4  22 (21) 
 
Information about the TIA 
Patients were asked to indicate which day of the week that they had their TIA, and 
if they couldn’t remember, to state whether it was a weekday or a weekend (see 
figure 3.8). For analysis, patients were grouped into whether they had their TIA ©NCCSDO 2008  Page 38 
during the week or at the weekend (see table 3.15). Unsurprisingly, more people 
had their TIA during the week, although the proportion of people having their 
symptoms at the weekend was slightly higher than may be expected when taking 
the difference in number of days into account. 
 
Table 3.15: Day of TIA   
    
Day of TIA  Number 
(%) 
Weekday 64(61.5) 
Weekend 33  (32) 
Not known  3 (3) 
 
 
 
Figure 3.8: Number of Patients having TIA by Day of the Week 
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Patient Action at Time of TIA 
Patients were also asked what they did when they experienced their symptoms, 
and patients report a variety of responses (figure 3.9). Most people visited their 
GP, although many chose to go to their local accident and emergency department. 
Nearly a fifth of people did nothing initially, although all subsequently sought help.  
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Figure 3.9: Patient Action at Time of TIA 
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To look at whether people take different actions if they experience their symptoms 
at the weekend than they do if they are ill during the week, actions taken were 
grouped into: contacted GP (patients who visited their GP or requested a home 
visit); visited hospital (patients who visited A & E or dialled 999); or other (patients 
who contacted NHS Direct, saw an optician or went to a specialist eye hospital and 
patients who did nothing). Patients who had their TIA at the weekend were more 
likely to visit hospital than their GP. (See table 3.16)  
 
Table 3.16: Patient Action by Day of TIA 
Day of TIA  Action taken  Number (%)  p value 
Weekday Contacted  GP  26  (41)  0.025 
 Visited  hospital  17 (27)   
 Other  20  (32)   
Weekend Contacted  GP  6 (18)   
 Visited  hospital  17  (51.5)   
 Other  10  (30)   
 
It is also possible that the specific symptoms experienced influenced the action a 
patient took. The questionnaire asked patients to indicate what symptoms they 
suffered (see figure 3.10) ©NCCSDO 2008  Page 40 
 
Figure 3.10: Patient Reported Symptoms 
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The most commonly reported symptom was problems with speech, with 48% of 
responders having suffered this. Many people also reported dizziness, weakness 
and confusion, and some suffered loss of consciousness. Patients who reported 
having ‘other’ symptoms described headaches, vomiting and difficulty with food. 
However, the type of symptom experienced by a patient did not influence what 
course of action they decided to take, with the exception of temporary loss of 
consciousness, which made people more likely to call 999 or visit A & E (see table 
3.17). 
 
Table 3.17: Patient Action by Reported Symptom 
Symptom   Contacted  GP   
Number (%) 
Visited 
hospital 
Number (%) 
Other 
Number 
(%) 
p 
value* 
Difficulty speaking  Yes  15 (30)  18 (36)  17 (34)   
 No  18  (36)  18 (36)  14 (28)   
Weakness/numbness Yes  14  (35)  14 (35)  12 (30)   
 No  19  (32)  22 (37)  19 (32)   
Dizziness/giddiness Yes  15  (36)  19 (45)  9 (19)   
 No  18  (31)  17 (29)  23 (40)   
Confusion Yes  12  (27)  18 (41)  13 (32)   
 No  21  (37.5)  18 (32)  17 (30)   
Problem with eyesight  Yes  7 (25)  14 (50)  7 (25)   
 No  26  (36)  22 (31)  24 (33)   
Loss of consciousness  Yes  2 (12)  10 (59)  5 (29)  0.046 
 No  31  (37)  26 (31)  26 (31)   
Other Yes  3  (27)  4 (36)  4 (36)   
 No  30  (34)  32 (36)  27 (30)   
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Patients who initially did not seek medical attention about their symptoms all 
subsequently sought advice. The average time lapse between TIA and seeking 
medical attention for this group was 263 hours (11 days), although there was wide 
variation in the delay (range 1 hour – 84 days). Slightly more women than men 
took no immediate action (10 (56%) versus 8 (44%)) but this was not a significant 
difference. Type of symptom did not influence whether or not a patient would seek 
medical advice, including loss of consciousness (2 patients who suffered this did not 
seek assistance). Most patients who did nothing subsequently visited their GP, 
although one patient did visit a consultant one week post TIA. 
Patients who contacted a GP 
Patients who either visited a GP or had a home visit from a locum (n=33) were 
asked to give details about the outcome of that appointment. The most frequent 
outcome was referral to hospital outpatients, although a number of people were 
sent to A & E or admitted to hospital. In a number of cases, the GP managed the 
patient themselves, giving them further appointments and/or prescriptions. (See 
figure 3.11) 
 
Figure 3.11: Outcome of GP Appointment* 
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*Does not total 33 as outcomes are not mutually exclusive 
Patient Preference 
Patients were asked to tell us about what kind of TIA service they would prefer. 
They were asked to rank 3 options: treatment by GP; treatment at A&E; urgent 
referral to a specialist.  
 
The option of treatment by GP was ranked as the favourite option most often, with 
42 (40%) of patients choosing this type of service; urgent referral to a specialist 
was cited by the fewest patients as being their preferred method of service 
provision. However, treatment by a specialist was given as second choice by the 
highest number of people. (See table 3.18)  
 
Responses were allocated a score (1=favourite option; 2=second favourite option; 
3=least favourite option) and a mean score for each response was calculated. 
Treatment by GP was still the favoured option (mean 1.78, Standard Deviation ©NCCSDO 2008  Page 42 
(SD) 0.81); with hospital the second choice (mean 2.02, SD 0.85) and specialist 
treatment the least favoured option (mean 2.14, SD 0.76). 
 
Table 3.18: Patient Preference of Service Provision 
 GP   
Number (%) 
Hospital 
Number (%) 
Specialist 
Number (%) 
1
st Choice  42 (40)  29 (28)  19 (18) 
2
nd Choice  29 (28)  25 (24)  34 (33) 
3
rd Choice  22 (21)  31 (30)  31 (30 
Patient Costs 
To identify what costs were incurred by patients when they had their TIA, people 
were asked how they travelled to their GP or hospital and how much they paid in 
fares or parking fees. These costs relate only to the initial visit to health services 
after TIA, and does not include costs incurred by further appointments or referral 
elsewhere. Therefore, costs incurred by patients having multiple trips to surgeries 
or hospitals would be higher. 
 
Most patients travelled by car (57 (55%)) although 21 (20%) did go to hospital by 
ambulance. 8 (8%) people walked, and 6 (6%) went by public transport. The mean 
journey length (one way) was 4.65 miles (range 1-35), although that relates only 
to the 46 patients who provided an estimate of the distance. The mean cost in 
parking fees for those travelling by car was £1.43 (range £0 - £12.00). Only one 
patient who used public transport paid a fare (£5.50); other patients were 
presumably entitled to free use of public transport. The difference in mean costs for 
patients who visited their GP and those who went to hospital were tested; the 
mean for GP visits was £0.59 (SD 1.91) per visit, while the mean for a hospital visit 
was £1.63 (SD 3.1). 
 
3.4.3 Pilot data results 
 
No demographic data were collected about the OXVASC patients, as the aim of this 
phase of the study was to test the suitability of the questionnaire. Therefore, no 
response rate has been calculated and no description of the responder’s 
characteristics has been given. However, the analysis performed on the main 
questionnaire has been repeated on the pilot patients.  
 
18 people completed and returned a questionnaire. Seventeen questionnaires were 
completed by the patients themselves (for the remaining questionnaire it was not 
known who completed it). Six (33%) of people were in paid employment, while 10 
(56%) of patients stated that they were retired. The remaining 2 (11%) people 
were carers for a relative. 
 
Again, patients were asked to indicate which day of the week that they had their 
TIA. (See figure 3.12) When grouped into whether they had their TIA during the 
week or at the weekend it was found that 13 (72%) of patients had their TIA 
during the week, and 4 (22%) at the weekend (for 1 patient time of TIA is 
unknown). Unlike the results found in the main questionnaire, for this group of 
patients the proportion of patients having a TIA at the weekend was slightly lower 
than might be expected. 
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Figure 3.12: Number of Patients having TIA by Day of the Week – pilot 
data 
0
1
2
3
4
5
Mon
Tues
Wed
Thurs
Fri
Sat
Sun
Weekday
Day
N
o
.
 
P
a
t
i
e
n
t
s
     
 
When asked what they did when they experienced their symptoms, the results 
showed a similar pattern to that of the main questionnaire. Again, most people 
visited their GP or their local hospital, and 22% of patients took no immediate 
action. (See figure 3.12).  Patients who took ‘other’ action cited contacting NHS 
Direct or contacting a specialist eye hospital as the course of action followed. 
 
 
Figure 3.13: Patient Action at Time of TIA – pilot data 
0
1
2
3
4
5
6
Visit GP GP Home
Visit
A & E 999 Did nothing Other
Patient Action
N
o
.
 
P
a
t
i
e
n
t
s
 
 
Patients were again grouped into contacted GP, visited hospital, or other to 
determine whether or not day of the week influenced actions. A slightly different 
pattern was found than was found in the main questionnaire results, with a higher 
proportion of patients having a TIA at the weekend contacting their GP rather than 
going to hospital (see table 3.19). 
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Table 3.19: Patient Action by Day of TIA – pilot data 
Day of TIA  Action Taken  Number (%) 
Weekday Contacted  GP  3 (25) 
 Visited  Hospital  3 (25) 
 Other  6 (50) 
Weekend  Contacted GP  3 (75) 
 Visited  Hospital  1 (25) 
 Other  0 (0) 
 
People who did nothing initially all sought subsequent advice, but only two people 
gave an estimate of the time delay – 1-21 days. Type of symptom suffered had no 
influence on the course of action taken. 
Patient Reported Symptoms 
The most commonly reported symptom in this group of patients was weakness or 
numbness down one side of the body with 10 (56%) of patients having suffered 
this. Many people also reported having problems with their eyesight or difficulty 
with speech (see figure 3.14). 
 
Figure 3.14: Patient Reported Symptoms – pilot data 
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Again, the type of symptom experienced by a patient did not influence what course 
of action they took.  ©NCCSDO 2008  Page 45 
 
Table 3.20: Patient Action by Reported Symptom – pilot data 
Symptom   Contacted  GP 
Number (%) 
Visited 
Hospital 
Number (%) 
Other 
Number 
(%) 
Difficulty speaking  Yes  4 (57)  2 (29)  1 (14) 
 No  3  (30)  2 (20)  5 (50) 
Weakness/Numbness Yes  4  (44)  2 (22)  3 (33) 
 No  3  (37.5)    2 (25)  3 (37.5) 
Dizziness/Giddiness Yes  1  (33)  0 (0)  2 (67) 
 No  6  (43)  4 (29)  4 (29) 
Confusion Yes  3  (50)  2 (33)  1 (17) 
 No  4  (36)  2 (18)  5 (45.5) 
Problems with eyesight  Yes  3 (37.5)  1 (12.5)  4 (50) 
 No  4  (36)  2 (18)  5 (45.5) 
Loss of consciousness  Yes  0 (0)  0(0) 1  (100) 
 No  7  (44)  4 (25)  5 (31) 
 
Patients who contacted a GP 
Patients who either visited a GP or had a home visit from a locum (n=7) also 
provided information on the outcome of the appointment. In this population, all 
patients were both referred to A & E and given further GP appointments. Only 1 
patient was given a prescription (see figure 3.15). 
 
Figure 3.15: Outcome of GP Appointment – pilot data* 
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* Does not total 7 as outcomes are not mutually exclusive. 
 
Patient Preference 
Analysis of the patient choice of which type of TIA service they prefer was carried 
out as for the main questionnaire. In this population, urgent referral to a specialist 
clinic was given as first choice by the most patients, with referral to hospital the 
favourite option of the fewest number of people. (See table 3.21) 
 
Table 3.21: Patient Preference of Service Provision – pilot data 
 GP  Hospital  Specialist ©NCCSDO 2008  Page 46 
Number (%)  Number (%)  Number (%) 
1
st Choice  6 (33)  3 (17)  9 (50) 
2
nd Choice  7 (39)  4 (22)  5 (28) 
3
rd Choice  4 (22)  10 (56)  2 (11) 
 
The mean scores showed referral to specialist to be the favoured option (mean 
1.56, SD 0.73), with treatment by GP as the second choice (mean 1.88, SD 0.78) 
and referral to hospital as the least favourite (mean 2.41, SD 0.80) 
 
Patient Costs 
Costs were estimated using the same method as used for the main questionnaire. 
Again, most people travelled by car (12 (67%)) with 4 (22%) going by ambulance 
and 1 (6%) person walking. No one used any form of public transport. 12 patients 
provided an estimate of journey distance (mean 6.3 miles, range 1-10 miles). The 
mean cost in parking fees for the 12 patients who travelled by car was £0.83 
(range £0 - £4.00). The difference in mean costs for people who visited their GP 
and those who went to hospital were tested, with the mean for GP being £0.37 (SD 
0.75) per visit, while the mean for a hospital visit was £1.00 (SD 2.0) 
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3.5 Data from the literature 
 
3.5.1. Accuracy of GP diagnosis of TIA/minor stroke 
 
A review of the literature was carried out to identify studies that assessed accuracy 
of GP diagnosis of TIA. A summary of these studies is shown in table 3.19. Four 
sources (Gibbs, 2001; Martin, 1997; Ferro, 1996; Jempere, 1996) give a positive 
predictive value in the range 60-70%. Taking a PPV of 67% with a prevalence of 
50% and sensitivity of 80% gives a specificity of 60%. The sensitivity of 80% was 
derived from the study by Quik van Milligen et al. (Quik-van Milligen, 1992). 
 
Summary: 
The GP will make a diagnosis that the patient has or has not had a TIA/ minor 
stroke. The sensitivity and specificity of GP diagnosis is set at 80% and 60% 
respectively. 
 
Table 3.22: summary of studies looking at accuracy of GP diagnosis of TIA 
 
Paper Setting  Method  Results 
Ferro, 1996   Portugal  A list of 20 neurological 
symptoms was distributed to 
20 GPs and 22 neurologists 
who graded the compatibility of 
each diagnosis with a TIA 
diagnosis. At least 2 
neurologists validated the TIA 
diagnoses made by GPs for 
patients under their care. 
During the study period, the GPs 
diagnosed 103 TIAs and 52 
(50%) were referred for 
neurological evaluation. 
Validation of diagnosis by GP was 
confirmed in 10 patients (19%); 
TIA diagnosis was incorrect in 42 
patients. 26 (50%) patients had 
strokes and 16 (31%) had a 
noncerebrovascular disorder. 
Dennis, 
1989  
UK  Epidemiological study of the 
incidence of TIAs in patients 
registered with 50 GPs.  GPs 
notified the Oxfordshire Family 
Practitioners Committee of all 
patients suspected of suffering 
a TIA and one of the authors 
further assessed each of the 
patients and carried out 
investigations to confirm the 
diagnosis. 
Of 512 patients with supposed 
TIA referred by GPs, 195 (38%) 
did have a TIA and 317 (62%) 
had noncerebrovascular 
disorders. 
Quik-van 
Milligen, 
1992 
  
Holland A  questionnaire  that  included 
10 TIA cases was mailed to a 
random sample of 10% of all 
GPs in the Netherlands. 
80% of cases were correctly 
diagnosed.  
Jempere, 
1996 
Spain  Epidemiological study of TIA 
and minor strokes. 
GPs referred 193 patients with 
supposed TIA for neurological 
evaluation.  129 (67%) had a 
correct diagnosis and 64 (33%) 
were diagnosed with 
noncerebrovascular disorders. It 
is not mentioned how many 
minor strokes were labelled TIAs 
by the GPs.   
Gibbs, 2001   UK  The diagnosis made by a 
specialist was compared with 
the diagnostic code entered 
For the 27 patients referred with 
a diagnostic code for TIA, the GP 
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onto the General Practitioner 
Research Database (GPRD) by 
the GP to determine how often 
they were in agreement, as a 
test of the validity of the 
diagnostic data entered onto 
the GPRD. 
in 13 cases (48%).  Therefore, 
the specialist gave an alternative 
diagnosis for 14 (52%) patients. 
Tomasik, 
2003  
Poland  A questionnaire including 3 
pairs of TIA cases (3 cases of 
symptoms of transient 
monocular blindness (MB) and 
other 3 of hemispheral 
ischemia (HI)) was distributed 
to 100 GPs.  2 GPs with a 
specialist interest in vascular 
diseases rated the correctness 
of each diagnosis based on: 
correct = described as TIA, 
probably correct = description 
of vascular process but without 
specification and incorrect = no 
relationship with CV disease. 
89 GPs responded giving the 
following results for each of the 6 
cases: 
                             MB            
HI 
Correct:               18 (20%)    
41 (46%) 
Prob. Correct:      45 (51%)    11 
(12%)  
Incorrect:             26 (29%)    
37 (42%) 
Therefore, physicians confronted 
with TIA cases had difficulties 
diagnosing it.   
Mant, 
2003b 
UK  Identification of prevalent 
cases of stroke through 
reviews of GP-based computer 
systems, population surveys 
and hospital-based routine 
information systems. 
118 patients had a diagnosis of 
TIA by a GP, but only in 34 
(29%) of these was there 
evidence of confirmation of the 
diagnosis by a specialist. 
Martin, 
1997 
  
UK  The diagnosis of patients 
referred to the neurovascular 
clinic by the GPs was compared 
to that of the 2 neurologists. 
The specialists confirmed the 
referral diagnosis of TIA in 
200/332 (60%) patients. 
 
3.5.2 Optimal secondary prevention of stroke following TIA and 
minor stroke 
This was derived from the National Clinical Guidelines for stroke and the NICE 
guidance on use of dual anti-platelet therapy following a cerebrovascular event. 
(Intercollegiate Stroke Working Party, June 2004; National Institute for Health & 
Clinical Excellence, 2005) 
 
Optimal treatment is: 
o  warfarin for those diagnosed with AF; 
o  no antiplatelet therapy for those taking warfarin; 
o  antiplatelet dual therapy for all those not taking warfarin; 
o  statin if total cholesterol is greater than 3.5; 
o  antihypertensive if SBP is greater than 130mmHg; 
o  referral if suitable for assessment for carotid endarterectomy. 
  
Note that we have not modelled any delay in the measurement of cholesterol. 
 
If antihypertensive treatment is given, then it is assumed to lower the SBP by 
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after having received antihypertensive therapy, no further lowering of blood 
pressure is modelled.  
 
 
3.5.3 What delays are there to carotid endarterectomy following 
GP referral? 
 
The delays to carotid endarterectomy using the standard GP care were based upon 
the following:  
 
Carotid Endarterectomy 
Parameter Value  Source 
Median delay referral to assessment  24 days  Mehta, 2005 
Median delay assessment to surgery  67 days  Mehta, 2005 
Probability of stroke at CE  0.02  VascularWeb, 2006 
 
For patients who see a specialist whether in A&E or in a rapid access out-patient 
clinic, it is assumed that appropriate assessment for suitability for carotid 
endarterectomy is carried out at that time (i.e. there is no wait). However, the 
delay to surgery is still modelled on the Mehta et al data.  
 
3.5.4 What is the impact of treatments on subsequent stroke risk? 
 
The factors affecting the risk of stroke are as shown in table 3.20. For the risk of 
carotid endarterectomy, the data given by Rothwell et al (Rothwell, 2004b) were 
converted into odds ratios, which were interpreted as hazard ratios in the model. 
Data were given in four groups according to time from event. However, a common 
value has been used for groups in pairs. 
 
 
Table 3.23 Factors affecting risk of stroke  
Parameter Value  Source 
RR for 9mmHg increase in SBP  1.5  MacMahon, 1994 
RR for AF no warfarin (v no AF)  5  Wolf, 1991 
RR for AF with warfarin (v no AF)*  1.67  M Aguilar 
RR for antiplatelet mono (v no Rx)  0.75  Anti-thrombotic trialists’ 
collaboration, 2002 
RR for antiplatelet dual (v mono)  0.8  ESPIRIT, 2006 
RR for statin  0.84  Cholesterol Treatment Trialists’ 
Collaborators, 2005 
RR for diabetes  2.5  Ebrahim, 1999 
RR for carotid endarterectomy     
- within 2 weeks of event  0.28  Rothwell, 2004b  
- 2 to 4 weeks after event  0.28   
- 4 to 12 weeks after event  0.54   
- at least 12 weeks after event  0.54   
 
*This figure is only applied after patients have been on warfarin for at least 72 
hours. For the first 72 hours after initiating warfarin treatment, the risk for “AF no 
warfarin” is applied. 
 
For convenience, the baseline risk is defined as applying to a patient with systolic 
blood pressure (SBP) of 148mmHg without AF or diabetes and on no relevant 
medication. The relative risks indicated above are then applied. To produce the 
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each age and sex group in the modelled population, and then divide the overall 
incidence by this mean relative risk to give the baseline incidence. This is then 
converted into a figure in mean hours to event. The mean relative risks were found 
to be as follows:  
 
Table 3.24: Calculated mean relative risks for a non-diabetic not in AF with 
SBP 148mmHg on no relevant medication 
Age group  Males  Females 
< 35  2.37  1.76 
35 - 44  2.59  2.20 
45 - 54  2.23  2.00 
55 - 64  2.26  2.09 
65 - 74  2.42  2.52 
75 – 84  2.61  2.90 
≥ 85  3.25  3.20 
 
It is assumed that the risk factors applicable for stroke apply equally to genuine 
TIAs and strokes, but not to TIA mimics. Accordingly, the revised baseline risks 
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Table 3.25 Adjusted incidence of TIA mimic, genuine TIA, minor and major 
stroke 
(per 1,000 patients per year) 
 
Baseline incidence– males 
Age group  TIA mimic  Genuine TIA  Minor Stroke  Major Stroke 
< 35  0.01  0.01  0.00  0.00 
35 - 44  0.22  0.09  0.10  0.00 
45 - 54  0.33  0.15  0.17  0.16 
55 - 64  1.14  0.50  0.62  0.16 
65 - 74  3.39  1.40  2.08  0.59 
75 - 84  6.71  2.57  3.03  0.58 
≥ 85  10.32  3.17  4.39  1.67 
 
Baseline incidence– females 
Age group  TIA mimic  Genuine TIA  Minor Stroke  Major Stroke 
< 35  0.03  0.02  0.00  0.00 
35 - 44  0.05  0.02  0.07  0.00 
45 - 54  0.42  0.21  0.21  0.06 
55 - 64  1.40  0.67  0.53  0.30 
65 - 74  3.97  1.58  1.39  0.23 
75 - 84  8.67  2.99  2.33  1.29 
≥ 85  12.66  3.95  3.62  1.08 
 
3.5.6 What is the risk of subsequent events? 
 
TIA mimic 
The risk of TIA mimic is taken to be the same as the baseline risk, depending on 
age and sex only, regardless of all other patient attributes. 
 
Genuine TIA 
For risk of repeat genuine TIA, the baseline risk is modified by the risk factors for 
stroke. This applies following TIA mimic and (minor) stroke: there is a higher risk 
of repeat TIA following genuine TIA, which is currently modelled as a RR of 4. 
 
Stroke 
Following TIA mimic, the baseline risk is modified by the risk factors for stroke. 
 
Following TIA, it is essential to account for the increased risk of stroke in the first 
few days after the TIA. From the OXVASC data, time to stroke following TIA 
appears to follow a Weibull distribution. This distribution may be defined by its 
survival curve 
 
  () ( ), exp
γ λt t S − =  where t is time in days from the onset of the TIA. 
 
The two parameters γ and λ are known respectively as shape and scale 
parameters. If  , 1 = γ  then the distribution reduced to a (fixed risk) exponential 
distribution. If  , 1 < γ  then the risk is reducing over time. This is the form that is 
required here. 
 
We programmed a model with a fixed value of γ, and λ dependent on ABCD score. 
The model allows λ to be specified separately for each value of the ABCD score, but 
given the small number of events in the OXVASC data set it was appropriate to fit a 
model with a constant hazard ratio for each unit increase in ABCD score. Using this ©NCCSDO 2008  Page 52 
approach, the maximum likelihood estimator of γ was 0.298, with values of λ as 
shown below: 
 
ABCD score  0  1  2  3  4  5 6 
λ 0.0038  0.0045  0.0053  0.0062  0.0073  0.0085 0.0100 
 
Following stroke, we again have a Weibull distribution, but the ABCD score is not 
used. The maximum likelihood estimators are  348 . 0 = γ  and  . 0045 . 0 = λ  
 
In all cases, it is assumed that for patients aged under 75, one half of repeat 
strokes are major strokes, while for patients 75 or over, two thirds of strokes are 
major strokes.  
 
3.5.7 What is the mortality associated with minor stroke? 
 
Applying the general mortality to the population entering the model with minor 
stroke gives one-year mortality of 0.055, compared to observed mortality of 0.137 
using OXVASC data. The additional mortality here is modelled as stroke-related 
mortality. 
 
The factors affecting the risk of stroke-related mortality are as shown in the 
following table. These are based on the relative risk of repeat stroke with the 
assumption that 20% are fatal. 
 
Table 3.26: Factors affecting risk of stroke related mortality 
Parameter Value 
RR for 9mmHg increase in SBP  1.1 
RR for AF no warfarin (v no AF)  1.8 
RR for AF with warfarin (v no AF)*  1.2 
RR for antiplatelet mono (v no Rx)  0.95 
RR for antiplatelet dual (v mono)  0.96 
RR for statin  0.97 
RR for diabetes  1.3 
RR for carotid endarterectomy   
- within 2 weeks of event  0.86 
- 2 to 4 weeks after event  0.86 
- 4 to 12 weeks after event  0.91 
- at least 12 weeks after event  0.91 
 
*This figure is only applied after patients have been on warfarin for at least 72 
hours. For the first 72 hours after initiating warfarin treatment, the risk for “AF no 
warfarin” is applied. 
 
The relative risks are applied to a baseline risk of one additional death per 4900 
days at risk (incorporated into the model as a risk per hour). This was calibrated so 
that the number of stroke-related deaths was approximately equal to 1.5 times the 
number of other cause deaths in the stroke population. 
With regard to thrombolysis, we did not model the benefit of thrombolysis, but 
rather, the patient exited the model when they received thrombolysis and the event 
that led to receipt of thrombolysis (be it minor or major stroke) was not counted. 
This will have resulted in an over-estimate of the apparent effect of thrombolysis, 
since it is the equivalent of assuming that it is 100% effective.  
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Other Cause Death 
The probability of “other cause” death within one year of entry to the model is 
given by age group as follows. This is based on data from the government actuary’s 
department. (Government Actuary's Department, 2006). The values here are for 
England and Wales, and have been adjusted for stroke deaths. This was done by 
determining the proportion of deaths classed as cerebrovascular diseases (ICD-10 
codes I60-I69) among total deaths registered in England and Wales in 2006.
 
(Health Statistics Quarterly, 2007). 
 
Table 3.27: Probability of other cause death 
Age group  Males  Females 
20-25 0.000770  0.000268 
25-30 0.000751  0.000319 
30-35 0.001018  0.000459 
35-40 0.001256  0.000662 
40-45 0.001757  0.001090 
45-50 0.002834  0.001880 
50-55 0.004450  0.002760 
55-60 0.006986  0.004319 
60-65 0.011902  0.007055 
65-70 0.018369  0.011078 
70-75 0.030947  0.019340 
75-80 0.050886  0.032233 
80-85 0.082922  0.056332 
85-90 0.131553  0.096706 
90-95 0.195029  0.160009 
95-100 0.275590  0.237942 
 
Applying the general population mortality to the population entering the model with 
genuine TIA gives a one-year mortality risk of 0.057. The observed mortality in the 
OXVASC data set was 0.059, so it is likely that excess mortality is sufficiently 
accounted for by the mortality associated with strokes following TIA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ©NCCSDO 2008  Page 54 
4: Methods for the discrete event simulation model  
 
 
4.1 Aim of the model 
The aim is to compare the outcomes in terms of strokes prevented and cost of 
different patterns of service provision for people presenting with a transient 
ischaemic attack or minor stroke.  
 
4.2 Development of the Model 
The structure of the model was developed over a series of meetings involving the 
core Birmingham team. The face validity of the model was tested against the 
clinical experts (GF & PR), and modifications made as a result. The face validity was 
also explored with the Patient Advisory Group (PAG), who did not come up with 
different patterns of service delivery than were being proposed by the model.  
4.2.1 Study population represented by the model 
 
The study population is people who contact the health service with symptoms 
suggestive of a transient ischaemic attack (TIA) or minor stroke. Minor stroke for 
the purposes of this model is pragmatically defined as a stroke that does not lead 
to significant disability and does not result in hospital admission. The study 
population therefore comprises three sub-categories: people with a genuine TIA, 
people with a minor stroke, and people with symptoms that mimic a TIA/ minor 
stroke where the underlying diagnosis is not related to cerebrovascular disease.  
The population size is set at 500,000, with 1,000 people presenting per annum with 
symptoms suggestive of a TIA or minor stroke. This comprises 35% genuine TIAs, 
15% minor strokes and 50% ‘TIA mimics’, and equates to an annual incidence of 
TIA of 0.7 per 1,000, an incidence of minor stroke (not admitted to hospital) of 0.3 
per 1,000 and an incidence of TIA mimic of 1 per 1,000.  See 3.1.2.1.  
 
4.2.2 Patterns of service provision being tested in the model 
 
The basic comparison is between current practice and the introduction of a rapid 
access specialist clinic. The assumed benefits of a specialist clinic are that it will 
lead to more accurate diagnosis; optimal use of secondary prevention medication; 
and more rapid use of carotid endarterectomy where applicable.  
Within this basic comparison, we explore different referral thresholds to the 
specialist clinic based upon a simple scoring system that predicts risk of subsequent 
stroke following a TIA – the ABCD2 score. (Johnston, 2007).    
We also explore the impact of greater use of emergency ambulance services on the 
results of our model to reflect the recommendations of the National Stroke 
Strategy,
  (Department of Health, 2007) and the consequences of admitting people 
at high risk of stroke following a TIA to hospital. The assumed benefit of this is that 
it will enable greater early use of thrombolysis – an effective treatment for acute 
stroke. (Wardlaw, 2003) 
We also explore the impact of the provision of different types of specialist clinic: 
weekly and twice-weekly clinics with a fixed number of appointments, twice-weekly 
clinics with extra appointments added to avoid excess waiting, and same day 
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Finally, we test the conclusions of the model if GP diagnosis was more accurate, 
and if GP management in terms of secondary prevention reflected optimal rather 
than current practice.  
4.2.3 Consequences being evaluated in the model 
 
The principal outcomes are the number of strokes prevented – which are sub-
divided into strokes that would have led to a hospital admission and minor strokes 
that would not have led to a hospital admission, and cost. For the purposes of the 
model, a major stroke is defined pragmatically as a stroke that leads to a hospital 
admission. Cost includes the costs of clinics, interventions, and the costs of treating 
a stroke up until a maximum of 12 months after the event. The incremental cost 
per major stroke averted is calculated.  
 
4.2.4 Model Structure and logic 
 
The model is a discrete event simulation model, programmed in Borland Delphi. 
Important features of the model are that it tracks individuals who are occasionally 
competing for resources in a realistic representation of calendar time. In particular, 
the availability of certain services depends on time of day and day of week. 
The model runs using an event-based executive. The core of the model is the 
events list, each entry of which consists of a patient number and the time and 
nature of the next event involving that patient. Initially, the events list consists of 
the first occurrences of each of TIA mimic, genuine TIA, and minor stroke. 
When the patient characteristics have been sampled, the patient is set to no 
management, and the time of onset of symptoms is recorded. For modelling 
convenience, the patient taking action is modelled as a separate event. Processing 
entry into the model of a new patient also includes scheduling the entry of the next 
new patient of the same type (TIA mimic, genuine TIA, or stroke). 
At each step in the running of the model, (simulated) time is advanced to the 
earliest event on the events list, and the relevant event is processed. If the event is 
the entry into the model of a new patient, a new event is added to the list for the 
entry of the next patient of a similar type. (This implies that the events list can 
never be empty.) 
In all cases, the event is processed. The patient’s condition is updated, as are any 
relevant totals of resources used. If the event is the exit of a patient from the 
model, then no new event is scheduled for that patient. In other cases, the next 
event for that patient is scheduled. This may be the intended next event, such as 
attendance at an outpatient clinic. However, the risk of an adverse event (stroke or 
other cause death) is taken into account. Such an adverse event would prevent the 
intended next event from taking place. Note that any appointments missed as a 
result of adverse events are lost. 
Patient progression through the model 
Patient progress through the model is illustrated in figure 4.1.  The patient enters 
the model when they have an event, which is either a TIA, a minor stroke, or a TIA 
mimic. They are then managed depending upon which model of service delivery is 
used, and stay in the model until they die, go on to have a stroke that is either 
fatal or leads to hospital admission, or survive for 12 months without a further 
event. If they have a further TIA or stroke that does not lead to hospital admission, 
then they re-enter the model.  
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Figure 4.1: Patient progression through the model 
 
Entry to model:
Patient has symptoms
Management 
Exit model:
12 months without
stroke/ death
Exit: stroke leading to hospital 
Admission or death
Exit: other death
Re-entry: further TIA
Or minor stroke
 
 
Patient characteristics on entry 
On entry to the model, patients are characterised in terms of: 
•  Factors that predict risk of subsequent stroke (age; blood pressure; clinical 
features of event; duration of symptoms and previous diagnosis of diabetes 
mellitus) 
•  Additional factors that determine optimum treatment following the event (total 
cholesterol; atrial fibrillation status; current medications in terms of anti-platelet 
agents, anticoagulants, and statins; potential to benefit from carotid 
endarterectomy) 
•  Life expectancy if death (other than due to stroke) is to occur within 12 months 
 
Three separate groups enter the model. These are TIA mimic, genuine TIA, and 
minor stroke. Patient characteristics on entry are derived from the OXVASC data 
set (see OXVASC chapter).  On entry, patients are given the following 
characteristics: 
o  Actual condition type (TIA mimic, Genuine TIA, minor stroke); 
o  Age group (see note below); 
o  Sex; 
o  Systolic blood pressure (mmHg); 
o  High or not high blood pressure on onset (see note below); 
o  Clinical symptoms score (0=neither weakness nor speech disturbance, 1=speech    
disturbance without weakness, 2=any weakness); 
o  Duration score (0=0-9 mins; 1=10-59 mins; 2=60 mins or more); 
o  ABCD score (calculated from above); 
o  Total cholesterol (in mmol/l); 
o  AF status (no AF, AF no warfarin, AF warfarin); 
o  Already on antiplatelet therapy (monotherapy – see note below); 
o  Already on statin; 
o  Previous diagnosis of diabetes; ©NCCSDO 2008  Page 57 
o  Suitability for carotid endarterectomy (0=unsuitable for investigation, 1=suitable 
for investigation but not for CE, 2=suitable for CE: see below); 
o  Date of “other cause” death; 
 
Age groups are defined in units of 5 years. For ease of interpretation, they are 
numbered from 4 (20 to 25) to 19 (95 to 100) inclusive. 
 
High blood pressure on onset is selected if the systolic blood pressure is greater 
than 140mmHg. The OXVASC data set contains a small number of individuals with 
a systolic blood pressure below 140mmHg but a diastolic blood pressure over 
90mmHg, who are regarded as having high blood pressure on onset. For simplicity 
this model uses SBP only; the distribution used is adjusted to give the correct 
proportion of patients classified as having high blood pressure. 
 
It is assumed that all patients have the potential to benefit from blood lowering 
treatment on entering the model, i.e regardless of whether or not they have had a 
genuine TIA or minor stroke.  
 
The status of the patient with regard to antiplatelet therapy may be no therapy, 
monotherapy, or dual therapy (aspirin + dipyridamole). OXVASC data gives the 
proportion of patients on monotherapy: it is assumed that no patient is on dual 
therapy on entry to the model. Note that antiplatelet and warfarin are sampled 
independently, which means that some patients enter the model on both types of 
treatment. 
 
Suitability for carotid endarterectomy is taken as a two-stage process. First the 
patient must be suitable for investigation. For this, the territory must be carotid 
and there must be no contra-indication. Patients who are found to have 
symptomatic stenosis from 70-99% are deemed suitable for carotid 
endarterectomy. The proportions in these three categories are based on OXVASC 
data. It is assumed that the presence of a symptomatic stenosis category 
corresponds to suitability for investigation. 
 
The date of “other cause” death is sampled by taking account of the appropriate 
age/sex-related probability of death during the following year. Given the generally 
low values of this death rate, it is a reasonable approximation that death dates are 
uniformly distributed through the year. 
 
Modelling of patient management within the model 
An outline of the patient pathway options is shown in figure 7.2. The first option is 
whether the patient goes to Accident & Emergency (A&E) (B in figure 7.2), or 
whether they contact their general practitioner (A in figure 7.2). The model is 
concerned with people who contact the health service as a result of symptoms 
suggestive of a TIA or minor stroke, so people who take no action as a result of 
their symptoms are not included in the model. The model takes into account both 
the proportion of people that attend A&E (either under their own resources or 
through calling an ambulance) or contact their general practitioner (whether to 
request a home visit or to attend the practice). It also takes into account how long 
they take to contact health services.  See 3.1.2.2 for explanation of how initial 
patient actions were incorporated into the model..  
 
 
 
Figure 4.2: Patient pathways within the model 
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Patients who see GP 
The GP may manage the patient in primary care (A1), or refer to a specialist out-
patient clinic (A2). The baseline service provision being tested assumes that all 
patients are managed in primary care (A1). The model tests what would happen if 
a clinic was available, (A2) and the proportion referred depended on the basis of 
ABCD2 score and whether or not the GP made a diagnosis of TIA.  
The GP will make a diagnosis that the patient has or has not had a TIA/ minor 
stroke. The sensitivity and specificity of GP diagnosis is set at 80% and 60% 
respectively. See section 3.5.1 for supporting literature. 
If the patient is managed in primary care (A1), the GP will treat if they make a 
diagnosis of TIA/ minor stroke. Two patterns of GP treatment are modelled: 
standard treatment, which is based upon current practice, and optimal treatment, 
which is based on current best practice.  
Standard GP treatment 
Standard treatment is based on the results of our analysis of the QRESEARCH 
database (see section 3.3). There are fixed probabilities of each of the following, 
sampled independently for each separate category of treatment, but exclusively for 
alternatives within the same category: 
antiplatelet monotherapy if not already taken; 
antiplatelet dual therapy; 
statin if total cholesterol is greater than 3.5; 
immediate assessment for blood pressure and AF; 
 
delayed assessment for blood pressure and AF; 
referral if suitable for carotid endarterectomy. 
 
Assessment for blood pressure and AF results in antihypertensive therapy if systolic 
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medications the patient is already on) and warfarin if AF diagnosed. If warfarin 
treatment is initiated, then antiplatelet is stopped.  Based on the literature, delays 
were built in if the patient was referred for assessment for carotid endarterectomy 
(see 3.5.3). 
 
If the assessment is delayed, this means a second GP appointment is made. There 
is a minimum number of days delay, after which the time is sampled from an 
exponential distributed. The time so generated is then replaced by a random time 
between 9.30am and 5.30pm on the same day, except that appointments that 
would occur on Saturday are replaced by the previous day, and appointments that 
would occur on Sunday are replaced by the following day. 
Optimal GP treatment 
Optimal treatment is based on National guidelines, from the Intercollegiate Stroke 
Working Party and from NICE – see section 3.5.2. 
 
Patients referred to a specialist clinic 
If the patient is referred to a specialist out-patient clinic (A2), then the time it takes 
them to see the specialist depends upon the outpatient booking system being used.  
Four outpatient-booking systems are implemented in the model, as described 
below. Although there will be some variability in the time taken to see each patient, 
this variability is not important in the time scales of the model. Appointments are 
set at fixed intervals of 30 minutes each. If a patient does not attend the 
appointment, the appointment is lost. Note that the choice of day of the week for 
these clinics is somewhat arbitrary. The difference between the four service 
patterns is such that the model should be able to discriminate between them. It is 
not sensible to expect the model to determine an optimum time of week for 
outpatient clinics. 
 
It is assumed that patients are booked in sequence into the earliest available 
appointment. Allowing patients a choice of time within a particular day’s clinic 
would complicate the model to very little advantage. 
 
Weekly fixed 
Outpatient clinics occur once a week on Tuesday mornings. In each clinic, there are 
a total of six appointments, which are set at half-hourly intervals from 9.00am 
onwards. Appointments must be booked no later than 5.00pm on Monday. The next 
available appointment time is selected, no matter how far in the future that may 
be. 
 
Twice weekly fixed 
Outpatient clinics occur on Tuesday and Friday mornings. In each clinic, there are a 
total of six appointments, which are set at half-hourly intervals from 9.00am 
onwards. Appointments must be booked no later than 5.00pm on the day before 
the clinic. The next available appointment time is selected, no matter how far in the 
future that may be. 
 
Twice-weekly flexible 
Outpatient clinics occur on Tuesday and Friday mornings. In each clinic, there are a 
minimum of six appointments, which are set at half-hourly intervals from 9.00am 
onwards. Appointments must be booked no later than 5.00pm on the day before 
the clinic. The number of appointments in any clinic is extended if necessary so that 
no patient waits more than a specified number of days for an appointment. By 
default this number is set to 7, but it can be changed to any higher number if 
desired. 
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Same Day  
Appointments are available daily (Monday to Friday) at half-hourly intervals from 
4.00pm onwards up to a limited number. They must be booked by 4.00pm on that 
day. For simplicity, the issue of travelling time between booking and arrival at 
appointment is not considered in the model. 
 
Patients who go to A&E 
The A&E doctor is assumed to have the same diagnostic accuracy as the general 
practitioner for TIA/ minor stroke. If the A&E doctor makes a positive diagnosis, 
then it is assumed that the patient is referred to a specialist. If the A&E doctor 
makes a negative diagnosis, then the patient is discharged. 
Patients who see a specialist in A&E or attend a rapid access out-patient clinic 
These are treated in the model as being the same. The model is predicated on the 
assumption that specialist diagnosis (supported by brain scanning as appropriate) 
is 100 per cent accurate. While this assumption is in theory optimistic, there is no 
better “gold standard”, and in any case the treatment effects from trials of 
management of TIA are estimated on the basis of this assumption. It is assumed 
that patients are put onto optimal treatment, and will be assessed for carotid 
endarterectomy and be scheduled for surgery if appropriate  
Carotid endarterectomy 
Where appropriate, this is modelled in parallel to other progression. It is assumed 
that both assessment and surgery are available only between 9.00am and 5.00pm 
Monday to Friday. 
 
Referral for assessment takes place as indicated in the pathways above. When 
modelled, the delay to assessment is sampled from a suitable distribution. If this 
leads to a time on a Saturday, this is brought forward to the previous Friday, while 
if it leads to a time on a Sunday, this is moved on to the following Monday. The 
time is then adjusted to a random time between 9.00am and 5.00pm. Finally, if 
this leads to a time earlier than the referral time, then the referral is moved on to 
the same time on the first available working day. 
 
Assessment is assumed to be 100% sensitive and specific. If the patient is suitable 
for carotid endarterectomy, then the delay to surgery is set in the same way as the 
delay to assessment. 
 
Patients who are admitted to hospital 
The baseline assumption is that no patients are admitted to hospital – indeed the 
definition of the study population excludes those people with stroke that leads to 
hospital admission. However, one option is that if people are perceived to be at 
high risk of subsequent stroke (as reflected in ABCD2 score ≥ 4), then they could 
be admitted to hospital for a period of observation (set at 3 days) so that if they do 
have a repeat stroke they would receive immediate thrombolysis. It is assumed 
that all patients who are admitted because of high risk of stroke who go on to have 
a stroke while an in-patient are eligible for thrombolysis and receive it.  
4.2.5 Prediction of outcomes in the model 
 
In this model we have only modelled the effect of treatment on the risk of further 
TIA/stroke (not on ischaemic heart disease or other vascular events).  
The outcomes that need prediction following patient entry to the model are: 
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-new events (further TIA or minor stroke or TIA mimic) 
-non-stroke death 
 
The risks of these events occurring are based upon the epidemiology and the 
evidence of effectiveness of the available interventions.  The derivation of the 
impact of interventions is given in section 3.5.4-3.5.7.  The risk of an individual 
event is taken as the general population risk of that event (taking relevant risk 
factors into account, with the following exceptions: 
-following TIA, there is increased risk of stroke, particularly in the short term, 
based on the OXVASC data. (Rothwell, 2005) See section 3.1.1.3. 
 
-following a minor stroke, there is increased risk of repeat stroke and mortality. 
The excess mortality following a stroke is treated as stroke-related mortality.  
 
Given that impact of treatment on other vascular disease is not modelled, risk of 
non-stroke death is defined on patient entry to the model, and need not be 
modified if the patient changes treatment.  
 
Patients exit the model on stroke-related death or major stroke. A patient who has 
a TIA mimic or genuine TIA within the model normally re-enters the model at 
patient first action. The C and D components of the ABCD score are resampled in 
the case of genuine TIA, and set to zero in the case of TIA mimic; all other 
parameters are assumed unchanged. 
 
There are two exceptions to this. The first is if either of these events occurs while 
the patient is already in hospital as an inpatient. In the case of TIA mimic, the 
patient simply remains in hospital until the appointed discharge time, while in the 
case of genuine TIA, the hospital stay is extended to the minimum period (set at 
three days) following the new TIA. 
 
The second exception is if the patient is already on the way to an emergency 
contact. In that case, the patient continues with the original contact. 
 
In the case of minor stroke occurring within the model, patients normally re-enter 
the model. One exception is if the patient is in hospital as an inpatient when the 
minor stroke occurs. In this case thrombolysis is given. Patients exit the model on 
thrombolysis. Also, all strokes at carotid endarterectomy result in exit from the 
model.  
 
Days lost in the model due to major strokes are counted as the time from event to 
scheduled exit or other cause death, whichever is the earlier. 
Resource Use 
Unit costs are applied to medication and use of services. For A&E and daily OP 
clinics, only the time actually used is costed. For the weekly OP clinics, the 
appointments are staffed even if not all of them are used, and so the cost of 
running the clinics (for the standard three hours in the case of “twice weekly 
flexible” clinics) is included. The costs of care of a stroke were included up until the 
time the patient would have left the model if they had not had stroke. All the model 
outputs listed in table 4.1 (except for the index events) were costed.  The cost data 
used in the model is shown in the appendix.  
4.3 Running the model 
 
Since the model began with outpatient queues empty, it was necessary to run the 
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was set for one year. The model was then run for an “enrolment” period (ten 
years), in which all new patients contributed to the outcomes from the model. 
There was also a “follow up” period, which lasted until all “enrolled” patients had 
exited the model (one year of simulated time). New patients entered the model 
during the follow up period, but they were not included in the outcomes collected. 
The model was run 10,000 times to minimise the impact of random variation.  
 
4.3.1 Model outputs 
 
The process of care and output variables modelled were as shown in the table 
below: 
 
Table 4.1 Description of model outputs 
Item Description 
TIA mimics  Number of patients entering the model with a TIA mimic 
Genuine TIAs  Number of patients entering the model with a genuine TIA 
Minor strokes  Number of patients entering the model with a minor stroke 
Ambulances 1  Number of patients making emergency contact on entry to model 
Ambulances 2  Number of patients making emergency contact for a subsequent  
event (TIA, minor stroke or TIA mimic) 
GP first surgeries  Number of patients making initial contact through GP (including 
subsequent events) 
GP second 
surgeries 
Number of repeat appointments to allow for further assessment of 
blood pressure and atrial fibrillation status 
A&E doctors  Number of patients seeing A&E doctor 
Hospital 
specialists 
Number of patients seeing hospital specialist following referral from 
A&E doctor or from GP to A&E department 
Scheduled OP  Number of patients attending outpatient appointments on referral 
from GP to rapid access clinic. In the case of “twice weekly flexible”, 
only appointments within normal clinic time are counted in this 
category. 
Additional OP  Number of outpatient appointments outside normal clinic time for 
“twice weekly flexible” only  
Thrombolysis  Number of patients receiving thrombolysis (only applies when 
inpatient admission is used) 
Repeat mimic  Number of TIA mimics occurring during follow-up time 
Repeat TIA  Number of genuine TIAs occurring during follow-up time 
Repeat minor 
stroke 
Number of minor strokes occurring during follow-up time 
Repeat major 
stroke 
Number of major strokes occurring during follow-up time 
Days post maj 
strk 
Days not modelled because patients with major stroke exit the 
model early 
CE clinic assess  Assessments for carotid endarterectomy made during specialist clinic 
(either A&E or rapid access OP) 
CE appointment 
ass 
Assessments for carotid endarterectomy made during appointments 
specifically for that purpose 
CE surgery  Number of patients receiving carotid endarterectomy 
Stroke at CE  Number of strokes during carotid endarterectomy 
Stroke related 
death 
Additional deaths following minor stroke due to increased risk of 
mortality 
Other cause 
death 
Deaths from other causes during the follow up period – this number 
would be expected to increase slightly if stroke-related deaths are 
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Item Description 
Normal exit  Number of patients exiting the model at 12 months 
Antiplatelet 
therapy 
 
Change no to 
mono 
Number of patients switching from no antiplatelet to monotherapy 
Change no to 
dual 
Number of patients switching from no antiplatelet to dual therapy 
Chnge mono to 
dual 
Number of patients switching from antiplatelet monotherapy to dual 
therapy 
Monotherapy 
weeks 
Number of weeks spent by patients on antiplatelet monotherapy 
Dual therapy 
weeks 
Number of weeks spent by patients on antiplatelet dual therapy 
Warfarin started  Number of patients starting warfarin 
Warfarin weeks  Number of weeks spent by patients on warfarin 
Statin started  Number of patients starting statin 
Statin weeks  Number of weeks spent by patients on statin 
Antihypertensive  
Started  Number of patients starting antihypertensive therapy 
Weeks  Number of weeks spent by patients on antihypertensive therapy 
IP admissions  Number of patients admitted as inpatients (only applies when 
inpatient admission is used) 
Inpatient days  Number of days spent as inpatient (only applies when inpatient 
admission is used) 
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5: Results of the Model 
 
 
5.1. Initial analysis 
 
For the initial analysis, the baseline that is used for comparison is current practice 
as derived from our analysis of the general practice database QRESEARCH (see 
chapter 3). We assume that patients make some use of ambulance and A&E 
services based on the analysis of OXVASC data reported by Giles et al, (Giles, 
2006) and that no patients are admitted to hospital for observation. We assume 
that every patient who presents to A&E in whom the A&E doctor diagnoses a TIA or 
minor stroke is seen by a specialist while at the A&E department. This baseline 
pattern of service delivery is illustrated in figure 5.1 below: 
Figure 5.1: Baseline service provision. Xs indicate this option not available. 
Heavy line denotes major pathway of care. 
 
Entry Initial 
event
A and E 
doctor
Sees 
GP
Specialist 
opinion in 
A&E
Rapid access 
OP clinic
Managed in 
primary care
Inpatient 
stay
Discharge
A
B
A1
X
X
X
 
 
This is compared with availability of a daily (Monday-Friday) rapid access specialist 
clinic. Nine different referral thresholds are modelled, from refer all possible cases 
of TIA/minor stroke (regardless of whether the GP makes a positive diagnosis), 
through eight possible referral thresholds for positive diagnoses based upon the 
ABCD2 score (which can vary form 0 to 7).   
The detailed results showing the impact of these ten different patterns of service 
provision are shown in table 5.14 at the end of this chapter. In general, as one 
would anticipate, the lower the referral threshold, the lower the number of 
predicted cerebrovascular events. The model predicts 70 fewer strokes (7 per 
annum) leading to hospital admission and 65 fewer TIAs and minor strokes if all 
possible cases are referred to a specialist clinic as compared to current 
management in general practice. Below a referral threshold of 3 on the ABCD2 
score there is no reduction in predicted cerebrovascular events, indeed there is a ©NCCSDO 2008  Page 65 
small increase. This is because fewer patients with a ‘false positive’ diagnosis are 
receiving treatment from the GP, which they would not receive following correct 
diagnosis by a specialist. The model allows for benefit from such treatment (since 
lowering blood pressure will lower risk of a subsequent stroke), and hence the 
small rise in predicted number of strokes at low ABCD2 referral thresholds. Referral 
of all possible cases leads to the best possible outcome since here the additional 
benefit of treatment of genuine TIAs by the specialist who had not been diagnosed 
by the GP outweighs the loss of the ‘benefit’ through incorrect treatment of ‘false 
positives’.  
A referral threshold of ABCD2 score of 4 would generate 2,123 outpatient 
appointments over the 10 years – about 4 patients per week. If all suspected cases 
were referred, the workload would rise to 8,337 appointments per week, or 16 
patients per week.  
A proportion of strokes that lead to hospital admission are fatal. Since the patient 
exits the model on occurrence of a major stroke, such deaths are not counted. 
However, there are stroke related deaths that occur following a minor stroke (to 
reflect the higher mortality of people following a minor stroke than the general 
population). These are included in the model. There is a small reduction in these 
(0.7 deaths per year) moving from current practice to refer all cases to a specialist 
clinic.  
The total cost and the number of strokes that lead to hospital admission (labelled 
‘major stroke’) that are predicted to occur in each pattern of care are shown in 
table 5.1 below: 
 
Table 5.1: Costs and major strokes under base case assumptions 
Strategy  Costs (£k)  Major strokes 
Baseline (no referral)  5004  341 
Refer at  ABCD2 score 7  5023  339 
Refer at ABCD2 score 6  5331  323 
Refer at ABCD2 score 5  5723  312 
Refer at ABCD2 score 4  6068  302 
Refer at ABCD2 score 3  6348  297 
Refer at ABCD2 score 2  6563  298 
Refer at ABCD2 score 1  6671  298 
Refer all diagnoses of TIA/minor stroke  6688  298 
Refer all suspected cases  7616  272 
 
In general, the more patients are referred by GP to outpatient clinic, the more 
costly the strategy is overall, but the lower the number of major strokes. However, 
as noted above, the strategies which retain GP diagnosis, but involve referral at a 
threshold ABCD
2 score of below 3 actually lead to a small increase in the number of 
major strokes, compared to “refer at 3”.  
Where a strategy costs more and is less effective (in this case, leads to more major 
strokes) than another strategy, it is said to be simply dominated. In this case, the 
strategies “refer at 2”, “refer at 1”, and “refer all +ve diagnoses” are each 
dominated by “refer at 3”. Where a strategy costs more, but leads to fewer major 
strokes than, another strategy, an incremental cost-effectiveness ratio (ICER) can 
be calculated. This represents the additional cost of preventing one major stroke. 
The ICERs are shown in table 9.2. In each case, the ICER reflects the cost and 
benefit of a strategy as compared to the strategy on the row above. Thus, to move ©NCCSDO 2008  Page 66 
from the baseline strategy of current practice to a strategy where patients are 
referred to a specialist clinic with an ABCD2 score of 7 will cost an additional 
£19,000, and prevent an additional 3 major strokes, leading to an ICER of £7,000 
per stroke averted.  
It can be seen that the ICER in moving from refer at ABCD2 score of 3 to refer all 
suspect (£50,000 per stroke prevented) is lower than the ICER of moving from 
refer at ABCD2 score of 4 to refer at 3 (£53,000 per stroke prevented). Thus, the 
option to refer at 3 can never be the preferred option at any cost-effectiveness 
threshold. This option is said to be excluded by extended dominance. The 
remaining options are potentially cost effective and are shown in table 5.2.  
 
Table 5.2: Cost-effectiveness analysis for base case excluding simple 
dominance only 
Strategy Costs  (£k) 
Major 
strokes 
Incremental 
cost (£k) 
Major 
strokes ICER 
Baseline 5004  341     averted   
Refer at 7  5023  339  19  3  7 
Refer at 6  5331  323  308  15  20 
Refer at 5  5741  312  410  12  35 
Refer at 4  6089  302  348  10  36 
Refer at 3  6348  297  259  5  53 
Refer all 
suspect 7616  272  1268  26  50 
ICER = incremental cost-effectiveness ratio (in this case, incremental cost per 
major stroke averted.) Incremental cost, major strokes averted and ICER are 
calculated with reference to the strategy shown on the previous line. Model results 
are averages per 10,000 patients. These are shown to the nearest integer, but full 
accuracy has been preserved for the calculation of the ICER. 
 
Table 5.3: Potentially cost-effective options under base case assumptions 
(counting major strokes averted only) 
Strategy Costs  (£k) 
Major 
strokes 
Incremental 
cost (£k) 
Major 
strokes ICER 
Baseline 5004  341     averted     
Refer at 7  5023  339  19  3  7 
Refer at 6  5331  323  308  15  20 
Refer at 5  5741  312  410  12  35 
Refer at 4  6089  302  348  10  36 
Refer all 
suspect 7616  272  1527  30  50 
ICER = incremental cost-effectiveness ratio (in this case, incremental cost per 
major stroke averted.) Incremental cost, major strokes averted and ICER are 
calculated with reference to the strategy shown on the previous line. Model results 
are averages per 10,000 patients. These are shown to the nearest integer, but full 
accuracy has been preserved for the calculation of the ICER. 
 
This suggests that there are several possible cost effective strategies for 
implementing rapid access clinics, with the choice of strategy (if purely dependent 
upon cost-effectiveness) depending upon the value attached to preventing a major 
stroke. Referring at an ABCD2 score of 7,6,5 and 4 are all potentially cost-effective, 
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thresholds is not cost effective, except for the option of referring all possible cases, 
regardless of whether or not the GP has made a diagnosis of TIA.  
If a referral threshold was set at an ABCD2 score of 4 or more for this service, then 
the additional cost per annum would be of the order of £108,500 per annum 
compared to current practice and result in the prevention of 4 strokes per annum. 
If all suspect cases were referred, the additional cost as compared to current 
practice would be £261,200 per annum, and result in the prevention of 7 strokes 
per annum (at an incremental cost per stroke prevented of £50,000 as compared to 
refer at threshold score of 4).  
We have also considered a composite outcome made up of repeat minor strokes, 
major strokes, and strokes at carotid endarterectomy, The use of cost per stroke 
averted is not ideal, as it implicitly weights all strokes equally. However, given that 
the proportions of the different types of stroke remain much the same, the same 
strategies remain potentially cost-effective when this outcome is used, as shown in 
Table 5.4 though the incremental cost per stroke avoided is lower. 
 
Table 5.4: Potentially cost-effective options under base case assumptions 
(counting all strokes averted) 
 
Strategy Costs  (£k)  All  strokes  Inc cost  Strokes  ICER 
Baseline 5004  609     averted    
Refer at 7  5023  604  19  5  4 
Refer at 6  5331  579  308  25  12 
Refer at 5  5723  560  392  19  20 
Refer at 4  6068  544  346  16  21 
Refer all 
suspect 7616  495  1548  49  32 
 
Figure 5.2 shows the various strategies in terms of incremental cost and major 
strokes prevented compared to baseline. The scales on these graphs are set to 
allow comparison with the alternatives considered later.  ©NCCSDO 2008  Page 68 
Figure 5.2a: Base case result, major strokes only 
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Figure 5.2b: All strokes 
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In each of these graphs, the potentially cost effective options are joined up by a 
line. The steeper the gradient of the line the higher the ICER. Points that appear 
above the line represent those strategies that are not cost –effective 
(“dominated”).  
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5.2. Analyses to consider different strategic alternatives 
 
In this set of analyses, we consider what the optimal referral threshold would be if 
other strategies were in place. The alternative strategies that we considered were: 
•  Admission of patients who see a stroke specialist (whether in A&E or in a rapid 
access out-patient clinic) with an ABCD2 score ≥ 4 
•  Alternative frequencies of rapid access out-patient clinics (weekly or twice 
weekly as compared to daily) 
 
In these analyses, the model was run 2,000 times (as opposed to 10,000 times in 
the initial analyses). 
5.2.1 Inclusion of inpatient admission 
 
In this analysis, patients with an ABCD2 score ≥ 4 who see a specialist are 
admitted for 72 hours for observation, and to allow thrombolysis should they have 
a stroke. The number of admissions varies from 118 per year if in-patient 
admission is simply added on to current practice, through to 378 admissions per 
year if the GP refers all suspected cases for specialist opinion (see table 9.13 at end 
of chapter). This results in between 2 and 4 patients per year receiving 
thrombolysis.  
The impact on total costs and number of major strokes of in-patient admissions is 
shown in table 5.5. In general, the pattern is similar to the initial analysis, but the 
costs are higher, and the number of strokes that occur marginally lower.  
 
 
Table 5.5: Inclusion of inpatient admission 
(a) Costs and outcomes for all options 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 5727  339 
Refer at 7  5804  337 
Refer at 6  6567  321 
Refer at 5  7453  309 
Refer at 4  8244  299 
Refer at 3  8526  296 
Refer at 2  8736  296 
Refer at 1  8846  296 
Refer all +ve 
diag 8864  296 
Refer all 
suspect 10129  269 
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(b) Potentially cost-effective strategies 
Strategy Costs  (£k) 
Maj 
strokes Inc  cost  Maj  strk 
Inc cost 
per 
Baseline 5727  339     averted 
maj strk 
avert 
Refer at 6  6584  321  856  18  49 
Refer all 
suspect 10152  269  3569  52  69 
 
It can be seen that if in-patient admissions occur, then there are fewer cost 
effective options, with referral to rapid access outpatient clinic with an ABCD2 score 
≥ 6 or refer all suspected cases being the only strategies that are potentially more 
cost effective than current practice.  
 
Figure 5.3: Cost-effectiveness plane for inclusion of inpatient admission 
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5.2.2 Alternative frequencies of rapid access clinics 
 
The initial analyses assessed the impact of introduction of a rapid access clinic that 
was available daily (Monday to Friday). We also explored the potential impact of 
different clinic frequencies: weekly fixed; twice weekly fixed; and twice weekly 
flexible. The fixed clinics are of fixed capacity. The flexible clinics allow for extra 
appointments if necessary so that no patient needs to wait longer than 7 days.  
The predicted impact of these different patterns of service provision on occurrence 
of major stroke is shown in table 9.6. ©NCCSDO 2008  Page 71 
 
Table 5.6: Predicted numbers of major strokes for all combinations of 
referral strategy and clinic availability 
 Daily 
Twice weekly 
flexible 
Twice weekly 
fixed 
Once weekly 
fixed 
Baseline 341  342  342  342 
Refer at 7  339  339  339  340 
Refer at 6  323  325  325  328 
Refer at 5  312  316  316  320 
Refer at 4  302  308  307  312 
Refer at 3  297  305  304  314 
Refer at 2  298  305  305  408 
Refer at 1  298  307  307  415 
Refer all +ve 
diag 
298 307 307 416 
Refer all 
suspect 
272 288 412 416 
(The difference in baseline between daily and other clinic patterns is a random 
effect due to the reduced number of replications of the model.) 
 
The italicised numbers in the table reflect that this pattern of clinic provision is 
inadequate to cope with the number of referrals, and that queues develop, and the 
rapid access to a specialist can no longer be provided. Thus, a once weekly fixed 
clinic cannot sustain a policy of referral at ABCD2 score ≥ 2 (or lower) and a twice 
weekly fixed clinic cannot cope with a policy of referral of all suspect cases. It is not 
plausible that GPs would refer to a “rapid access” clinic with a long waiting time, so 
these options are excluded from the cost effectiveness analysis. More strokes occur 
in the twice weekly options as compared to the daily option, and in the weekly 
option as compared to the other options. This reflects the longer time delay before 
a patient sees a specialist.  
With regards to costing the clinics, the analyses have been run using two different 
assumptions. In the first, we have assumed that only clinic spaces that are actually 
used incur a cost (in other words, the staff would be doing something else if there 
were no patients to see). In the second, we have assumed that these are fully 
staffed even if the allocation of six places per day is not used. In the case of twice 
weekly flexible, there is an additional cost for appointments beyond the minimum 
of six on any given day. For the daily clinic, where there is no set clinic time, there 
are no fixed costs, only the costs of each clinic appointment.  
Twice weekly flexible clinics 
The results for “twice weekly flexible” are shown in Table 5.7 and Figure 5.4. If only 
clinics used are costed, the pattern is similar to the base case. Costs are similar 
with a slight increase in the number of major strokes. If unused clinics are costed 
at full price, the pattern changes considerably. Any referral strategy at a high 
threshold will incur a large cost for unused clinics, so that only the “refer all” 
strategy is potentially cost-effective in that case. However, this would require on 
average 4 additional appointments per week in addition to scheduled appointments 
to prevent a waiting list developing.  ©NCCSDO 2008  Page 72 
 
Table 5.7: Results for twice-weekly flexible clinics 
(a) Costs and outcomes costing only clinics used 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 5004  342 
Refer at 7  5029  339 
Refer at 6  5349  325 
Refer at 5  5751  316 
Refer at 4  6108  308 
Refer at 3  6398  305 
Refer at 2  6613  305 
Refer at 1  6735  307 
Refer all +ve 
diag 6747  307 
Refer all 
suspect 7730  288 
 
 
(b) Potentially cost-effective strategies costing only clinics used 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per 
Baseline 5004  342     averted 
maj strk 
avert 
Refer at 7  5029  339  25  2  10 
Refer at 6  5349  325  319  14  23 
Refer at 4  6108  308  759  17  44 
Refer all 
suspect 7730  288  1623  20  83 
 
(c) Costs and outcomes costing full price for unused clinics 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 5004  342 
Refer at 7  6307  339 
Refer at 6  6489  325 
Refer at 5  6740  316 
Refer at 4  6964  308 
Refer at 3  7140  305 
Refer at 2  7134  305 
Refer at 1  7067  307 
Refer all +ve 
diag 7060  307 
Refer all 
suspect 7740  288 
 
(d) Potentially cost-effective strategies costing full price for unused clinics 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per 
Baseline 5004  342     averted  maj  strk ©NCCSDO 2008  Page 73 
avert 
Refer all 
suspect 7740  288  2735  53  51 
 
Figure 5.4: Cost-effectiveness plane for twice-weekly clinics 
(a) Costing only clinics used 
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(b) Costing full price for unused clinics 
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Twice weekly fixed clinics 
For “twice weekly fixed” see Table 5.8 and Figure 5.5. These are broadly similar to 
the results for “twice weekly flexible” except for the omission of the strategy “refer 
all suspect”, which is unsustainable with fixed clinics of insufficient capacity. This 
means that “refer at 3” becomes the most effective feasible strategy in this case, 
and it replaces “refer all suspect” in the list of potentially cost-effective strategies. 
 
Table 5.8: Costs and outcomes for twice weekly fixed clinics 
(a) Costs and outcomes costing only clinics used 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 5004  342 
Refer at 7  5029  339 
Refer at 6  5349  325 
Refer at 5  5751  316 
Refer at 4  6105  307 
Refer at 3  6395  304 
Refer at 2  6612  305 
Refer at 1  6730  307 
Refer all +ve 
diag 6749  307 
 
(b) Potentially cost-effective strategies costing only clinics used 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per 
Baseline 5004  342     averted 
maj strk 
avert 
Refer at 7  5029  339  25  2  10 
Refer at 6  5349  325  319  14  23 
Refer at 4  6105  307  757  18  42 
Refer at 3  6395  304  289  3  87 
 
(c) Cost and outcomes costing full price for unused clinics 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 5004  342 
Refer at 7  6307  339 
Refer at 6  6489  325 
Refer at 5  6740  316 
Refer at 4  6962  307 
Refer at 3  7136  304 
Refer at 2  7133  305 
Refer at 1  7059  307 
Refer all +ve 
diag 7057  307 
 
(d) Potentially cost-effective strategies costing full price for unused clinics 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per ©NCCSDO 2008  Page 75 
Baseline 5004  342     averted 
maj strk 
avert 
Refer at 3  7136  304  2132  38  57 
 
Figure 5.5: Cost-effectiveness plane for twice weekly fixed clinics 
(a) Costing only for clinics used 
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(b) Costing full price for unused clinics 
-1000
-500
0
500
1000
1500
2000
2500
3000
3500
4000
-20 0 20 40 60 80
Major strokes averted
I
n
c
r
e
m
e
n
t
a
l
 
c
o
s
t
 
(
£
k
)
Baseline
Refer at 7
Refer at 6
Refer at 5
Refer at 4
Refer at 3
Refer at 2
Refer at 1
Refer at 0
CE Frontier
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Finally in this section the results for weekly fixed clinics are shown in Table 5.9 and 
Figure 5.6. Compared to twice weekly clinics, a wider range of strategies become 
infeasible, and “refer at 3” has become appreciably worse. This is a case where the 
waiting time for clinics does not build up indefinitely but is still appreciable.  
For the strategies which are feasible, the pattern when costing only clinics used is 
again similar to that for twice weekly, with a further small increase in the number 
of major strokes reflecting the additional waiting time to weekly clinics. When 
costing full price for clinics unused, the cost of weekly clinics is only half that of 
twice weekly clinics of the same length. 
 
Table 5.9: Costs and outcomes for weekly fixed clinics 
(a) Costs and outcomes costing only clinics used 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 5004  342 
Refer at 7  5028  340 
Refer at 6  5365  328 
Refer at 5  5782  320 
Refer at 4  6138  312 
Refer at 3  6461  314 
 
(b) Potentially cost-effective strategies costing only clinics used 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per 
Baseline 5004  342     averted 
maj strk 
avert 
Refer at 7  5028  340  24  2  13 
Refer at 6  5365  328  336  12  28 
Refer at 4  6138  312  773  16  49 
 
(c) Costs and outcomes costing full price for clinics not used 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 5004  341.65 
Refer at 7  5661  340 
Refer at 6  5861  328 
Refer at 5  6127  320 
Refer at 4  6351  312 
Refer at 3  6563  314 
 
(d) Potentially cost-effective strategies costing full price for clinics not used 
Strategy Costs  (£k) 
Maj 
strokes Inc  cost  Maj  strk 
Inc cost 
per 
Baseline 5004  342     averted 
maj strk 
avert 
Refer at 4  6351  312  1347  30  46 ©NCCSDO 2008  Page 77 
Figure 5.6: Cost-effectiveness plane for weekly fixed clinics 
(a) Costing only clinics used 
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(b) Costing full price for clinics not used 
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5.2.3 Direct comparison of different patterns of out-patient 
provision and in-patient admission 
 
Figure 5.7 shows a combined plot of all the above strategies compared to the initial 
analysis (with daily clinics). In this analysis, we have costed only the clinics used.  
 
Figure 5.7: Combined cost-effectiveness plane for five strategy sets 
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It can be seen from this graph that the different patterns of outpatient clinic are all 
dominated by the baseline analysis (daily clinics), since they all fall above the cost 
effectiveness plane. In patient admission in combination with referral of all suspect 
TIAs is not dominated, but gives an ICER of over £1,000,000 per major stroke 
prevented.  
 
5.3. Sensitivity analyses 
 
We also performed sensitivity analyses to test the robustness of our results under 
different assumptions. The assumptions we tested were: 
•  Increased use of emergency ambulances 
•  Optimal management by GPs 
•  Better diagnosis by GPs 
5.3.1 Increased use of emergency ambulances 
 
Part of the National Stroke Strategy involves a publicity campaign to alert people to 
the symptoms and signs of stroke, and to encourage them to seek emergency care 
if they experience such symptoms. This is to enable prompter access to specialist 
services so that greater and more effective use can be made of thrombolysis and ©NCCSDO 2008  Page 79 
other acute medical treatments. A consequence of this, if effective, will be that a 
higher proportion of people who are experiencing symptoms of a TIA will contact 
the emergency services, and will go to A&E, bypassing the general practitioner. 
Therefore, we performed a sensitivity analysis exploring what impact such a change 
in behaviour would have on the outcomes of our model. We did this by increasing 
by 20% the baseline probability that the patient would treat the TIA as an 
emergency. 
The impact on costs and outcomes of this assumption is shown in table 5.9. The 
general pattern is similar to the initial analysis, with costs generally higher and the 
number of major strokes slightly lower (with the exception of ‘refer all suspect’). 
 
Table 5.9: Costs and outcomes with enhanced use of 999 service 
(a) Costs and outcomes for all options 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 5417  331 
Refer at 7  5432  329 
Refer at 6  5639  318 
Refer at 5  5960  307 
Refer at 4  6277  298 
Refer at 3  6548  294 
Refer at 2  6746  295 
Refer at 1  6849  294 
Refer all +ve 
diag 6855  294 
Refer all 
suspect 7718  272 
 
(b) Potentially cost-effective strategies 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per 
Baseline 5417  331     averted 
maj strk 
avert 
Refer at 7  5432  329  15  2  8 
Refer at 6  5639  318  207  11  18 
Refer at 5  5960  307  321  10  31 
Refer at 4  6277  298  317  9  35 
Refer all 
suspect 7718  272  1441  26  55 
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Figure 5.8: Cost-effectiveness plane for enhanced 999 services 
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The cost effective options if greater use of emergency services is made are the 
same as for the initial analyses, with similar ICERs.  
Figure 5.9 shows direct comparison of greater use of emergency services with the 
other strategies. For clarity, the dominated strategy sets involving once and twice 
weekly clinics have been omitted. All strategies involving enhanced 999 services 
are excluded by simple or extended dominance. This suggests that greater use of 
patients of emergency services will not lead to more cost effective management of 
TIAs and minor strokes.  
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Figure 5.9: Cost-effectiveness plane for strategy sets including greater use 
of emergency services 
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5.3.2 Optimal management by GPs 
 
In this sensitivity analysis, we assume that if the GP makes a diagnosis of TIA and 
minor stroke, then they will initiate optimal medical therapy if they don’t make a 
referral to a specialist clinic.  
Costs for most strategies here are higher and number of major strokes that occur 
considerably lower than the initial analyses, reflecting the greater use of 
medications. The exception is the ‘refer all suspect’ strategy, where no patients are 
managed by the GP, so there is no difference between this and referring all suspect 
strategy in the initial analysis.  
The reduction in costs that occurs when the referral threshold drops below 3 
reflects the reduced number of referrals by the GP for assessment for carotid 
endarterectomy resulting from false positive diagnoses.  
If optimal GP management is assumed, then the only possible cost effective use of 
rapid access clinics would be to refer all positive diagnoses or to refer all suspected 
cases. Referring all positive diagnoses is potentially cost effective as it reduces 
unnecessary referrals for carotid endarterectomy assessment (see above); 
referring all suspected cases is potentially cost-effective as it picks up the GP false 
negative diagnoses.  
In comparison to baseline (i.e optimal GP management with no use of rapid access 
clinics), referring all positive diagnoses is a less expensive strategy that results in 
prevention of fewer strokes (i.e. it is in the south west quadrant of the cost 
effectiveness plane). This means that it would be cost effective to move from the 
baseline strategy to refer all positive diagnoses at any threshold below £49,000 per ©NCCSDO 2008  Page 82 
major stroke averted. Since it is cost-effective to move from baseline to “refer all 
suspect” at any threshold above £29,000 per major stroke averted, the baseline 
strategy itself is excluded by extended dominance between the two potentially 
cost-effective strategies. 
 
Table 5.10: Costs and outcomes for optimal GP management 
(a) Costs and outcomes for all strategies 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 7098  290 
Refer at 7  7119  291 
Refer at 6  7219  291 
Refer at 5  7319  293 
Refer at 4  7405  293 
Refer at 3  7443  294 
Refer at 2  7103  297 
Refer at 1  6725  298 
Refer all +ve 
diag 6689  298 
Refer all 
suspect 7621  272 
 
(b) Potentially cost-effective strategies 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per 
Refer all +ve 
diag 6689  298      averted 
maj strk 
avert 
Refer all 
suspect 7621  272  932  27  35 
 
(c) Potentially cost-effective strategies shown relative to baseline (current practice) 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per 
No use of OP 
clinic 7098  290      averted 
maj strk 
avert 
Refer all +ve 
diag 6689  298  -409  -8  **49** 
Refer all 
suspect 7621  272  523  18  29 
Incremental cost-effectiveness ratios (ICERs) here are relative to the baseline 
strategy. 
** The ICER in italics is in the south-west quadrant of the cost-effectiveness plane. 
This means that it is cost-effective to move from the baseline strategy to “refer all 
positive diagnosis” at any threshold below £49,000 per major stroke averted. 
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Figure 5.10: Cost-effectiveness plane for optimal GP management 
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5.3.3 Better diagnosis by GPs 
 
The initial analyses were based upon an accuracy of GP diagnosis of 80% sensitivity 
and 60% specificity. In this sensitivity analysis, these parameters are changed to 
90% sensitivity 80% specificity respectively. The results are shown in table 5.11 
and figure 5.11.  
Table 5.11: Costs and outcomes for improved GP diagnostic ability 
(a) Costs and outcomes for all strategies 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 5356  315 
Refer at 7  5377  313 
Refer at 6  5611  301 
Refer at 5  5967  290 
Refer at 4  6324  280 
Refer at 3  6611  274 
Refer at 2  6799  274 
Refer at 1  6874  274 
Refer all +ve 
diag 6876  274 
Refer all 
suspect 7785  263 ©NCCSDO 2008  Page 84 
  
(b) Potentially cost-effective strategies 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per 
Baseline 5356  315     averted 
maj strk 
avert 
Refer at 7  5377  313  21  2  10 
Refer at 6  5611  301  234  12  20 
Refer at 5  5967  290  356  11  31 
Refer at 4  6324  280  358  10  36 
Refer at 3  6611  274  287  6  51 
Refer all 
suspect 7785  263  1174  11  104 
 
Figure 5.11: Cost-effectiveness plane for improved GP diagnosis 
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The impact of improved GP diagnosis in general is to raise costs (as more people 
are correctly identified and treated) but to reduce the number of major strokes that 
occur. The advantage of moving from refer at 3 to refer all suspect is comparatively 
less than in the base case, reflected in the higher ICER, but otherwise improving GP 
diagnosis makes little difference to the ICERs in the initial analyses. 
5.3.4 Better diagnosis and optimal management by GP 
 
Finally we considered the joint effect of improved diagnosis with optimal 
management. The results are in Table 5.12. As was the case when optimal 
management was combined with baseline diagnostic ability, referring additional 
patients with positive diagnosis mainly results in delayed treatment. This time the 
baseline strategy (i.e. no use of out patient services) remains the least costly. The 
strategy “refer at 7” appears to reduce the number of major of strokes slightly, but ©NCCSDO 2008  Page 85 
this is within the range of random error within the model. The only possible cost-
effective use of rapid access clinics in a scenario where GPs diagnose more 
accurately and manage optimally is for GPs to refer all suspected cases, with an 
ICER of £127,000 per major stroke prevented. 
 
Table 5.12: Costs and outcomes for improved GP diagnosis and 
management 
(a) Costs and outcomes for all strategies 
Strategy Costs  (£k) 
Maj 
strokes 
Baseline 6670  272 
Refer at 7  6677  272 
Refer at 6  6785  273 
Refer at 5  6902  274 
Refer at 4  6997  275 
Refer at 3  7056  276 
Refer at 2  6910  277 
Refer at 1  6725  278 
Refer all +ve 
diag 6710  278 
Refer all 
suspect 7658  265 
 
(b) Potentially cost-effective strategies 
Strategy Costs  (£k) 
Maj 
strokes  Inc cost  Maj strk 
Inc cost 
per 
Baseline 9183  272     averted 
maj strk 
avert 
Refer at 7  9187  272  4  0  See below 
Refer all 
suspect  10115  265  928 7 127 
Note: the difference in costs and outcomes between “baseline” and “refer at 7” is 
well within the randomness of the model in this case. It is therefore not meaningful 
to calculate an incremental cost-effectiveness ratio here. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Cost-effectiveness plane for improved GP diagnosis and 
management  ©NCCSDO 2008  Page 86 
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5.4 Estimation of outcome in terms of QALYS 
Relevant background information 
1.  Median age group of stroke is 75-84 (Rothwell, 2004a) 
2.  Life expectancy for healthy 75-84 year old is: 6-10 years for a man; 7-12 
years for a woman. (Government Actuary's Department, 2006) Assume average life 
expectancy of 8 years. 
3.  Most people who have a stroke have underlying cardiovascular disease, so 
assume that if patient did not have stroke, life expectancy would be less than 8 
years – say 6 years.  
4.  30 day case fatality following stroke is 17% (Rothwell, 2004a) 
5.  One year case fatality following stroke is 31%, and commonest cause of 
death is still stroke. (Dennis, 1993) 
6.  Two year case fatality following stroke is 43%. (Samsa, 1999) 
7.  Absolute annual mortality after two years is 7%. (Dennis, 1993) 
8.  Incidence of stroke by severity is: 0.55 (34%) minor (Rankin score 0-1 at 
30 days); 0.47 moderate (29%) (Rankin score 2-3 at 30 days); 0.60 (37%) severe 
(Rankin score 4-6 at 30 days). (Rothwell, 2004a) 
9.  Quality Adjusted life year associated with a moderate to severe stroke is 
0.39; Quality adjusted life year associated with a mild stroke is 0.75 (O’Brien, 
2005) 
Assumptions 
1.  The early mortality (i.e up to two years) following stroke is in people who 
have moderate/severe strokes. 
2.  The mean survival of people with minor strokes is 6 years (which is the 
same survival as in people whose stroke was prevented) 
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Calculation 
Note that in the model the major outcome is a major stroke. For the purposes of 
the model, this is defined as one that results in hospital admission.  
1.  Minor strokes: these comprise 34% of total strokes that lead to hospital 
admission. No loss of life expectancy, but a QALY loss of 0.25 per year for 6 years 
– i.e. 1.5 QALYs per minor stroke. 
2.  Moderate/severe strokes: these comprise 66% of total strokes. Loss of life 
expectancy is as shown below: 
At 1 month: 26% mortality (17/66) 
At 1 year: an additional 21% have died (14/66) 
At two years: an additional 18% have died (12/66) 
At three years: an additional 11% have died (7/66) 
At four years: an additional 11% have died (7/66) 
At five years: an additional 11% have died (7/66) 
The remainder will die during the 6
th year (with no loss of life expectancy).  
 
From this, QALY losses for 100 moderate/severe strokes may be estimated as 
follows:  
26: loss of 6 QALYs 
21: loss of 5.61 QALYs (loss of 5 years of life, with 1 year with QALY of 0.39) 
18: loss of 5.22 QALYs (loss of 4 years of life, with 2 years with QALY of 0.39) 
11: loss of 4.83 QALYs (loss of 3 years of life, with 3 years with QALY of 0.39) 
11: loss of 4.44 QALYs (loss of 2 years of life, with 4 years with QALY of 0.39) 
11: loss of 4.05 QALYs (loss of 1 year of life, with 5 years with QALY of 0.39) 
2: loss of 3.66 QALYs (no loss of life, with 6 years with QALY of 0.39) 
 
Table 5.13: Estimated QALY loss per stroke in the model 
 
Proportion of 
total  QALY loss  Weighted QALY loss 
Minor strokes  33.33%  1.5  0.5 
Mod/ severe strokes  17.33%  6  1.04 
 14.00%  5.61  0.7854 
 12.00%  5.22  0.6264 
 7.33%  4.83  0.3542 
 7.33%  4.44  0.3256 
 7.33%  4.05  0.297 
 1.33%  3.66  0.0488 
 100.00%    3.9774 
 
This gives an estimated 4 QALY loss per stroke.  
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Table 5.14: Complete results tables for all scenario and sensitivity analysis 
 
The following tables show the model outputs for the various scenarios considered in Chapter [model results]. Rows consisting 
entirely of zeroes have been omitted. 
For each, a comparison of baseline care is made against different referral thresholds to a daily clinic 
 
Initial analysis 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
TIA mimics  4998  4997  4998  4999  4998  4997  4998  4998  4997  4997 
Genuine TIAs  3504  3505  3504  3504  3504  3505  3503  3503  3504  3505 
Minor strokes  1499  1498  1498  1498  1498  1499  1499  1499  1499  1498 
Ambulances 1  1716  1716  1716  1715  1716  1716  1716  1716  1716  1716 
Ambulances 2  169  168  161  155  151  148  151  150  151  138 
GP first surgeries  8394  8393  8387  8382  8376  8374  8377  8377  8377  8365 
GP second 
surgeries  1629 1609 1397 1152  935  743  368  36  0  0 
A&E doctors  1872  1871  1864  1858  1854  1852  1854  1854  1854  1841 
Hospital specialists  1370  1369  1364  1359  1356  1355  1356  1356  1356  1346 
Scheduled OP  0  68  738  1475  2123  2679  3747  4682  4782  8337 
Repeat mimic  58  58  58  58  58  58  58  58  58  58 
Repeat  TIA  82 81 78 76 72 72 75 75 75 67 
Repeat minor 
stroke  265 263 252 243 236 232 235 235 235 216 
Repeat major 
stroke  341 339 323 312 302 297 298 298 298 272 
Days post maj strk  97203  96425  92359  89256  86571  85204  85273  85162  85246  78283 
CE clinic assess  898  943  1411  1937  2399  2740  2898  2942  2948  3439 
CE appointment 
ass  517 510 440 359 289 229 113  11  0  0 
CE surgery  181  185  235  293  344  380  386  378  378  441 
Stroke at CE  3  3  4  5  6  6  6 6  6  7 
Stroke related 
death  118 118 116 114 114 113 114 113 114 111 
Other cause death  517  516  517  518  519  518  519  519  518  520 
Normal exit  9021  9024  9040  9051  9060  9065  9063  9063  9063  9090 ©NCCSDO 2008  Page 89 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Antiplatelet 
t h e r a p y             
Change no to mono  723  714  618  507  408  322  163  21  0  0 
Change no to dual  773  797  1048  1345  1613  1815  1880  1873  1872  2188 
Chnge mono to 
dual  607  628  839  1072 1275 1417 1448 1433 1433 1676 
Monotherapy 
weeks  204786 203395 188292 170708 155084 143447 136229 132251 131204 117040 
Dual therapy 
weeks  65836  67949  90209  116476 140104 157512 162510 161536 161463 189328 
Warfarin started  612  615  639  662  681  688  609  525  522  599 
Warfarin weeks  49560  49635  50953  52364  53577  54075  50596  46875  46712  50512 
Statin started  1656  1690  2039  2433  2781  3024  3008  2900  2890  3368 
Statin weeks  197864  199464  216226  235673  253059  265372  264401  259033  258477  282457 
Antihypertensive                    
Started  4152 4158 4204 4240 4271 4216 3496 3222 3200 3714 
Weeks 185556  186098  191004  195303  199160  198313  166462  154236  153226  178674 
* This refers to a strategy where the GP refers all suspect TIAs to outpatient clinic 
 
 
 
Inpatient admission 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
TIA mimics  5000  4997  5000  4998  4998  4996  4997  4997  4996  4998 
Genuine TIAs  3502  3503  3502  3504  3504  3505  3504  3505  3506  3504 
Minor strokes  1498  1499  1497  1498  1498  1499  1499  1498  1498  1497 
Ambulances 1  1717  1717  1715  1717  1715  1716  1716  1715  1716  1716 
Ambulances 2  164  162  153  146  141  139  140  140  141  127 
GP first surgeries  8390  8388  8383  8374  8370  8367  8371  8371  8371  8357 
GP second 
surgeries  1628 1608 1396 1154  934  744  368  36  0  0 
A&E doctors  1868  1866  1856  1851  1844  1842  1844  1843  1844  1831 ©NCCSDO 2008  Page 90 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Hospital specialists  1367  1366  1358  1353  1348  1347  1348  1347  1349  1338 
Scheduled OP  0  68  735  1470  2118  2674  3743  4677  4777  8329 
Thrombolysis 19  20  27  32  37  37  37  37  37  40 
Repeat mimic  58  58  58  58  58  58  58  58  58  58 
Repeat TIA  81  81  78  75  72  71  74  74  75  67 
Repeat minor 
stroke  263 261 250 240 234 231 233 233 234 213 
Repeat major 
stroke  339 337 321 309 299 296 296 296 296 269 
Days post maj strk  96442  96103  91803  88522  85873  84771  84610  84596  84479  77686 
CE clinic assess  898  943  1411  1936  2399  2738  2900  2941  2948  3436 
CE appointment 
ass  517 511 440 360 289 228 113  11  0  0 
CE surgery  180  184  236  292  343  379  385  377  377  439 
Stroke at CE  3  3  4  5  6  6  6 6  6  7 
Stroke related 
death  117 117 115 113 113 112 113 112 112 110 
Other cause death  516  516  516  518  518  518  518  517  518  519 
Normal exit  9017  9018  9033  9042  9048  9053  9052  9054  9053  9078 
Antiplatelet 
t h e r a p y             
Change no to mono  723  714  618  508  408  321  163  21  0  0 
Change no to dual  773  797  1048  1343  1613  1815  1881  1874  1872  2187 
Chnge mono to 
dual  607  627  839  1072 1274 1418 1447 1432 1433 1675 
Monotherapy 
weeks  204816 203332 188248 170612 155068 143331 136199 132263 131158 117061 
Dual therapy 
weeks  65706  67771  90002  116143 139789 157219 162180 161196 161183 188963 
Warfarin started  612  616  639  664  681  688  610  526  523  600 
Warfarin weeks  49419  49578  50782  52201  53279  53763  50343  46638  46470  50208 
Statin started  1655  1689  2038  2434  2780  3025  3008  2901  2892  3367 
Statin weeks  197594  199073  215830  235224  252508  264723  263923  258437  258020  281839 ©NCCSDO 2008  Page 91 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Antihypertensive                    
Started 4151  4157  4203  4241  4273  4219  3497  3222  3202  3712 
Weeks 185302  185797  190603  194806  198682  197849  165924  153647  152756  177989 
IP admissions  1184  1251  1909  2640  3284  3283  3284  3284  3286  3788 
Inpatient days  4072  4323  6817  9587  12024  12016  12013  12003  12010  13881 
* This refers to a strategy where the GP refers all suspect TIAs to outpatient clinic 
 
Twice weekly flexible outpatient appointment system for rapid access outpatient clinic 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
TIA mimics  4996  4998  4998  4999  4997  4997  5001  4997  4998  4999 
Genuine TIAs  3505  3504  3504  3504  3503  3504  3501  3504  3503  3502 
Minor strokes  1499  1498  1499  1498  1500  1499  1498  1499  1499  1499 
Ambulances 1  1715  1716  1717  1715  1716  1716  1716  1715  1715  1714 
Ambulances 2  169  168  162  157  153  152  154  154  154  144 
GP first surgeries 8394  8393  8387  8383  8377  8375  8378  8379  8379  8370 
GP second 
surgeries  1629 1609 1396 1153  935  744  369  36  0  0 
A&E  doctors  1871 1871 1866 1860 1856 1855 1857 1857 1857 1846 
Hospital specialists  1369  1369  1365  1361  1358  1357  1358  1358  1358  1351 
Scheduled OP  0  67  730  1460  2104  2659  3720  4638  4731  6195 
Overflow  OP  0 0 0  0  0  0  1 18  22  2082 
Repeat mimic  58  58  58  58  58  58  58  58  58  59 
Repeat TIA  82  81  78  76  72  72  74  75  74  67 
Repeat minor 
stroke  265 263 253 246 240 238 240 241 241 226 
Repeat major 
stroke  342 339 325 316 308 305 305 307 307 288 
Days post maj strk  97231  96762  93066  90738  88666  87734  87861  88206  88245  84276 
CE clinic assess  897  942  1406  1928  2387  2727  2883  2927  2931  3408 
CE appointment 
ass  518 510 439 359 289 229 113  11  0  0 
CE surgery  181  185  236  292  343  379  385  377  376  438 ©NCCSDO 2008  Page 92 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Stroke at CE  3  3  4  5  6  6  7 6  6  7 
Stroke related 
death  118 117 116 114 114 114 114 114 114 112 
Other cause death  517  516  518  518  519  518  518  517  517  519 
Normal exit  9020  9024  9037  9047  9054  9057  9056  9056  9056  9074 
Antiplatelet 
t h e r a p y             
Change no to mono  723  712  618  507  408  321  164  21  0  0 
Change no to dual  773  797  1046  1342  1608  1811  1873  1866  1863  2172 
Chnge mono to 
dual  606  627  838  1068 1272 1412 1443 1430 1429 1668 
Monotherapy 
weeks  204894 203428 188287 170822 155358 143669 136614 132648 131720 117978 
Dual therapy 
weeks  65788  67881  89980  116027 139525 156789 161572 160619 160370 186979 
Warfarin started  612  615  637  658  677  683  603  518  515  586 
Warfarin weeks  49514  49694  50976  52280  53425  53911  50370  46566  46469  49838 
Statin started  1655  1688  2036  2426  2771  3015  2994  2887  2874  3339 
Statin  weeks  197807 199364 215950 235153 252415 264558 263451 258021 257374 279976 
Antihypertensive                    
Started 4152  4158  4198  4231  4260  4202  3478  3204  3181  3673 
Weeks 185557  186115  190702  194822  198569  197483  165432  153124  152085  175931 
* This refers to a strategy where the GP refers all suspect TIAs to outpatient clinic 
 
Twice weekly fixed appointment system for rapid access outpatient clinic 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
TIA mimics  4996  4998  4998  4999  4998  4998  4996  4998  4998  4998 
Genuine TIAs  3505  3504  3504  3504  3504  3504  3506  3504  3503  3504 
Minor strokes  1499  1498  1499  1498  1498  1498  1498  1497  1499  1498 
Ambulances 1  1715  1716  1717  1715  1716  1716  1717  1715  1716  1716 
Ambulances 2  169  168  162  157  153  151  153  154  154  203 
GP first surgeries  8394  8393  8387  8383  8377  8375  8377  8380  8379  8426 ©NCCSDO 2008  Page 93 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
GP second 
surgeries  1629 1609 1396 1153  935  744  368  36  0  0 
A&E doctors  1871  1871  1866  1860  1856  1855  1858  1856  1857  1905 
Hospital specialists  1369  1369  1365  1361  1358  1356  1359  1357  1358  1396 
Scheduled OP  0  67  730  1460  2104  2657  3724  4654  4753  1487 
Repeat mimic  58  58  58  58  58  58  58  58  59  57 
Repeat TIA  82  81  78  76  73  71  74  75  75  102 
Repeat minor 
stroke  265 263 253 246 239 237 240 240 240 318 
Repeat major 
stroke  342 339 325 316 307 304 305 307 307 412 
Days post maj strk  97231  96762  93066  90738  88522  87580  87764  88246  88195  115362 
CE clinic assess  897  942  1406  1928  2388  2726  2886  2928  2930  1482 
CE appointment 
ass  518 510 439 359 289 229 113  11  0  0 
CE  surgery  181 185 236 292 343 379 385 376 377 182 
Stroke at CE  3  3  4  5  6  6  6 6  6  3 
Stroke related 
death  118 117 116 114 114 114 114 114 114 124 
Other cause death  517  516  518  518  518  518  518  518  518  513 
Normal exit  9020  9024  9037  9047  9055  9058  9056  9055  9054  8949 
Antiplatelet 
t h e r a p y             
Change no to mono  723  712  618  507  408  322  163  21  0  0 
Change no to dual  773  797  1046  1342  1609  1810  1876  1866  1864  858 
Chnge mono to 
dual  606  627  838  1068 1272 1411 1444 1429 1428  657 
Monotherapy 
weeks  204894 203428 188287 170822 155261 143719 136571 132621 131734 184671 
Dual therapy 
weeks  65788  67881  89980  116027 139569 156717 161785 160543 160338  56724 
Warfarin started  612  615  637  658  677  683  603  519  515  247 
Warfarin weeks  49514  49694  50976  52280  53380  53883  50354  46556  46487  31892 ©NCCSDO 2008  Page 94 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Statin started  1655  1688  2036  2426  2770  3012  2997  2886  2875  1332 
Statin weeks  197807  199364  215950  235153  252432  264526  263645  257935  257355  167685 
Antihypertensive                    
Started 4152  4158  4198  4231  4259  4202  3480  3203  3180  1508 
Weeks 185557  186115  190702  194822  198503  197469  165574  153078  151974  56543 
* This refers to a strategy where the GP refers all suspect TIAs to outpatient clinic 
 
Once weekly fixed appointment system for rapid access outpatient clinic 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
TIA mimics  4996  4998  4995  4996  4997  4995  4996  4997  4997  4997 
Genuine TIAs  3505  3505  3506  3505  3504  3507  3504  3504  3504  3505 
Minor strokes  1499  1498  1499  1499  1498  1498  1500  1498  1498  1498 
Ambulances 1  1715  1716  1717  1717  1716  1716  1716  1717  1717  1715 
Ambulances 2  169  168  162  158  154  155  202  206  206  207 
GP first surgeries 8394  8392  8386  8382  8378  8378  8423  8427  8428  8432 
GP second 
surgeries  1629 1609 1398 1153  935  743  369  36  0  0 
A&E  doctors  1871 1871 1867 1863 1857 1858 1905 1909 1909 1908 
Hospital specialists  1369  1370  1367  1363  1359  1359  1396  1399  1399  1398 
Scheduled OP  0  66  724  1451  2087  2627  1253  405  364  0 
Repeat mimic  58  58  58  58  58  58  58  58  58  58 
Repeat TIA  82  81  78  76  72  72  100  103  104  104 
Repeat minor 
stroke  265 263 255 248 242 244 316 321 321 323 
Repeat major 
stroke  342 340 328 320 312 314 408 415 416 416 
Days post maj strk  97231  96734  93867  92034  90153  91221  114760  115738  115787  115725 
CE clinic assess  897  942  1404  1923  2378  2707  1634  1223  1205  1035 
CE appointment 
ass  518 511 439 358 289 229 112  11  0  0 
CE surgery  181  185  235  293  342  376  215  153  150  130 
Stroke at CE  3  3  4  5  6  6  4 2  2  2 ©NCCSDO 2008  Page 95 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Stroke related 
death  118 117 115 114 114 114 123 124 124 124 
Other cause death  517  517  517  518  518  517  514  513  513  513 
Normal exit  9020  9023  9035  9043  9050  9048  8952  8946  8945  8945 
Antiplatelet 
t h e r a p y             
Change no to mono  723  713  617  506  407  322  164  21  0  0 
Change no to dual  773  797  1046  1339  1604  1801  1055  694  673  572 
Chnge mono to 
dual  606 628 838  1069  1269  1406  809 527 515 437 
Monotherapy 
weeks  204894 203314 188354 170933 155605 144404 184574 188622 188057 189192 
Dual therapy 
weeks  65788 67895 89913  115688  138809  155015  68161 51048 50142 47861 
Warfarin started  612  613  635  656  672  676  375  215  208  188 
Warfarin weeks  49514  49627  50821  52112  53157  53511  37033  31305  31063  30814 
Statin started  1655  1690  2033  2421  2763  2997  1725  1094  1056  908 
Statin weeks  197807  199330  215802  234878  251625  262885  182354  163390  162151  160231 
A n t i h y p e r t e n s i v e             
Started 4152  4156  4196  4225  4248  4183  2082  1263  1216  1059 
Weeks 185557  185999  190509  194366  197672  195713  78190  52249  50680  48678 
* This refers to a strategy where the GP refers all suspect TIAs to outpatient clinic 
 
 Greater use of 999 service 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
TIA mimics  4998  4995  4997  4999  4997  4998  4997  4998  4998  4996 
Genuine TIAs  3504  3506  3505  3503  3505  3504  3505  3504  3504  3505 
Minor strokes  1498  1498  1499  1499  1498  1497  1498  1499  1498  1499 
Ambulances 1  2438  2441  2440  2441  2441  2441  2442  2441  2440  2441 
Ambulances 2  219  218  211  205  198  196  200  199  199  184 
GP first surgeries  7644  7640  7639  7634  7631  7630  7631  7632  7633  7625 
GP second  1456  1441  1296  1092  892  712  353  35  0  0 ©NCCSDO 2008  Page 96 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
surgeries 
A&E doctors  2640  2642  2634  2629  2622  2620  2624  2623  2623  2608 
Hospital specialists  1902  1904  1898  1894  1888  1887  1890  1888  1888  1877 
Scheduled OP  0  45  509  1124  1726  2248  3271  4165  4262  7592 
Repeat mimic  58  58  58  58  59  58  58  58  58  59 
Repeat TIA  81  81  78  75  73  72  75  75  75  69 
Repeat minor 
stroke  257 256 248 240 233 230 233 233 233 216 
Repeat major 
stroke  331 329 318 307 298 294 295 294 294 272 
Days post maj strk  94007  93491  90490  87722  85280  84226  84057  83862  83577  78065 
CE clinic assess  1218  1250  1573  2011  2437  2755  2908  2950  2955  3372 
CE appointment 
ass  462 456 408 341 276 219 108  10  0  0 
CE surgery  214  217  252  300  346  382  386  379  378  432 
Stroke at CE  4  4  4  5  6  6  6 6  6  7 
Stroke related 
death 116  116  115  114  113  114  114  114  113  112 
Other cause death  518  516  518  518  519  519  519  519  519  521 
Normal exit  9031  9035  9045  9056  9063  9067  9066  9066  9067  9087 
Antiplatelet 
t h e r a p y             
Change no to mono  646  640  572  480  389  308  156  20  0  0 
Change no to dual  949  967  1140  1386  1631  1820  1883  1876  1875  2144 
Chnge mono to 
dual  744  759  905  1100 1287 1418 1449 1435 1436 1642 
Monotherapy 
weeks  194365 193396 182849 168136 153731 142819 135879 132010 131207 119010 
Dual therapy 
weeks  81046  82587  98032  119970 141707 157890 162772 161809 161826 185598 
Warfarin started  624  626  641  661  679  684  609  529  524  591 
Warfarin weeks  50158  50288  51123  52320  53433  53889  50575  46978  46806  50047 
Statin started  1885  1910  2150  2478  2798  3027  3011  2907  2896  3304 ©NCCSDO 2008  Page 97 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Statin weeks  208871  210068  221658  237903  253986  265352  264532  259437  258876  279301 
Antihypertensive                    
Started 4142  4147  4178  4206  4236  4182  3493  3229  3208  3644 
Weeks 186715  187147  190533  194129  197754  196810  166348  154522  153548  175231 
* This refers to a strategy where the GP refers all suspect TIAs to outpatient clinic 
 
Optimal GP management 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
TIA mimics  4999  4998  4999  4995  4996  4998  4997  4998  4996  4996 
Genuine TIAs  3504  3504  3502  3506  3505  3503  3504  3503  3504  3506 
Minor strokes  1497  1498  1498  1499  1499  1499  1499  1498  1499  1498 
Ambulances 1  1715  1716  1716  1716  1717  1717  1716  1717  1716  1717 
Ambulances 2  144  144  144  145  145  146  150  151  151  138 
GP first surgeries  8371  8370  8370  8370  8369  8370  8377  8376  8378  8364 
A&E doctors  1847  1847  1848  1848  1849  1850  1854  1855  1854  1843 
Hospital specialists  1350  1351  1351  1352  1352  1353  1355  1356  1356  1347 
Scheduled OP  0  67  731  1469  2120  2674  3747  4681  4783  8336 
Repeat mimic  59  58  59  59  58  58  59  58  59  58 
Repeat TIA  69  69  69  69  68  70  74  75  75  67 
Repeat minor 
stroke  225 225 226 227 227 229 235 235 236 216 
Repeat major 
stroke  290 291 291 293 293 294 297 298 298 272 
Days post maj strk  82906  83169  83411  83905  84080  84395  84993  85344  85318  78266 
CE clinic assess  868  915  1381  1915  2387  2730  2898  2941  2948  3440 
CE appointment 
ass  3422 3378 2920 2391 1924 1522  749  72  0  0 
CE surgery  553  554  556  555  555  549  468  385  377  442 
Stroke at CE  9  9  9  9  9  9  8 7  6  7 
Stroke related 
death  113 114 114 113 113 114 114 114 114 111 
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    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Normal exit  9069  9067  9067  9066  9066  9065  9062  9063  9063  9090 
Antiplatelet 
t h e r a p y             
Change no to dual  2811  2810  2798  2789  2778  2735  2352  1935  1872  2188 
Chnge mono to 
dual  2163 2164 2153 2142 2136 2097 1776 1457 1432 1676 
Monotherapy 
weeks  89532 89564 89536 89623 89620 91517  110801  130000  131244  117053 
Dual therapy 
weeks  245343 245322 244408 243477 242747 238663 203117 165967 161452 189330 
Warfarin started  650  651  667  683  697  700  614  525  522  600 
Warfarin weeks  53329  53368  54103  54920  55646  55746  51319  46858  46705  50523 
Statin started  4244  4245  4240  4238  4238  4178  3578  2955  2890  3370 
Statin weeks  326913  326899  326652  326594  326532  323556  293289  261903  258488  282515 
Antihypertensive                    
Started  4374 4377 4371 4368 4366 4284 3515 3223 3200 3714 
Weeks 212442  212547  212350  212313  212260  208084  169206  154425  153219  178693 
* This refers to a strategy where the GP refers all suspect TIAs to outpatient clinic 
 
 Improved GP diagnosis 
Sensitivity 90% specificity 80% 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
TIA mimics  4998  4998  4996  4998  4997  4997  4998  4998  4999  4999 
Genuine TIAs  3504  3504  3504  3505  3506  3506  3503  3504  3503  3503 
Minor strokes  1498  1498  1500  1497  1498  1498  1498  1498  1498  1498 
Ambulances 1  2439  2440  2441  2441  2440  2439  2440  2440  2440  2439 
Ambulances 2  211  210  203  195  189  185  186  186  185  179 
GP first surgeries  7640  7638  7635  7631  7627  7628  7627  7627  7627  7624 
GP second 
surgeries  1233 1219 1056  826  600  415  191  19  0  0 
A&E doctors  2633  2634  2627  2619  2613  2608  2609  2609  2608  2602 
Hospital specialists  2007  2008  2003  1995  1989  1984  1986  1985  1986  1980 ©NCCSDO 2008  Page 99 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Scheduled OP  0  50  572  1263  1937  2478  3117  3601  3653  7591 
Repeat mimic  59  58  58  59  59  59  59  58  58  59 
Repeat TIA  80  79  77  73  70  69  70  70  70  67 
Repeat minor 
stroke  247 245 238 228 221 217 217 217 217 209 
Repeat major 
stroke  315 313 301 290 280 274 274 274 274 263 
Days post maj strk  89691  89159  85998  82863  80162  78648  78479  78326  78243  75624 
CE clinic assess  1362  1396  1758  2247  2724  3082  3251  3300  3304  3511 
CE appointment 
ass  395 390 334 259 186 128  58  6  0  0 
CE surgery  224  228  266  319  371  411  425  424  423  451 
Stroke at CE  4  4  4  6  6  7  7 7  7  8 
Stroke related 
death  115 114 113 112 111 111 112 111 111 110 
Other  cause  death  518 517 519 519 520 520 520 521 520 520 
Normal exit  9049  9052  9063  9073  9082  9087  9087  9088  9088  9099 
Antiplatelet 
t h e r a p y             
Change no to mono  555  548  473  370  268  183  86  11  0  0 
Change no to dual  1011  1031  1224  1499  1773  1989  2080  2095  2096  2230 
Chnge mono to 
dual  794  809  974  1191 1401 1551 1604 1606 1608 1709 
Monotherapy 
weeks  188667 187487 175779 159324 143213 131045 124497 121722 121119 115086 
Dual therapy 
weeks  86449  88065  105462 129957 154343 172888 180215 181249 181363 193108 
Warfarin started  587  589  606  627  648  658  624  584  583  615 
Warfarin weeks  48474  48593  49556  50855  52114  52843  51366  49590  49591  51184 
Statin started  1928  1953  2224  2589  2946  3210  3272  3240  3237  3439 
Statin weeks  210700  211935  225071  243095  261162  274424  277536  275933  275750  285923 
Antihypertensive                    
Started 3974  3980  4014  4048  4080  4062  3723  3592  3582  3794 ©NCCSDO 2008  Page 100 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Weeks 179421  179933  183671  187752  191819  192746  178135  172393  171959  182512 
* This refers to a strategy where the GP refers all suspect TIAs to outpatient clinic 
 
 
 
Improved GP management and diagnosis 
    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
TIA mimics  4996  4998  4997  4999  4998  5000  4995  4998  4997  4998 
Genuine TIAs  3505  3504  3504  3503  3505  3501  3506  3504  3504  3504 
Minor strokes  1499  1498  1500  1498  1497  1499  1498  1498  1499  1498 
Ambulances 1  1716  1716  1716  1715  1716  1715  1717  1717  1716  1715 
Ambulances 2  137  137  137  137  138  138  141  140  141  134 
GP first surgeries  8365  8365  8365  8365  8365  8366  8368  8367  8368  8362 
GP second 
surgeries  0 0 0 0 0 0 0 0 0 0 
A&E doctors  1841  1841  1842  1841  1841  1842  1845  1845  1844  1838 
Hospital specialists  1439  1437  1438  1438  1439  1439  1441  1441  1442  1436 
Scheduled  OP  0  75  820  1648 2379 2952 3626 4128 4184 8335 
Repeat mimic  59  58  58  58  58  58  58  58  58  58 
Repeat TIA  68  68  68  67  67  68  70  70  70  66 
Repeat minor 
stroke  214 215 215 215 216 217 220 219 220 210 
Repeat major 
stroke  272 272 273 274 275 276 277 278 278 265 
Days post maj strk  77907  77808  78250  78701  78980  79342  79721  79910  79877  76385 
CE clinic assess  971  1020  1543  2139  2670  3058  3242  3290  3296  3539 
CE appointment 
ass  2987 2936 2425 1830 1304  890  406  40  0  0 
CE surgery  510  510  510  511  510  507  467  426  423  453 
Stroke at CE  9  9  9  9  9  8  8 7  7  8 
Stroke related 
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    Referral threshold ABCD
2 score  Refer all 
Per 10000 patients  Baseline  7  6  5  4  3  2 1  0  Cases* 
Other cause death  519  519  520  520  519  519  519  519  519  522 
Normal exit  9088  9089  9088  9086  9087  9085  9084  9085  9084  9096 
Antiplatelet 
t h e r a p y             
Change no to dual  2592  2589  2577  2563  2554  2527  2335  2124  2095  2251 
Chnge mono to 
dual  1993 1992 1982 1970 1961 1940 1779 1618 1604 1725 
Monotherapy 
weeks  100324 100345 100381 100391 100462 101429 110941 120649 121262 114246 
Dual therapy 
weeks  225200 225054 224173 223023 222231 219802 202039 183275 181023 194862 
Warfarin started  606  607  623  641  656  663  624  580  579  616 
Warfarin weeks  50911  50934  51714  52641  53405  53705  51684  49520  49427  51324 
Statin started  3914  3913  3910  3906  3904  3872  3576  3262  3230  3466 
Statin weeks  309947  309827  309758  309465  309466  307882  292918  277081  275408  287270 
A n t i h y p e r t e n s i v e             
Started 4169  4167  4164  4158  4155  4114  3731  3583  3571  3825 
Weeks 201464  201380  201296  201083  201039  198881  179588  172086  171467  184057 
* This refers to a strategy where the GP refers all suspect TIAs to outpatient clinic ©NCCSDO 2008  Page 102 
6: Discussion  
 
6.1 Summary of findings of model 
 
In this model, we explored the likely outcome of different patterns of service 
provision for people presenting with TIA or minor stroke in a population of 500,000. 
Our initial analysis suggested that it would be cost effective to introduce daily 
specialist rapid access clinics as compared to current practice. If a referral 
threshold were set at an ABCD2 score of 4 or more for this service, then the 
additional cost per annum would be of the order of £108,500 per annum compared 
to current practice and result in the prevention of 4 major strokes per annum. The 
strategy that would be most effective would be to refer all suspect cases. This 
would prevent 7 major strokes per annum. The incremental cost effectiveness ratio 
of moving from referring patients with an ABCD2 score of 4 or more to referring all 
suspected cases is £50,000 per major stroke averted. The number of patients seen 
per week in the rapid access clinic would rise from 4 to 16 per week.  
If patients with an ABCD2 score of 4 or more were admitted to hospital, this made 
referral strategies more expensive, with referral at an ABCD2 of 6 or more or refer 
all suspect cases the only potentially cost effective options, though the ICER of the 
latter at £69,000 per stroke prevented is at the borderline of what would be 
considered value for money. When admission to hospital was compared to a 
strategy of non-admission, then it became apparent that this strategy was not cost 
effective, with the ICER rising to over £1,000,000 per stroke prevented.  
With regard to different patterns of clinic provision, we found that daily clinics were 
the most effective and the most cost effective. Twice weekly clinics were effective 
with an ICER of £44,000 per major stroke prevented at a referral threshold of 
ABCD2 of 4 or more, but not at lower thresholds. How clinics were costed was 
crucial to determining cost-effectiveness. If unused clinic slots were costed, then 
the only cost effective option for twice weekly clinics that are flexible becomes 
seeing all suspected cases (with an ICER of £51,000 per stroke prevented) to 
ensure minimal wastage of capacity. However, this would require on average an 
additional 4 appointments per week above the scheduled appointments to avoid 
waiting lists developing. If the twice weekly clinics are of fixed capacity and unused 
slots are costed, then a referral threshold of 3 is the only potentially cost effective 
option with an ICER of £57,000 per stroke prevented. A weekly clinic is the least 
effective option, but would be cost effective at an ABCD2 referral threshold of 4 or 
more. 
We explored the impact of greater use of emergency services, and found that our 
initial conclusions still applied – namely that it would be cost effective to refer 
patients to a daily rapid access clinic at different referral thresholds down to an 
ABCD2 score of 4, or to refer all suspected cases. Comparing greater use with 
current use, we found that current use (for the management of TIA and minor 
stroke) was the more cost effective.  
If GPs treated patients optimally, then the most cost effective option is for all 
suspected patients to be referred to a rapid access clinic. If GPs are better 
diagnostically, but do not change their management, then a referral threshold of 
ABCD2 score of 3 or 4 appears the most effective option that is still cost effective. 
If GPs treated patients optimally and were better diagnostically, then there would 
be no need for specialist rapid access clinics. 
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6.2 Interpretation of findings of model 
 
Our analysis suggests that introduction of rapid access specialist clinics for 
management of patients with TIA and minor stroke will be cost effective. The 
optimal option would appear to be for all patients with suspected TIA to be referred 
to such a clinic. However, this conclusion depends upon capacity – with an 
expected 16 referrals per week for a population of 500,000. If this capacity is 
impractical, then a strategy that GPs refer patients with an ABCD2 score of 4 or 
more would require on average only four consultations per week. Daily clinics are 
more effective than other options, which reflect the high early risk of stroke 
following TIA and the importance of minimising delay. However, if daily clinics 
cannot be provided, then twice weekly clinics or weekly clinics are cost effective 
options, but of inferior effectiveness (and cost-effectiveness) as compared to daily 
clinics. How the clinics are costed is of crucial importance to the cost effectiveness 
analysis. Given the random variability of new onset of TIA and minor stroke, fixed 
capacity clinics (where unused slots cost resource) are less efficient than flexible 
clinics where it is assumed that the resources can be used for other purposes if not 
needed to see TIA patients. If fixed capacity clinics are all that can be provided, 
then it becomes most cost effective to have referral thresholds as low as possible 
without allowing queues to develop.   
Admitting patients at high risk of stroke in order to allow for early use of 
thrombolysis did not appear a cost effective strategy in this model. This only 
resulted in the prevention of 2-3 additional major strokes over the 10-year period 
as compared to if patients were not admitted to hospital, and resulted in higher 
costs and very high incremental cost effectiveness ratio (over £1,000,000 per 
stroke prevented). Furthermore, the way the model was constructed (with patients 
exiting on receipt of thrombolysis) will have resulted in over-estimate of the 
benefits of the treatment. If we had lowered the length of stay in hospital or raised 
the admission threshold this would have reduced costs, but the small return in 
terms of better stroke prevention would have been lower still. However, it should 
be noted that the risk of full stroke was estimated by fitting a curve to data for the 
time risk of stroke from the available data from the OXVASC study, so it may be 
that we underestimated risk in the first three days. Therefore, while these results 
provide no support for a policy of admitting patients, in places where this does 
occur, rather than discontinue the practice it would be valuable to audit the results 
that were being achieved with this policy.  
If more patients use emergency services, this makes no major differences to the 
results of the model, suggesting that our conclusions will be robust to changes in 
use of services that might result as a result of implementation of the National 
Stroke Strategy. (Department of Health, 2007). However, our finding that 
strategies involving greater use of emergency services are not cost-effective 
suggests that any publicity campaign should focus on the importance of use of 
emergency services for people suffering a suspected stroke, as opposed to a TIA. A 
similar conclusion was reached in an analysis of a possible 24 hour admission 
following TIA performed using US data. (Nguyen-Huynh, 2005) 
If GPs initiate immediate optimal medical therapy in all patients in whom they 
diagnose TIA (namely statins, blood pressure lowering and dual anti-platelet 
therapy), then the role of the rapid access clinic becomes primarily one of diagnosis 
rather than treatment – both identifying TIA in cases where the GP did not make 
the diagnosis, and stopping treatments where the GP diagnosis of TIA was 
incorrect. This is reflected in that when we modelled optimal medical therapy by 
the GP, the most cost effective option was for all patients with suspected TIA to be 
referred to the clinic.  ©NCCSDO 2008  Page 104 
If GPs are better diagnostically, then it is no longer cost effective (ICER of over 
£100,000 per stroke prevented) for GPs to refer all suspected TIAs, as opposed to 
a strategy of referring patients with an ABCD2 score of 3 or more. This makes 
sense, since the value of the refer all suspected cases was gained largely through 
the errors in diagnosis of the GP that were assumed in the model.  
If better GP diagnosis is combined with better GP management, then the specialist 
rapid access clinic no longer has a cost-effective role, since its only value left that is 
modelled is in ensuring faster access to carotid endarterectomy. This raises the 
question: should policy be directed towards training GPs rather than setting up 
specialist clinics? The model cannot answer this question, since we do not know 
what the costs or effectiveness of such a programme would be. A cluster 
randomised trial of implementation of stroke prevention guidelines for people with 
atrial fibrillation and TIA in primary care found that this did lead to increased 
uptake of effective medications, and suggested that the development and 
implementation of the local guidelines was highly cost effective. (Wright 2007). 
However, it is not clear what interventions would lead to better diagnosis of TIA by 
GPs. The underlying problem is that TIA is a relatively rare diagnosis for a GP – 
with an incidence of 0.7 per 1,000 population, a GP with a list size of 2,000 patients 
would only expect to see 1 or 2 cases per year.  
 
6.3 Limitations of model 
 
Our principal measure of outcome has been occurrence of major stroke, which for 
the purposes of this model has been defined as a stroke that would have led to 
hospital admission under current practice. We have not taken into account 
prevention of minor strokes or TIAs (though these are reported in the model 
outputs). More importantly, we have not taken into account the impacts of 
treatment on cardiovascular risk as a whole. The medical treatments for stroke 
prevention will also reduce risk of other vascular events such as myocardial 
infarction. Therefore, we will have under-estimated the benefits of specialist 
referral.  
The accuracy of the predictions made by the model depends upon the quality of the 
data inputs. The key data included: 
Data on the epidemiology of TIA and minor stroke, including its incidence and 
prognosis in terms of risk of further strokes. 
• Data on the effectiveness of medical and surgical interventions. 
• Data on current practice 
The data on epidemiology of TIA and minor stroke was drawn from the OXVASC 
study, (Rothwell, 2004a) which is a unique data set, which provides accurate data 
on the epidemiology of TIA through its intensive and multi-faceted approach to 
identification and verification of possible events.  
The data on the effectiveness of medical and surgical interventions was drawn from 
randomised controlled trials. For some of these interventions, e.g. carotid 
endartectomy, there are good data on the effectiveness in relation to time after 
event. For others, e.g. blood pressure and cholesterol lowering, the evidence is 
lacking, in that our evidence base is not in people who had an event in the 
preceding couple of days. We have assumed that the relative risk reduction 
achieved by these therapies in the chronic treatment of an individual post TIA/ 
stroke also applies to the early phases of treatment. There is now some 
observational evidence to support this. (Rothwell, 2007; Lavallée, 2007)   
The data on current practice was drawn from the QRESEARCH database, which is a 
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there is likely to be some error in diagnostic coding, (Mant, 2003a) the recording of 
pharmaceutical interventions is complete and accurate, since prescribing is 
invariably done using the GP computer system. The errors in diagnostic coding are 
unlikely to have a serious impact on the results of the model, and the treatments 
observed reflect how GPs manage people with a diagnosis of TIA (even if that 
diagnosis is inaccurate). 
The area where the evidence was weakest concerned the accuracy with which 
general practitioners diagnose transient ischaemic attack. Several studies (Dennis, 
1989; Gibbs, 2001; Martin, 1997; Jempere, 1996) have reported how many 
patients referred to a specialist clinic have a final diagnosis of TIA or stroke, but we 
found no studies that had looked at people in whom the GP did not diagnose a TIA 
or stroke who had actually had one. As a result, it is relatively straightforward to 
determine predictive value of a GP diagnosis of TIA, but not sensitivity and 
specificity. We managed to make estimates of these from the literature (80% and 
60%) respectively, but these are subject to error. Therefore, we performed a 
sensitivity analysis to test the results of the model in circumstances where the GPs 
were able to diagnose TIA more accurately (with 90% sensitivity and 80% 
specificity). This made some differences to the results of the model, implying that 
while the most effective strategy would still be to refer all suspected cases, this 
would probably not be cost effective (with an ICER of over £100,000 per stroke 
prevented).  
We have assumed that the specialist clinic is 100% accurate in diagnosing TIA. TIA 
is essentially a clinical diagnosis, with no gold standard test, so it is impossible to 
validate this assumption. However, the clinical trials of therapy on which the model 
is based are all based upon clinical diagnosis of TIA, so the assumption is unlikely 
to have had a significant effect on the results of the model.  
While we have assumed that the specialist clinic will enable a ‘one stop’ assessment 
with carotid ultrasound available on the same day if appropriate, we have still 
assumed that the delay to surgery will reflect current availability in the NHS – 
which is a median delay of 67 days following assessment. (Mehta, 2005) Shorter 
waiting times would result in better results from surgery, (Rothwell, 2004b) and 
therefore increase the cost effectiveness of the specialist clinic option.  
In terms of clinic costs, we have modelled the costs of investigation of carotid 
disease, but not the use of brain imaging such as CT or MRI. There is evidence that 
diffusion weighted MRI can provide clinically useful information in the assessment 
of TIA and minor stroke, (Schulz, 2004) but use of MRI will not have influenced the 
outcomes in the model, so use of such investigations were not tested.   
To enable a decision to be made as to whether a specific strategy is cost effective, 
it is useful to be able to present the results in terms of quality adjusted life years 
(QALYs). QALYS were not incorporated into the model, but we have estimated that 
prevention of a stroke that would have led to a hospital admission is the equivalent 
of about a gain of 3-4 QALYs. This suggests that a strategy that costs up to around 
£60-80,000 per stroke prevented is likely to be considered cost effective.  
6.4 Discussion of implications of studies to collect data 
for the model 
 
While the principal purpose of these studies was to obtain data to inform the 
model, two of the additional pieces of work that were done to support the model 
development should be considered in their own right. These are the QRESEARCH 
analysis, and the patient survey.  
6.4.1 QRESEARCH study 
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This study has shown that of a cohort of 3405 individuals suffering a TIA between 
2004 and 2005 whilst registered with 463 practices, 6.5 % had died one year later.  
This compares to mortality rates of 3% of all women and 2% of all men aged 72 in 
the general population of England in the years 2003-5 suggesting that a diagnosis 
of TIA is associated with significant mortality risk over and above that in the 
general population.  As expected from the OXVASC data, most non fatal strokes 
following TIA occurred in the first month following the diagnosis. (Rothwell, 2005) 
 
At the time of diagnosis of TIA, most people had had a blood pressure 
measurement in the last year but for around half of individuals this reading was 
above 140 mmHg.  The majority of those with a last reading above 140mmHg were 
not receiving antihypertensive medication although above 160 mmHg the number 
was very small.  Current guidelines are to treat people with systolic blood pressure 
between 140 and 159 mmHg on the basis of cardiovascular risk and so these 
results may well reflect guideline compliant primary prevention.  Furthermore, this 
analysis does not take into account the need for multiple BP readings to confirm 
raised pressure or side effects / intolerances that patients may have suffered in the 
past precluding treatment.   
 
Following TIA, blood pressure dropped by 6/3 mmHg – equivalent to the addition of 
a low dose antihypertensive to all patients. This was associated with better 
achievement of the QOF (150/90 mmHg) and NICE (140/90 mmHg) targets of 80% 
and 60% respectively.  One year after TIA half of the cohort were being prescribed 
an antihypertensive suggesting that the results from PROGRESS were not accepted 
or perhaps just not implemented in primary care. (Progress Collaborative Group, 
2001; Mant, 2006) 
 
The situation for cholesterol was different with less than half having a recorded 
total cholesterol before suffering a TIA suggesting that routine measurement of 
cholesterol for primary preventative purposes is less frequent despite being 
required for risk calculation in those with moderately raised blood pressure.  This 
may be due to the relative difficulty of measuring cholesterol in comparison to 
blood pressure or may reflect that current practice is for less frequent screening of 
cholesterol, possibly using the estimations that are built into the EMIS clinical 
system.  Where cholesterol was measured, 80% of those recorded as having a total 
cholesterol over 5 mmol/l were not prescribed a statin which as with blood pressure 
probably reflects current guidelines which do not recommend lipid lowering 
medication in the absence of raised overall risk.  Post TIA there was a change in 
behaviour with the vast majority (83%) with a recorded cholesterol in the year 
following diagnosis and a more than doubling in the rate of statin prescription.  
However, even one year after TIA, less than half of individuals were being 
prescribed a statin.  
 
The evidence for statin use post TIA comes from two sources: firstly studies of 
primary or secondary cardiovascular risk reduction such as the Heart Protection 
Study and secondly from specific stroke trials such as the recently reported SPARCL 
trial.  These show benefit for people with stroke or TIA from lowering cholesterol 
although arguably most convincing in terms of cardiovascular risk reduction as 
opposed to cerebrovascular risk reduction. (Heart Protection Study Collaborative 
Group, 2002; SPARCL, 2006). It appears that as with the prescription of 
antihypertensives, widespread use of statins after TIA has yet to be implemented. 
 
This study has utilised a large database of routinely collected patient data to 
assemble a cohort of individuals suffering TIA within the same year drawn from the 
very recent past.  As such it provides high quality information concerning the 
management of individuals in actual practice as opposed to trial conditions.  The ©NCCSDO 2008  Page 107 
dataset has been shown to be representative of the population of England and 
Wales although it is under represented in Scotland and Northern 
Ireland.{www.qresearch.org} 
 
The size of the cohort – over 3000 individuals suffering first TIA in a single financial 
year reduces some possibly biases that occur in database work.  In particular by 
only including recent diagnoses made during the first year of implementation of the 
Quality and Outcomes Framework of the new GMS GP contract it is likely that the 
threshold for entering a diagnosis was higher and therefore more likely to be 
accurate: all presumptive stroke diagnoses need to be accompanied by evidence of 
objective investigation by neuroradiological scanning.  Whilst this is not the case for 
TIA, the need to provide appropriate secondary preventative treatment in the form 
of smoking cessation and blood pressure and cholesterol measurement is likely to 
have ensured a higher standard of coding. 
 
Perhaps the biggest concern with a study such as this is the verification of 
diagnosis.  The design of the QRESEARCH database precludes tracking back to 
individual records or practices in order to validate data.  However, age adjusted 
prevalence of Stroke or TIA in the database as a whole in 2004 was 14.5 / 1000 
which is similar to that previously reported from community surveys. (Hippisley-
Cox, 2004; Geddes, 1996; O’Mahony, 1999)    
 
It is likely that a proportion of primary diagnoses of TIA will have been incorrect.  
Secondary Care Clinics report 50-60% of primary care referrals to have a 
confirmed TIA diagnosis following specialist review, but other than in research 
projects rarely see the patient within 24 hours.  (Martin, 1997; Murray, 2007). We 
have no information regarding the validity of individual diagnoses for patients in 
our cohort.  The age and sex distribution were similar to that found in the OXVASC 
study: age 72 vs 74  (Rothwell, 2004a) and proportion female 56% vs 52%.  
(Rothwell, 2004a)   
 
It is interesting to note that patients in our cohort had a similar mortality rate to 
that found in a previous well validated study: The Oxford Community Stroke Project 
reported an average actuarial risk of death was approximately 6.3%/yr following 
TIA in the mid 1980’s. (Dennis, 1989) This suggests that whilst a GP diagnosis of 
TIA may not be accurate in terms of a neurovascular deficit, it is still associated 
with significant risk: A similar pattern has been found for heart failure: the ECHOES 
study (Hobbs, 2007) showed that 5 year mortality in individuals with a clinical 
diagnosis of heart failure was similar to those with confirmed heart failure even 
though only around a third of the former were confirmed on objective testing as 
falling in the latter group. 
 
The pre TIA risk factor control found in this study was similar to that found in 
Oxfordshire in OXVASC two years earlier: blood pressure was marginally lower in 
our cohort (145/80 vs 147/80 mmHg) and cholesterol was also lower (5.3 vs 5.6 
mmol/l). (Rothwell, 2004a) There were similar proportions in both studies receiving 
primary stroke prevention medication in the form of antithrombotics, 
antihypertensives and lipid lowering agents.  Post TIA the data obtained by the 
National Stroke Audit (which includes both stroke and TIA) are better in terms of 
anti thrombotic therapy (100% vs 79%) but contraindications to such therapy are 
not included in our figures.  Interestingly, the current data are better than the 
North American data from Ontario and North Carolina showing better levels of 
antithrombotic prescribing even one month after TIA.by UK GPs in comparison to 
their North American equivalents in the ER and primary care.  (Gladstone, 2004; 
Goldstein, 1995)  
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Twelve months after TIA, the proportions of men and women receiving 
antihypertensive or statin medication were similar, suggesting (albeit without 
correcting for age), that there is little evidence that men are more likely to receive 
secondary preventative treatment compared to women. 
 
Improving the management of people post TIA might be done in several ways.  The 
early risk of stroke observed in both these data and those from community studies 
with strict validation of diagnoses is such that early intervention is needed.  Two 
broad models tested in the wider study are improving primary care management, 
perhaps through education or inducements such as Quality and Outcomes 
Framework points or a fast track secondary care service utilising one stop clinics 
and / or increased use of the ambulance service.  The recently presented EXPRESS 
study has shown that through the use of tailored protocols in a rapid access clinic, 
effective intensive early secondary prevention of TIA via can be delivered. 
(Rothwell, 2007)     
  
In conclusion, this study has shown the current state of management of 
cardiovascular risk factors for people suffering a TIA in Primary Care in England and 
Wales.  Whilst there are some methodological issues regarding the ascertainment 
of cases of TIA, the characteristics of the cohort are similar to those from previous 
studies.  Although both clinically and statistically significant improvements in risk 
factor management are occurring in people with a clinical label of transient 
ischaemic attack, one year following TIA, sub optimal proportions of individuals are 
receiving gold standard treatment with antithrombotics, antihypertensives and lipid 
lowering drugs.   
 
Implications for service delivery 
These findings very much reinforce the overall thrust of the National Stroke 
Strategy – they suggest that management of TIA is sub-optimal both in the short 
and the medium term following an event. Introduction of rapid access 
neurovascular clinics is the mechanism that the National Strategy has selected to 
try and improve the immediate management of a TIA.  Improving the longer-term 
management of people with a TIA is likely to require a multi-faceted response, 
perhaps including educational initiatives in primary care, more use of GPs with 
special interest in stroke, and greater efforts to establish links between specialists 
and primary care practitioners.  
 
 
6.4.2 Patient survey 
 
The results of the pilot questionnaire differ in some areas to those found in the 
main questionnaire. For example, the findings of the main questionnaire indicate 
that patients would prefer to have their TIA managed by their GP rather than a 
specialist. This could be due to the fact that it may be easier for people to attend 
their local surgery, and appointments are often available with their GP quickly and 
at a time convenient to the patient. Although the patient preference question gave 
urgent referral to a specialist as a choice, it is possible that patients would still 
expect a longer delay before they were able to see a specialist than they would get 
if they went to see their GP; a perceived delay in access to specialists may account 
for the fact that this is the least favourite option. 
 
This theory is somewhat supported by the results of the pilot questionnaire. These 
patients favoured rapid access to a specialist, with visiting their GP as a second 
choice. However, these patients are all part of the OXVASC study and so would 
have had the opportunity to see a specialist very quickly. GPs participating in this 
study would refer any patient with a suspected TIA either directly to a specialist 
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pilot questionnaire, all patients visiting their GP with TIA symptoms were referred 
to A & E, whereas, only 11% of main questionnaire patients were referred there). 
On attending A & E, OXVASC patients would then be referred directly to the 
OXVASC team. This is not standard practice for treatment of suspected TIA, but is 
peculiar to the OXVASC region.  
 
It is possible that OXVASC patients prefer the urgent specialist appointment option 
because their treatment experience demonstrated that genuine rapid access is 
possible. It could, therefore, mean that less atypical patients would also choose this 
option if genuinely rapid access to a specialist was available to them. However, it 
must also be remembered that the number of patients completing a pilot 
questionnaire was very small, so the views expressed in their responses may not 
be representative of all OXVASC participants. 
 
As well as the differences in how a patient presenting with TIA symptoms are 
treated and differences in service preferences, there were also slight differences in 
the proportions of patients reporting different symptoms, with weakness/numbness 
down one side being the most common symptom in pilot patients and problems 
with speech being the most common symptom in the main questionnaire. 
Furthermore, there was a difference in the proportion of patients having their TIA 
at weekends and during the week between the groups. Again, this is probably 
explained by the small numbers of patients in the pilot study, making it more likely 
that the results found in the main questionnaire are more representative of the 
population as a whole than are those found in the pilot questionnaire results, an 
assumption that is supported by the similarities found between the pilot and the 
main results. 
 
Patients in both groups behaved in a similar manner when they had their TIA 
symptoms. Most patients visited their GP or went to hospital. There were similar 
proportions of people in both the pilot and the main questionnaire who took no 
immediate action when they had their symptoms (22% and 17% respectively). This 
implies that there is no more awareness of stroke/TIA symptoms in the OXVASC 
region than there is elsewhere in the country, and that how people describe what 
they did when they had their symptoms is likely to be representative of what the 
general population would also do. It is only after patients have sought advice about 
their symptoms that differences become evident, as demonstrated by the outcome 
of their GP appointment. This implies that patient preference may be influenced by 
the type or standard of service they have received.  
Patient Preference and Implications for Service Provision 
Patient choice and preference is an important consideration when looking at how a 
health service is best delivered. It is important that people are satisfied with the 
service that is available to them. However, the results of this questionnaire survey 
imply that patient preference is not an important issue when deciding on the most 
appropriate form of service delivery for people who have a suspected TIA. As 
demonstrated by the different priorities given in the pilot study to those seen in the 
main survey, people seem to choose the service they have had experience of as 
their prime choice.  
 
It is probable that patient preference also relies on what standard of service they 
received. For example, it is likely that OXVASC patients received a quick, high 
standard service, which is why they preferred the urgent referral to a specialist 
option. The main questionnaire results, which are likely to be more representative 
of the general population, found the complete opposite, and may well reflect the 
fact that people generally expect there to be long waiting times to see a specialist. 
If it could be demonstrated that a fast comprehensive service is available and 
effective, then their preferences may change. ©NCCSDO 2008  Page 110 
 
If patient preferences are, in fact, so influenced both by the kind of service they 
have experience of and by the effectiveness of that service, then it would be 
unwise to allow patient preference to have a profound influence on what type of 
service delivery is offered. If a new model of service delivery were successfully 
introduced it would seem that patients who have experienced the system would cite 
that as their main preference, regardless of what their choice would have been 
prior to that service implementation. 
 
 
6.5 Implications for the National Stroke Strategy 
 
The National Stroke Strategy made the following recommendations with regard to 
TIA and minor stroke: (Department of Health, 2007) 
•  Immediate referral for appropriately urgent specialist assessment and 
investigation should be considered in all patients presenting with a recent TIA or 
minor stroke.  
•  All patients with minor stroke and all higher risk patients with TIA and minor 
stroke (e.g. ABCD2 ≥ 4) need to be assessed by a specialist and treated within 
24 hours.  
•  Lower risk patients are best investigated within seven days of the event. Non-
urgent referral for TIA or minor stroke is appropriate only for very low risk 
patients, such as those presenting with events that occurred several weeks or 
months previously. 
•  Patients who are assessed as an emergency in the community should be taken by 
ambulance to an appropriate acute stroke service if their symptoms have not 
resolved, or if they are otherwise considered to be at high risk of stroke. 
•  Patients who attend emergency departments soon after a TIA or minor stroke 
must be treated and must not be sent home and simply told to see their GP in 
due course. 
•  Those at highest risk may justify immediate hospital admission  
•  Carotid imaging should ideally be performed at initial assessment and should not 
be delayed for more than 24 hours after first clinical assessment in TIA patients 
at high risk of stroke (for example ABCD2 score ≥4) or in patients with non-
cardioembolic carotid-territory minor stroke 
•  Carotid endarterectomy for recently symptomatic severe carotid stenosis should 
be regarded as an emergency procedure in patients who are neurologically stable, 
and should ideally be performed within 48 hours of a TIA or minor stroke 
 
The results of the model are broadly consistent with these recommendations, and 
clarify the thresholds at which it is most cost-effective to regard patients as high 
risk. The model did not differentiate between urgent and non-urgent referrals, with 
non-urgent referrals being handled in primary care. The model did not find it cost-
effective to refer patients with low ABCD2 scores to specialist care, but did find it 
cost-effective to refer all patients with suspected TIAs. The model did not find it 
cost effective to admit high risk patients. This is the main area where the model did 
not support the National Strategy.   ©NCCSDO 2008  Page 111 
 7: Recommendations 
 
 
 
7.1 For service delivery 
 
7.1.1 Configuration of rapid access neurovascular clinics 
 
•  Where possible, these should allow for same day referrals. Daily clinics are more 
cost effective than less frequent clinics (e.g. twice weekly or weekly) 
We found that a same day clinic (Monday – Friday) was both more effective and 
more cost effective than other patterns of clinic provision – see figure 5.7.  The 
same day clinic that we modelled did not incur fixed costs, since we recognised that 
the expected demand would not sustain a same day fixed clinic pattern. For 
example, for a clinic even with a catchment population of 500,000, we found that 
only 4 suspected patients would be referred per week with an ABCD2 score ≥ 4.  
The assumption was that the appointments would take place on the ward, in A&E, 
or in out-patients after the regular clinic had finished.   
•  The referral threshold for these clinics can be varied according to clinic capacity 
using an ABCD2 score cut off between 4 and 7.  
•  On grounds of cost-effectiveness the optimal threshold would be to refer patients 
with suspected TIA with an ABCD2 score of 4 or more if capacity is limited to 
around 1 patient per day (serving a population of 500,000) 
We found that within the strategy of the same day clinic, it was cost effective to 
refer at any ABCD2 score between 4 and 7 (see table 5.3 and figure 5.2).  The 
lower the threshold (between 4 and 7) the more major strokes there were 
prevented, and the higher the incremental cost effectiveness ratio. At a referral 
threshold of 4, the ICER was £36,000 per major stroke averted, which is well within 
the bounds by which interventions are generally regarded as cost effective given 
that we estimate that each stroke prevented in the model equates to 3-4 QALYS 
(see table 5.13).  Therefore, we felt that the key determinant of ABCD2 cut off (if 
selected above 4) would be on capacity rather than cost effectiveness.  
•  If capacity is not limited, then it is cost effective to see all possible TIAs  
We found that it was cost effective (ICER of £50,000 per stroke averted moving to 
this strategy from a strategy of only seeing patients with an ABCD2 score ≥4) for a 
specialist clinic to see all patients with suspected TIA. The anticipated number of 
patients for such a clinic in a hospital with a catchment population of 500,000 is of 
the order of 16 patients per week, and we recognise that this level of demand 
might stretch the flexibility of the service if additional fixed costs are not to be 
incurred.  
•  If daily clinics are not possible, twice or once weekly clinics are cost effective with 
a referral threshold of ABCD2 of 4 or more.  
•  Flexible clinics, i.e where staff can do other work when capacity is not required on 
a given day, are more cost-effective than fixed clinics.  
We found that both twice weekly flexible clinics (table 5.7, figure 5.4), twice weekly 
fixed clinics (table 5.8, figure 5.5), and weekly fixed clinics (table 5.9, figure 5.6) 
were all cost effective at an ABCD2 referral threshold of ≥ 4.  The ICERs were lower 
for flexible clinics. This pattern of clinic was tested to provide a direct comparison 
to the same day clinics, and so we made the same assumption about such clinics – 
that the consultation would take place in A&E, at the end of out-patients, or on a ©NCCSDO 2008  Page 112 
ward.  The justification is that expected demand is low at the threshold of ABCD2 ≥ 
4.  
7.1.2 In patient admission 
 
•  We do not recommend in-patient admission to facilitate thrombolysis for patients 
at high risk of stroke because of high ABCD2 score 
We found the use of in-patient admission to be dominated by other strategies in all 
cases except for the strategy of refer all suspected TIAs – see figure 5.7. However, 
the ICER (over £1,000,000 per major stroke averted) suggested that in-patient 
admission as an addition to the strategy of referring all suspected TIAs was too 
high to be cost effective.  
7.1.3 Use of emergency services 
 
•  We do not recommend that patients are encouraged to use 999 services where 
symptoms have resolved 
 
We found that if more patients with TIA come via a 999 service, costs are generally 
higher – see table 5.9. When we compared a strategy of enhanced use of 
emergency services with other options, we found that the other optinons 
dominated enhanced 999 use – see figure 5.9.  
 
 
7.2 For research/ audit 
 
7.2.1 In patient admission 
 
•  Services that do admit patients with high ABCD2 scores for periods of observation 
should audit their results to determine what proportion of admitted patients 
actually receive thrombolysis 
We did not find admission for observation to be cost effective. Nevertheless, it is a 
strategy that is supported by the National Stroke Strategy. Therefore, it may be 
that some units do adopt this policy, perhaps partly to ensure rapid assessment 
and treatment for those patients who would benefit from carotid endarterectomy 
(which we did not model as a benefit of admission).  If units do admit such 
patients, it would be valuable to audit what proportion receive thrombolysis and/ or 
carotid endarterectomy to make an empirical as opposed to model based 
judgement as to the cost effectiveness of the strategy. 
7.2.2 Primary care 
 
•   Would initiation of secondary prevention medications acutely by GPs prior to 
referral to a specialist improve outcome? 
We did not find that a GP instituting optimal management without referral was 
cost-effective (see section 5.3.2). However, in the light of the positive results of 
EPXRESS and SOS-TIA (Rothwell, 2007; Lavallée, 2007) it may be that an effective 
way of expediting therapy would be for the GP to give the secondary prevention 
drugs prior to referral to the specialist, who could then review whether or not the 
drugs were indicated.  ©NCCSDO 2008  Page 113 
•  How accurate is GP diagnosis of TIA? 
We found no studies that could adequately address the likelihood that GPs make 
false negative diagnoses – see section 3.5.1.  This would be valuable data in 
informing future service development. If GP diagnosis was significantly better than 
we modelled, it is conceivable that it might be possible to deliver the bulk of early 
treatment for TIA in primary care without referral to specialist clinics (except where 
carotid endarterectomy was a possible treatment).   113
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Appendices 
 
1. Read Codes for TIA used in the QRESEARCH analysis 
 
Read 
Code 
Description 
 
F4236 Amaurosis  fugax 
G65..  Transient cerebral ischaemia 
G65.. Drop  attack 
G65..  Transient ischaemic attack 
G65.. Vertebro-basilar  insufficiency 
G650.  Basilar artery syndrome 
G650.  Insufficiency - basilar artery 
G651.  Vertebral artery syndrome 
G6510 Vertebro-basilar  artery  syndrome 
G652.  Subclavian steal syndrome 
G653.  Carotid artery syndrome hemispheric 
G654. 
Multiple and bilateral precerebral artery 
syndromes 
G656. Vertebrobasilar  insufficiency 
G65y.  Other transient cerebral ischaemia 
G65z.  Transient cerebral ischaemia NOS 
G65z1  Intermittent cerebral ischaemia 
G65zz  Transient cerebral ischaemia NOS   119
2. QOF Criteria for Stroke / TIA and hypertension during the 
QRESEARCH study period (2004-5) 
 
 
Stroke and Transient Ischaemic Attacks
Indicator  PointsPayment Stages 
  
Records 
STROKE 1. The practice can produce a register of 
patients with Stroke or TIA  
4
 
  
STROKE 2. The percentage of new patients with 
presumptive stroke (presenting after 1 April 2003) who 
have been referred for confirmation of the diagnosis by 
CT or MRI scan  
2 25-80% 
  
Ongoing Management 
STROKE 3. The percentage of patients with TIA or 
stroke who have a record of smoking status in the last 15 
months, except those who have never smoked where 
smoking status need be recorded only once since 
diagnosis 
3 25-90% 
  
STROKE 4. The percentage of patients with a history of 
TIA or stroke who smoke and whose notes contain a 
record that smoking cessation advice or referral to a 
specialist service, if available, has been offered in the last 
15 months  
2 25-70% 
  
STROKE 5. The percentage of patients with TIA or 
stroke who have a record of blood pressure in the notes in 
the preceding 15 months 
2 25-90% 
  
STROKE 6. The percentage of patients with a history of 
TIA or stroke in whom the last blood pressure reading 
(measured in last 15 months) is 150/90 or less 
5 25-70% 
  
STROKE 7. The percentage of patients with TIA or 
stroke who have a record of total cholesterol in the last 15 
months  
2 25-90%   120
  
STROKE 8. The percentage of patients with TIA or 
stroke whose last measured total cholesterol (measured in 
last 15 months) is 5 mmol/l or less 
5 25-60% 
  
STROKE 9. The percentage of patients with a stroke 
shown to be non-haemorrhagic, or a history of TIA, who 
have a record that aspirin, an alternative anti-platelet 
therapy, or an anti-coagulant is being taken (unless a 
contraindication or side-effects are recorded)
4 25-90% 
  
STROKE 10. The percentage of patients with TIA or 
stroke who have had influenza immunisation in the 
preceding 1 September to 31 March 
2 25-85%   121
 
Hypertension 
Indicator  PointsPayment Stages 
 
Records 
BP 1. The practice can produce a register of patients with 
established hypertension  
9
 
  
Diagnosis and initial management
BP 2. The percentage of patients with hypertension 
whose notes record smoking status at least once since 
diagnosis 
10 25-90% 
  
BP 3. The percentage of patients with hypertension who 
smoke, whose notes contain a record that smoking 
cessation advice or referral to a specialist service, if 
available, has been offered at least once 
10 25-90% 
  
Ongoing Management 
BP 4. The percentage of patients with hypertension in 
whom there is a record of the blood pressure in the past 9 
months 
20 25-90% 
  
BP 5. The percentage of patients with hypertension in 
whom the last blood pressure (measured in the last 9 
months) is 150/90 or less 
56 25-70% 
   122
3. Additional Tables from QRESEARCH analysis 
 
Table A3.1: Cross tabulation of last SBP by number of antihypertensive 
medications prescribed one year after TIA 
  Number of antihypertensive medications   
Last SBP 
mmHg 
0 1 2 3 4 5  Total 
          
1-100 28  7  8 4 0 0  47   
Row%  59.57  14.89  17.02  8.51 0.00 0.00  100.00 
Column%  2.03 0.89 1.62 2.15 0.00 0.00  1.63   
          
101-120 232  114  53  22  3  0  424   
Row%  54.72  26.89  12.50  5.19 0.71 0.00  100.00 
Column% 16.80  14.45  10.75  11.83  9.68  0.00  14.70   
          
121-140  639  351  209  80 11 2  1,292   
Row%  49.46  27.17  16.18  6.19 0.85 0.15  100.00 
Column%  46.27 44.49 42.39 43.01 35.48 40.00  44.78   
          
141-160  364  254  165  51 13 2  849   
Row%  42.87  29.92  19.43  6.01 1.53 0.24  100.00 
Column%  26.36 32.19 33.47 27.42 41.94 40.00  29.43   
          
161-180 78  44  41  19  3  1  186   
Row% 41.94 23.66  22.04  10.22  1.61  0.54  100.00 
Column% 5.65  5.58  8.32  10.22  9.68  20.00  6.45   
          
181-200  30  18  13  9 1 0  71   
Row% 42.25 25.35  18.31  12.68  1.41  0.00  100.00 
Column%  2.17 2.28 2.64 4.84 3.23 0.00  2.46   
          
>200  10  1 4 1 0 0  16   
Row%  62.50  6.25 25.00  6.25 0.00 0.00  100.00 
Column%  0.72 0.13 0.81 0.54 0.00 0.00  0.55   
          
Total 1,381  789  493  186  31  5  2,885   
Row%  47.87  27.35  17.09  6.45 1.07 0.17  100.00 
Column%  100.00 100.00 100.00 100.00 100.00 100.00  100.00 
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Table A3.2: Cross tab of last total cholesterol by treated with Statins one year after 
TIA 
 
totalband  0            1  Total 
      
0-3.0  29           55  84  
Row%  34.52        65.48  100.00  
Column%  2.30         4.81  3.49  
      
3.1-4.0  223          417  640  
Row%  34.84        65.16  100.00  
Column%  17.67        36.48  26.61  
      
4.1-5.0  463          456  919  
Row%  50.38        49.62  100.00  
Column%  36.69        39.90  38.21  
      
5.1-6.0  319          137  456  
Row%  69.96        30.04  100.00  
Column%  25.28        11.99  18.96  
      
6.1-7.0  172           58  230  
Row%  74.78        25.22  100.00  
Column%  13.63         5.07  9.56  
      
7.1-8.0  46           14  60  
Row%  76.67        23.33  100.00  
Column%  3.65         1.22  2.49  
      
>8.0  10            6  16  
Row%  62.50        37.50  100.00  
Column%  0.79         0.52  0.67  
      
Total  1,262        1,143  2,405  
Row%  52.47        47.53  100.00  
Column%  100.00       100.00  100.00 
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Table A3.3: Cross tab of last total cholesterol at one year after TIA by prescribed 
with statins  
Total Cholesterol 
Mmol/l 
Prescribed 
at statin 
(n=2405) 
  
0-3.0 55  (5) 
  
3.1-4.0 417  (36)
  
4.1-5.0 456  (40) 
  
5.1-6.0 137  (12) 
  
6.1-7.0 58  (5) 
  
7.1-8.0 14  (1) 
  
>8.0 6  (0) 
  
Total 1,143 
Row% 47.53 
Column% 100.00   125
Table A3.4: Cross tabulation of last SBP by number of antihypertensive 
medications prescribed one month before TIA 
Last SBP 
mmHg 
0 1 2 3 4 5 Total 
         
1-100  23  7 7 0 1 0 38   
Row%  60.53 18.42 18.42 0.00  2.63  0.00  100.00   
Column%  1.64 1.01 1.73 0.00 3.23 0.00 1.42   
         
101-120  185  78 35 10 0  0  308   
Row%  60.06 25.32 11.36 3.25  0.00  0.00  100.00   
Column%  13.18  11.21  8.66 7.14 0.00 0.00 11.51   
         
121-140  544 259 136 54  8  1  1,002   
Row%  54.29 25.85 13.57 5.39  0.80  0.10  100.00   
Column%  38.75 37.21 33.66 38.57 25.81 50.00 37.43   
         
141-160  443 210 148 39  17  1  858   
Row%  51.63 24.48 17.25 4.55  1.98  0.12  100.00   
Column%  31.55 30.17 36.63 27.86 54.84 50.00 32.05   
         
161-180  148  99 54 23 3  0  327   
Row%  45.26 30.28 16.51 7.03  0.92  0.00  100.00   
Column%  10.54 14.22 13.37 16.43 9.68  0.00  12.22   
         
181-200  51 26 19 11 2  0  109   
Row%  46.79 23.85 17.43 10.09 1.83  0.00  100.00   
Column%  3.63 3.74 4.70 7.86 6.45 0.00 4.07   
         
>200  10  17  5 3 0 0 35   
Row%  28.57 48.57 14.29 8.57  0.00  0.00  100.00   
Column%  0.71 2.44 1.24 2.14 0.00 0.00 1.31   
         
Total  1,404  696 404 140 31  2  2,677   
Row%  52.45 26.00 15.09 5.23  1.16  0.07  100.00   
Column%  100.00 100.00 100.00 100.00 100.00 100.00 100.00   
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Table A3.5: Cross tab of last total cholesterol by treated with Statins one month 
before TIA 
     
Last total 
cholesterol 
No 
statin 
Prescribed 
statin 
Total 
      
0-3.0  8           14  22  
Row%  36.36     63.64  100.00 
Column%  0.79       2.87  1.47  
      
3.1-4.0  95          126  221  
Row%  42.99     57.01  100.00 
Column%  9.41       25.87  14.76  
      
4.1-5.0  242        180  422  
Row%  57.35     42.65  100.00 
Column%  23.96     36.96  28.19  
      
5.1-6.0  360        94  454  
Row%  79.30     20.70  100.00 
Column%  35.64     19.30  30.33  
      
6.1-7.0  209        47  256  
Row%  81.64     18.36  100.00 
Column%  20.69     9.65  17.10  
      
7.1-8.0  72          18  90  
Row%  80.00     20.00  100.00 
Column%  7.13       3.70  6.01  
      
>8.0  24          8  32  
Row%  75.0       25.0  100.00 
Column%  2.38       1.44  2.07  
      
Total  1,010     487  1,497  
Row%  67.47     32.53  100.00 
Column%  100.00   100.00  100.00 
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4. Cost data used in the model 
 
Final Drug Costs 
Drug costs  (generic unless otherwise stated)  BNF, March 2007       
              
Monotherapy             
   cost cost per week (£)   Deflate one year     
Aspirin              
(75mg od)  56  £1.89 0.2363  0.226       
Dual therapy              
Dipyridamole            
84 tablets  100mg  £5.17 0.8617  0.824       
(200mg bd)              
             
Simvastatin     
28 tablets  40mg  £3.40 0.8500  0.813       
40mg od              
    
Antihypertensives              
Bendrofulmethiazide              
2.5mg od  28 tablets  £1.15 0.2875  0.275       
             
Anticoagulant for AF              
Warfarin            
28 tablets  5mg  £1.47         
See final cost data sheet for warfarin clinic visit unit costs        
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Other Final Costs 
  
Cost 
(£) Price  year  Source  Notes     
Ambulance                
Urban/rural amber incident, 
stroke/CVA 197  2005/6 
NHS Reference Costs 
05/06  NHS trust & PCT combined   
      (Weighted cost using figures for urban and rural ambulance services - amber as almost all  
     stroke/CVA  in  category)         
GP 
consultation                
10 minute consultation  18  2005/6  Curtis & Netten, 06  excluding qualifications & direct care staff costs 
                
A&E doctor                
Lower cost investigation  80  2005/6 
NHS Reference Costs 
05/06  NHS trust & PCT combined   
                
A&E specialist  O/P clinic 30 mins   
General 
medicine 1st  attendance  207  2005/6 
NHS Reference Costs 
05/06  NHS trust & PCT combined  Length of clinic unknown 
                
Scheduled OP                
Costed as A&E specialist               
                
Major stroke (acute)              
Non-transient stroke or 
cerebrovascular 2462  2005/6 
NHS Reference Costs 
05/06  NHS trust & PCT combined  Non-elective inpatient 
accident (11 days as inpatient)              >69 or w cc 
                
Major stroke (chronic)  per day             
Long term care disabled  41.78  2005/6  Chambers, 2002  Inflated to 05/06 using HCHS price index 
Long term care not disabled  3.23  2005/6  Chambers, 2002  Inflated to 05/06 using HCHS price index   
Cost calculated as 40% disabled, 30% not disabled, 30% dead = 17.68 per day         129
 
     
CE clinical assessment (as part of O/P appt or with specialist) - additional cost of ultrasound     
Doppler Ultrasound  87  2005/6 
NHS Reference Costs 
05/06  NHS trust & PCT combined   
                
CE appointment assessment (if separate and additional appointment)  
General 
medicine 
Follow up 
attendance 118  2005/6 
NHS Reference Costs 
05/06  NHS trust & PCT combined   
plus Doppler Ultrasound as above              
              
CE surgery                
Extracranial or upper limb arterial 
surgery 4352 2005/6
NHS Reference Costs 
05/06 NHS trust & PCT combined Elective inpatient
(3 days as inpatient)               
                
Inpatient days                
Cost per bed day stroke  182  2005/6  Curtis & Netten, 06  From NHS reference costs   
                
Anticoagulation (A/C) clinic              
                
First outpatient visit day 1  27  2005/6  NHS Reference costs 05/06  1st attendance A/C clinic, face to face, NHS Trust & PCT combined 
Follow up visit day 5  22  2005/6  NHS Reference costs 05/06  Follow up attendance A/C clinic, face to face, NHS Trust & PCT combined 
Follow up visit day 8  22  2005/6  NHS Reference costs 05/06  Follow up attendance A/Con clinic, face to face, NHS Trust & PCT combined 
Follow up visit day 15  7.62  2005/6 
SMART study, hospital clinic 
estimate  (NHS Reference cost non-face to face visit (standard) is £8) 
Follow up visit day 29  7.62  2005/6 
SMART study, hospital clinic 
estimate      
Standard monthly visit  7.62  2005/6 
SMART study, hospital clinic 
estimate      
               
Assumptions: Initiation of warfarin in hospital, regular checks in first month then attends hospital clinic monthly 
Assume first three visits are face to face when stabilising warfarin dose, remainder are non face to face       
Warfarin start up costs made up of three first clinics, monthly costs 7.62 clinic plus 1.47 pack of 28 tablets     
 
 This document was published by the National Coordinating Centre for the Service Delivery 
and Organisation (NCCSDO) research programme, managed by the London School of 
Hygiene & Tropical Medicine.  
 
The management of the Service Delivery and Organisation (SDO) programme has now 
transferred to the National Institute for Health Research Evaluations, Trials and Studies 
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